<SEC-DOCUMENT>0001213900-25-120759.txt : 20251211
<SEC-HEADER>0001213900-25-120759.hdr.sgml : 20251211
<ACCEPTANCE-DATETIME>20251211170024
ACCESSION NUMBER:		0001213900-25-120759
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		21
CONFORMED PERIOD OF REPORT:	20251210
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251211
DATE AS OF CHANGE:		20251211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41277
		FILM NUMBER:		251565650

	BUSINESS ADDRESS:	
		STREET 1:		10740 THORNMINT ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-800-3500

	MAIL ADDRESS:	
		STREET 1:		10740 THORNMINT ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0269264-8k_modular.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:MODD="http://modularmedical.com/20251210">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_MODD_modularmedical.com_20251210 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20251210_20251210 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001074871 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-12-10" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-12-10" id="Fact000004" name="dei:EntityCentralIndexKey">0001074871</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="modd-20251210.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-12-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-10</xbrli:startDate>
        <xbrli:endDate>2025-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90E_edei--DocumentType_c20251210__20251210_zg9FYoNijvqe"><ix:nonNumeric contextRef="AsOf2025-12-10" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_909_edei--DocumentPeriodEndDate_c20251210__20251210_zeYzkZjiXcB6"><ix:nonNumeric contextRef="AsOf2025-12-10" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">December 10, 2025</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20251210__20251210_zNSw6Sxr3OBd"><ix:nonNumeric contextRef="AsOf2025-12-10" id="Fact000011" name="dei:EntityRegistrantName">MODULAR MEDICAL, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityFileNumber_c20251210__20251210_zBxHlh4SRtB1"><ix:nonNumeric contextRef="AsOf2025-12-10" id="Fact000012" name="dei:EntityFileNumber">001-41277</ix:nonNumeric></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 49%"><span style="font-size: 10pt"><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20251210__20251210_z4AcrZXuIzzh"><ix:nonNumeric contextRef="AsOf2025-12-10" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 49%"><span style="font-size: 10pt"><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20251210__20251210_zISAPQPALs9l"><ix:nonNumeric contextRef="AsOf2025-12-10" id="Fact000014" name="dei:EntityTaxIdentificationNumber">87-0620495</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(State or Other Jurisdiction<br/>
of Incorporation)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(I.R.S. Employer<br/>
Identification Number)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20251210__20251210_zJNizUQdHTql"><ix:nonNumeric contextRef="AsOf2025-12-10" id="Fact000015" name="dei:EntityAddressAddressLine1">10740 Thornmint Road</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20251210__20251210_zAAs4uoXdNo"><ix:nonNumeric contextRef="AsOf2025-12-10" id="Fact000016" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20251210__20251210_zZpYgClz6dXd"><ix:nonNumeric contextRef="AsOf2025-12-10" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_909_edei--EntityAddressPostalZipCode_c20251210__20251210_zGLwURvO8g77"><ix:nonNumeric contextRef="AsOf2025-12-10" id="Fact000018" name="dei:EntityAddressPostalZipCode">92127</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices, with zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_907_edei--CityAreaCode_c20251210__20251210_zsidB0HRTXRi"><ix:nonNumeric contextRef="AsOf2025-12-10" id="Fact000019" name="dei:CityAreaCode">858</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20251210__20251210_zOvzhvV4X3X2"><ix:nonNumeric contextRef="AsOf2025-12-10" id="Fact000020" name="dei:LocalPhoneNumber">800-3500</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--WrittenCommunications_c20251210__20251210_zgrtkJfchFY3"><ix:nonNumeric contextRef="AsOf2025-12-10" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--SolicitingMaterial_c20251210__20251210_z229Iy7GS0K3"><ix:nonNumeric contextRef="AsOf2025-12-10" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20251210__20251210_z1GeYcob9IVb"><ix:nonNumeric contextRef="AsOf2025-12-10" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20251210__20251210_zhaDDV4Bf2Z6"><ix:nonNumeric contextRef="AsOf2025-12-10" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; padding-left: 11.9pt; text-align: center; width: 32%"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20251210__20251210_zL1NSsOIW6h5"><ix:nonNumeric contextRef="AsOf2025-12-10" id="Fact000025" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20251210__20251210_z0CnWX98kxa5"><ix:nonNumeric contextRef="AsOf2025-12-10" id="Fact000026" name="dei:TradingSymbol">MODD</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_905_edei--SecurityExchangeName_c20251210__20251210_z2QniQXgroIj"><ix:nonNumeric contextRef="AsOf2025-12-10" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR&#167;230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20251210__20251210_zvXr1ydk4o28"><ix:nonNumeric contextRef="AsOf2025-12-10" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 1.01 Entry into
a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On December 10, 2025,
Modular Medical, Inc. (the &#8220;Company&#8221;) entered into an Underwriting Agreement (the &#8220;Agreement&#8221;) with Newbridge
Securities Corporation (the &#8220;Underwriter&#8221;), relating to a firm commitment underwritten offering (the &#8220;Offering&#8221;)
of (i) 12,173,000 shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), referred to
as the &#8220;Firm Shares,&#8221; and (ii) accompanying warrants exercisable to purchase up to 6,086,500 shares of Common Stock (the &#8220;Warrants&#8221;),
referred to as the &#8220;Firm Warrants.&#8221; The gross proceeds to the Company from the Offering will be approximately $4.68 million,
before deducting underwriting discounts and commissions and offering expenses. Pursuant to the Agreement, the Company agreed to pay the
Underwriter a cash fee equal to 7% of the gross proceeds received from the Offering and to reimburse the Underwriter for its expenses
incurred in connection with the Offering in an amount up to $85,000.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Each two shares of Common Stock are being offered and sold together with one accompanying warrant at a combined price of $0.77, yielding
an effective price of $0.38 per share and $0.01 per warrant. The Warrants will have an exercise price of $0.45 per share (the &#8220;Exercise
Price&#8221;), are exercisable immediately upon issuance, and will expire five years following the date of issuance. The Warrants will
be issued pursuant to a warrant agency agreement to be entered into by and between the Company and Colonial Stock Transfer Company, Inc.,
as warrant agent. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Offering closed on December 11, 2025 (the &#8220;Closing Date&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Offering was made pursuant to an effective registration statement on Form S-3 (Registration Statement No. 333- 287313) previously
filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on May 15, 2025 and declared effective by the SEC on May 22,
2025, and a preliminary prospectus supplement relating to the Offering dated December 9, 2025 and a final prospectus supplement relating
to the Offering dated December 10, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the
Agreement, the Company has granted to the Underwriter a 30-day option (the &#8220;Over-allotment Option&#8221;) to purchase from the
Company (i) up to an additional 1,825,950 shares of Common Stock, representing 15% of the Firm Shares sold in the Offering (the
&#8220;Option Shares&#8221;), and/or (ii) additional Warrants to purchase up to 912,975 shares of Common Stock, representing fifteen
percent (15%) of the Firm Warrants sold in the Offering, solely for the purpose of covering over-allotments of such securities, if
any. The Company has also agreed to issue to the Underwriter on the Closing Date and each Over-allotment Option Closing Date, if
any, a warrant (the &#8220;Underwriter Warrant&#8221;) for the purchase of a number of shares of Common Stock equal to an aggregate
of 7% of the Firm Shares sold on the Closing Date (equal to 852,110 shares) and 7% of the Option Shares sold on each Over-allotment
Option Closing Date, if any. The Underwriter Warrant will have substantially the same terms as the Firm Warrants, except that the
Underwriter Warrant will have an exercise price equal to 120% of the Exercise Price, will not be exercisable for 180 days from the Closing Date and will include
piggyback registration rights that are triggered if there is not an effective registration statement covering all of the shares of
Common Stock issuable upon exercise of the Underwriter Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the Agreement, each of the Company&#8217;s directors and executive officers entered into &#8220;lock-up&#8221; agreements
with the Underwriter that, subject to certain exceptions, prohibit, without the prior written consent of the Underwriter, the sale, transfer,
or other disposition of securities of the Company for a period of 60 days from the date of the Offering. The Company has agreed not to,
subject to certain exceptions, offer, pledge, sell, contract to sell, sell any option, right or warrant to purchase, lend or otherwise
transfer or dispose, directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable
for shares of capital stock, for a period of 90 days from the date of the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The foregoing description
of the Agreement, the Warrants, and the Underwriter Warrant is not complete and is qualified in its entirety by reference to the full
text of the Agreement, the Form of Warrants, and the Underwriter Warrant, copies of which are filed herewith as Exhibits 1.1, 4.1, and
4.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">A copy of the legal opinion
of Lucosky Brookman, LLP relating to the Firm Securities is attached hereto as Exhibit 5.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This Current Report on
Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there
be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation, or sale would be unlawful prior
to registration or qualification under the securities laws of any such state.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company issued press
releases announcing the launch of the Offering on December 9, 2025 and the pricing of the Offering on December 10, 2025. Copies of these
press releases are attached hereto as Exhibits 99.1 and 99.2 and are each incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b></b></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 9.01 Financial
Statements and Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>(d) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following exhibits
are filed with this report:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-size: 10pt"><b>Exhibit<br/>
    Number</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 90%"><span style="font-size: 10pt"><b>Exhibit Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea026926401ex1-1_modular.htm">Underwriting Agreement, dated as of December 10, 2025, between the Company and Newbridge Securities Corporation</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">4.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea026926401ex4-1_modular.htm">Form of Warrant</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea026926401ex4-2_modular.htm">Form of Underwriter Warrant</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">5.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea026926401ex5-1_modular.htm">Opinion of Lucosky Brookman, LLP</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">23.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea026926401ex5-1_modular.htm">Consent of Lucosky Brookman, LLP (included in Exhibit 5.1)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">99.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea026926401ex99-1_modular.htm">Press Release dated December 9, 2025, regarding the launch of the Offering</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">99.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea026926401ex99-2_modular.htm">Press Release dated December 10, 2025, regarding the pricing of the Offering</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>MODULAR MEDICAL, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: December 11, 2025</span></td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><i>/s/ James E. Besser</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">James E. Besser</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6Lbpu6MUuHSrilDFEvC0uk2LXjLT+PZJvabchhkBIzvlOhJiIDa21QYbzsirgiG1nlEeosEFGe8HgyLe7DMKs8KqdZ2X9sP7AnAKDgVlMUxXug/OhHdYZyGQm41kyBymzNIVyL6Jez8k2ukbrtTKgbA0lU8caveL3mHBUL7LUvodPJ2SnyYa4aTzKH0himcCBHupJfHNQFLmIJkNFYsN074Jr9fJoexJWBtvwzo30v6MvxzZKVQ== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea026926401ex1-1_modular.htm
<DESCRIPTION>UNDERWRITING AGREEMENT, DATED AS OF DECEMBER 10, 2025, BETWEEN THE COMPANY AND NEWBRIDGE SECURITIES CORPORATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Execution Version</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>MODULAR
MEDICAL, inC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>NEWBRIDGE
SECURITIES CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">December 10, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Newbridge Securities Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1200 North Federal Highway, Suite 400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boca Raton, Florida 33432</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned, Modular Medical,
Inc., a corporation formed under the laws of the State of Nevada (the &ldquo;<B>Company</B>&rdquo;), hereby confirms its agreement (this
&ldquo;<B>Agreement</B>&rdquo;) with Newbridge Securities Corporation (hereinafter referred to as &ldquo;<B>you</B>&rdquo; or the &ldquo;<B>Underwriter</B>&rdquo;)
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">1.&nbsp;</FONT> <FONT STYLE="font-weight: normal"><U>Purchase and Sale of Securities</U>.</FONT></P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.1&nbsp;<U>Firm
Securities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">1.1.1.&nbsp;<U>Nature
and Purchase of Firm Securities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(i)&nbsp;<FONT STYLE="font-size: 10pt">On
the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the Company
agrees to issue and sell to the Underwriter an aggregate of (i) 12,173,000 (the &ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">Firm
Shares<FONT STYLE="font-weight: normal">&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;</FONT>Common
Stock<FONT STYLE="font-weight: normal">&rdquo;), and (B) warrants exercisable to purchase an aggregate of 6,086,500 shares of Common Stock,
in the form attached hereto as <U>Exhibit A</U> (the &ldquo;</FONT>Warrants<FONT STYLE="font-weight: normal">&rdquo;), which Warrants
will have an exercise price of $0.45 per share, subject to adjustment as provided for therein (the &ldquo;</FONT>Firm Warrants<FONT STYLE="font-weight: normal">&rdquo;
and together with the Firm Shares, the &ldquo;</FONT>Firm Securities<FONT STYLE="font-weight: normal">&rdquo;). The Firm Shares and the
Common Stock issuable upon the exercise of the Warrants (the &ldquo;</FONT>Warrant Shares<FONT STYLE="font-weight: normal">&rdquo;) consist
of authorized but unissued shares of Common Stock to be issued and sold by the Company.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(ii)&nbsp;<FONT STYLE="font-size: 10pt">The
Underwriter agrees to purchase from the Company the Firm Securities at a combined purchase price of $0.7161 for two Firm Shares and one
Firm Warrant (with $0.3534 allocated for the purchase price of each Firm Share and $0.0093 allocated for the purchase price of a full
Warrant to purchase one share of Common Stock). The Firm Securities are to be offered to the public (the &ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">Offering<FONT STYLE="font-weight: normal">&rdquo;)
at the combined offering price set forth on the cover page of the Prospectus (as defined in <U>Section 2.1.1</U>).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">1.1.2.&nbsp;<U>Firm
Securities Payment and Delivery.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(i)&nbsp;<FONT STYLE="font-size: 10pt">Delivery
and payment for the Firm Securities shall be made at 10:00 a.m., Eastern time, on December 11, 2025 or at such earlier time as shall be
agreed upon by the Underwriter and the Company, at the offices of McGuireWoods LLP, 1251 Avenue of the Americas, 20<SUP>th</SUP> Floor,
New York, New York 10020 (&ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">Underwriter&rsquo;s Counsel<FONT STYLE="font-weight: normal">&rdquo;),
or at such other place (or remotely by electronic transmission) as shall be agreed upon in writing by the Underwriter and the Company.
The hour and date of delivery and payment for the Firm Securities is called the &ldquo;</FONT>Closing Date<FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(ii)&nbsp;<FONT STYLE="font-size: 10pt">Payment
for the Firm Securities shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the Company
upon delivery of the certificates (in form and substance satisfactory to the Underwriter) representing the Firm Shares and the Firm Warrants
(or through the facilities of The Depository Trust Company (&ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">DTC<FONT STYLE="font-weight: normal">&rdquo;))
for the account of the Underwriter. The Firm Shares and the Firm Warrants shall each be registered in such name or names and in such authorized
denominations as the Underwriter may request in writing at least two (2) Business Days prior to the Closing Date. The Company shall not
be obligated to sell or deliver the Firm Securities except upon tender of payment by the Underwriter for all of the Firm Securities. The
term &ldquo;</FONT>Business Day<FONT STYLE="font-weight: normal">&rdquo; means any day other than a Saturday, a Sunday or a legal holiday
or a day on which banking institutions are authorized or obligated by law to close in New York, New York.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.2&nbsp;<U>Over-allotment
Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.1.&nbsp;<U>Option
Securities</U>. The Company hereby grants to the Underwriter an option (the &ldquo;</FONT>Over-allotment Option<FONT STYLE="font-weight: normal">&rdquo;)
to purchase from the Company (i) up to an additional 1,825,950 shares of Common Stock, representing up to 15% of the Firm Shares sold
in the Offering (the &ldquo;</FONT>Option Shares<FONT STYLE="font-weight: normal">&rdquo;), and (ii) additional Warrants to purchase up
to 912,975 shares of Common Stock, representing up to fifteen percent (15%) of the Firm Warrants sold in the Offering (the &ldquo;</FONT>Option
Warrants<FONT STYLE="font-weight: normal">,&rdquo; and together with the Option Shares, the &ldquo;</FONT>Option Securities<FONT STYLE="font-weight: normal">&rdquo;),
for the purpose of covering over-allotments of such securities, if any. The purchase price to be paid for the Option Shares and/or Option
Warrants will be the price set forth in <U>Section 1.1.1</U> for such securities. The Over-allotment Option may be elected with respect
to, at the Underwriter&rsquo;s sole discretion, Option Shares and Option Warrants together, solely Option Shares, solely Option Warrants,
or any combination thereof. The Firm Shares, the Firm Warrants, the Option Shares, the Option Warrants and the Warrant Shares are hereinafter
referred to collectively as the &ldquo;</FONT>Public Securities<FONT STYLE="font-weight: normal">.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.2.&nbsp;<U>Exercise
of the Option</U>. The Over-allotment Option granted pursuant to <U>Section 1.2.1</U> may be exercised by the Underwriter as to all (at
any time) or any part (from time to time) of the Option Shares and/or Option Warrants within 30 days after the date hereof. The Underwriter
shall not be under any obligation to purchase any Option Securities prior to the exercise of the Over-allotment Option. The Over-allotment
Option granted hereby shall be exercised by the giving of electronic notice to the Company from the Underwriter, which shall be confirmed
in writing by overnight mail or facsimile or other electronic transmission, setting forth the number of Option Securities to be purchased
and the date and time for delivery of and payment for the Option Securities (the &ldquo;</FONT>Option Closing Date<FONT STYLE="font-weight: normal">&rdquo;),
which shall not be later than five (5) full Business Days after the date of the notice or such other time as shall be agreed upon by the
Company and the Underwriter, at the offices of Underwriter&rsquo;s Counsel or at such other place (including remotely by electronic transmission)
as shall be agreed upon by the Company and the Underwriter. If such delivery and payment for the Option Securities does not occur on the
Closing Date, the applicable Option Closing Date will be as set forth in the notice. Upon exercise of the Over-allotment Option with respect
to all or any portion of the Option Securities, subject to the terms and conditions set forth herein, the Company shall become obligated
to sell to the Underwriter the number of Option Shares and/or Option Warrants specified in such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.3.&nbsp;<U>Payment
and Delivery</U>. Payment for the Option Securities shall be made on each Option Closing Date by wire transfer in Federal (same day) funds,
payable to the order of the Company upon delivery to you of certificates (in form and substance satisfactory to the Underwriter) representing
the Option Shares and/or Option Warrants (or through the facilities of DTC) for the account of the Underwriter. The Option Securities
shall be registered in such name or names and in such authorized denominations as the Underwriter may request in writing at least two
(2) Business Days prior to each Option Closing Date. The Company shall not be obligated to sell or deliver the Option Shares and/or Option
Warrants except upon tender of payment by the Underwriter for applicable Option Securities. An Option Closing Date may be simultaneous
with, but not earlier than, the Closing Date; and in the event that such time and date are simultaneous with the Closing Date, the term
&ldquo;Closing Date&rdquo; shall refer to the time and date of delivery of the Firm Securities and Option Securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.3&nbsp;<U>Underwriter
Warrants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.3.1.&nbsp;<U>Purchase
Warrants</U>. The Company hereby agrees to issue to the Underwriter (and/or its affiliates, employees or third-party designees) on the
Closing Date and each Option Closing Date, if any, an option (&ldquo;</FONT>Underwriter&rsquo;s Warrant<FONT STYLE="font-weight: normal">&rdquo;)
for the purchase of an aggregate of a number of shares of Common Stock, representing 7% of the Firm Shares sold on the Closing Date and
7% of the Option Shares sold each Option Closing Date, if any. The Underwriter&rsquo;s Warrant, in the form attached hereto as <U>Exhibit
C</U>, shall be exercisable, in whole or in part, commencing on the date that is 180 days after the date of the Prospectus Supplement
and expiring on the five-year anniversary of the date of the Prospectus Supplement at an initial exercise price per share of Common Stock
of $0.462, which is equal to 120% of the combined public offering price of the Firm Shares and Firm Warrants. The Underwriter&rsquo;s
Warrant and the shares of Common Stock issuable upon exercise thereof are hereinafter referred to together as the &ldquo;</FONT>Underwriter&rsquo;s
Securities<FONT STYLE="font-weight: normal">.&rdquo; The Underwriter understands and agrees that there are significant restrictions pursuant
to FINRA Rule 5110 against transferring the Underwriter&rsquo;s Warrant and the underlying shares of Common Stock during the one hundred
eighty (180) days after the date of the Prospectus Supplement and by its acceptance thereof shall agree that it will not sell, transfer,
assign, pledge or hypothecate the Underwriter&rsquo;s Warrant, or any portion thereof, or be the subject of any hedging, short sale, derivative,
put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty
(180) days following the date of the Prospectus Supplement to anyone other than (i) an Underwriter or a selected dealer in connection
with the Offering or (ii) a bona fide officer, partner, employee or registered representative of the Underwriter or selected dealer; and
only if any such transferee agrees to the foregoing lock-up restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.3.2.&nbsp;<U>Delivery</U>.
Delivery of the Underwriter&rsquo;s Warrant shall be made on the Closing Date and each Option Closing Date, if any, and shall be issued
in the name or names and in such authorized denominations as the Underwriter may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">2.&nbsp;<U>Representations
and Warranties of the Company</U>. The Company represents and warrants to the Underwriter as of the Applicable Time (as defined below),
as of the Closing Date and as of each Option Closing Date, if any, as follows:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.1&nbsp;<U>Filing
of Registration Statement</U></FONT><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.1.1.&nbsp;The
Company filed with the U.S. Securities and Exchange Commission (the &ldquo;</FONT>Commission<FONT STYLE="font-weight: normal">&rdquo;)
a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-287313), including any related prospectus or prospectuses, which
was declared effective by the Commission on May 22, 2025, for the registration under the Securities Act of 1933, as amended (the &ldquo;</FONT>Securities
Act<FONT STYLE="font-weight: normal">&rdquo;) of the offering and sale of the Public Securities, which registration statement was prepared
by the Company in all material respects in conformity with the requirements of the Securities Act and the rules and regulations of the
Commission under the Securities Act (the &ldquo;</FONT>Securities Act Regulations<FONT STYLE="font-weight: normal">&rdquo;) and contains
or will contain all material statements that are required to be stated therein in accordance with the Securities Act and the Securities
Act Regulations. Except as the context may otherwise require, such registration statement on file with the Commission at any given time,
including (i) any amendments thereto to such time, exhibits and schedules thereto at such time, documents filed as a part thereof or incorporated
pursuant to Item 12 of Form S-3 under the Securities Act at such time and the documents and information otherwise deemed to be a part
thereof or included therein pursuant to Rule 430B of the Securities Act Regulations (the &ldquo;</FONT>Rule 430B Information<FONT STYLE="font-weight: normal">&rdquo;)
or otherwise pursuant to the Securities Act Regulations at such time, is referred to herein as the &ldquo;</FONT>Registration Statement<FONT STYLE="font-weight: normal">.&rdquo;
The Registration Statement at the time it originally became effective is referred to herein as the &ldquo;</FONT>Initial Registration
Statement<FONT STYLE="font-weight: normal">.&rdquo; If the Company files any registration statement pursuant to Rule 462(b) of the Securities
Act Regulations, then after such filing, the term &ldquo;Registration Statement&rdquo; shall include such registration statement filed
pursuant to Rule 462(b). The prospectus in the form in which it was filed with the Commission in connection with the Initial Registration
Statement is herein called the &ldquo;</FONT>Base Prospectus<FONT STYLE="font-weight: normal">.&rdquo; Each preliminary prospectus supplement
to the Base Prospectus (including the Base Prospectus as so supplemented) that described the Public Securities and the Offering and omitted
the Rule 430B Information and that was used prior to the filing of the final prospectus supplement referred to in the following paragraph
is herein called a &ldquo;</FONT>Preliminary Prospectus<FONT STYLE="font-weight: normal">.&rdquo; Promptly after the execution and delivery
of this Agreement, the Company will prepare and file with the Commission a final prospectus supplement to the Base Prospectus relating
to the Public Securities and the Offering in accordance with the provisions of Rule 430B and Rule 424(b) of the Securities Act Regulations.
Such final prospectus supplement (including the Base Prospectus as so supplemented), in the form filed with the Commission pursuant to
Rule 424(b) under the Securities Act is herein called the &ldquo;</FONT>Prospectus<FONT STYLE="font-weight: normal">.&rdquo; Any reference
herein to the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated
by reference therein pursuant to Item 12 of Form S-3 under the Securities Act as of the date of such prospectus. All references in this
Agreement to the Registration Statement, the Preliminary Prospectus, the Prospectus or any amendment or supplement to any of the foregoing,
is deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System or any
successor system thereto (&ldquo;</FONT>EDGAR<FONT STYLE="font-weight: normal">&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Applicable Time</B>&rdquo;
means 6:30 a.m., Eastern time, on the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Disclosure Package</B>&rdquo;
means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Preliminary Prospectus dated December
9, 2025 and the information included on <U>Schedule 1-A</U> hereto, all considered together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Issuer Free Writing
Prospectus</B>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the Securities Act Regulations
(&ldquo;<B>Rule 433</B>&rdquo;), including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 of the
Securities Act Regulations) relating to the Public Securities that is (i) required to be filed with the Commission by the Company, (ii)
a &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed
with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of
the Public Securities or of the Offering that does not reflect the final terms, in each case in the form filed or required to be filed
with the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule 433(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Issuer General Use
Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors
(other than a &ldquo;<I>bona fide</I> electronic road show,&rdquo; as defined in Rule 433), as evidenced by its being specified in <U>Schedule
1-B</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Issuer Limited Use
Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.1.2.&nbsp;<U>Pursuant
to the Exchange Act.</U> The Common Stock is registered pursuant to Section 12(b) under the Securities Exchange Act of 1934, as amended
(the &ldquo;</FONT>Exchange Act<FONT STYLE="font-weight: normal">&rdquo;). The Company has taken no action designed to, or likely to have
the effect of, terminating the registration of the Common Stock under the Exchange Act, nor has the Company received any notification
that the Commission is contemplating terminating such registration.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.2&nbsp;<U>Stock
Exchange Listing.</U> The Common Stock is listed on The Nasdaq Capital Market (the &ldquo;</FONT><FONT STYLE="font-style: normal">NasdaqCM<FONT STYLE="font-weight: normal">&rdquo;),
and the Company has taken no action designed to, or likely to have the effect of, delisting the Common Stock from the NasdaqCM, nor has
the Company received any notification that the NasdaqCM is contemplating terminating such listing, except as described in the Registration
Statement, the Disclosure Package and the Prospectus.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.3&nbsp;<U>No
Stop Orders, etc</U>. Neither the Commission nor any state regulatory authority has issued any order preventing or suspending the use
of the Registration Statement, any Preliminary Prospectus or the Prospectus or has instituted or, to the Company&rsquo;s knowledge, threatened
to institute, any proceedings with respect to such an order. The Company has complied with each request (if any) from the Commission for
additional information.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.4&nbsp;<U>Disclosures
in Registration Statement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.1.&nbsp;<U>Compliance
with Securities Act; 10b-5 Representation</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(i)&nbsp;<FONT STYLE="font-size: 10pt">Each
of the Registration Statement and any post-effective amendment thereto, at the time it became effective (including each deemed effective
date with respect to the Underwriter pursuant to Rule 430B or otherwise under the Securities Act) complied and will comply in all material
respects with the requirements of the Securities Act and the Securities Act Regulations. The conditions for use of Form S-3, set forth
in the General Instructions thereto, including, but not limited to, General Instruction I.B.6 and other conditions related to the offer
and sale of the Public Securities, have been satisfied. Each Preliminary Prospectus and the Prospectus, at the time each was filed or
will be filed with the Commission, at the date of this Agreement and at the Closing Date and each Option Closing Date, complied or will
comply in all material respects with the requirements of the Securities Act and the Securities Act Regulations. The Preliminary Prospectus
delivered to the Underwriter for use in connection with this Offering and the Prospectus was or will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)&nbsp;<FONT STYLE="font-size: 10pt">Neither
the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time, or at the Closing Date or any
Option Closing Date contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state
a material fact required to be stated therein or necessary to make the statements therein not misleading.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iii)&nbsp;<FONT STYLE="font-size: 10pt">The
Disclosure Package, as of the Applicable Time, as of the date of this Agreement, at the Closing Date or at any Option Closing Date did
not, does not and will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Limited Use Free
Writing Prospectus hereto does not conflict with the information contained in the Registration Statement, the Preliminary Prospectus or
the Prospectus, and each such Issuer Limited Use Free Writing Prospectus, as supplemented by and taken together with the Prospectus as
of the Applicable Time, did not include an untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading; <I><U>provided</U></I>, <I><U>however</U></I>,
that this representation and warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with
written information furnished to the Company with respect to the Underwriter by the Underwriter expressly for use in the Registration
Statement, the Disclosure Package or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree
that such information provided by or on behalf of the Underwriter consists solely of the following disclosure contained in the &ldquo;Underwriting&rdquo;
section of the Prospectus: the third full paragraph under the heading &ldquo;Underwriting,&rdquo; the statements under the subheading
titled &ldquo;Price Stabilization, Short Positions and Penalty Bids&rdquo; and the statements under the subheading titled &ldquo;Electronic
Distribution&rdquo; (collectively, the &ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">Underwriter&rsquo;s Information<FONT STYLE="font-weight: normal">&rdquo;);
and</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iv)&nbsp;<FONT STYLE="font-size: 10pt">Neither
the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing
with the Commission pursuant to Rule 424(b) or at the Closing Date or any Option Closing Date, included, includes or will include an untrue
statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>, that this representation
and warranty shall not apply to the&nbsp;Underwriter&rsquo;s Information.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(v)&nbsp;<FONT STYLE="font-size: 10pt">The
documents incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus, when they became effective
or were filed with the Commission, as the case may be, conformed in all material respects to the requirements of the Securities Act or
the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and none of such documents contained any untrue
statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference
in the Registration Statement, the Disclosure Package and the Prospectus, when such documents become effective or are filed with the Commission,
as the case may be, will conform in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable,
and the rules and regulations of the Commission thereunder, and will not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which
they were made, not misleading.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.2.&nbsp;<U>Disclosure
of Agreements</U>. The agreements and documents described in the Registration Statement, the Disclosure Package and the Prospectus conform
in all material respects to the descriptions thereof contained or incorporated by reference therein, and there are no agreements or other
documents required by the Securities Act, the Securities Act Regulations or the Exchange Act to be described in the Registration Statement,
the Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement, or to be incorporated
by reference in the Registration Statement, the Disclosure Package or the Prospectus, that have not been so described or filed or incorporated
by reference. Each agreement or other instrument (however characterized or described) to which the Company or the Subsidiary is a party
or by which it is or may be bound or affected and (i)&nbsp;that is referred to or incorporated by reference in the Registration Statement,
the Disclosure Package or the Prospectus, or (ii)&nbsp;is material to the Company&rsquo;s business, has been duly authorized and validly
executed by the Company, is in full force and effect in all material respects and is enforceable against the Company and, to the Company&rsquo;s
knowledge, the other parties thereto, in accordance with its terms, except (x)&nbsp;as such enforceability may be limited by bankruptcy,
insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally, (y)&nbsp;as enforceability of any indemnification
or contribution provision may be limited under the federal or state securities laws, and (z)&nbsp;that the remedy of specific performance
and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before
which any proceeding therefor may be brought. None of such agreements or instruments has been assigned by the Company, and neither the
Company nor, to the Company&rsquo;s knowledge, any other party is in default thereunder and, to the Company&rsquo;s knowledge, no event
has occurred that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder. Performance by the
Company of the material provisions of such agreements or instruments will not result in a material violation of any existing applicable
law, rule, regulation, judgment, order or decree of any governmental or regulatory agency, body or court, domestic or foreign, having
jurisdiction over the Company or any of its assets or business (each, a &ldquo;</FONT>Governmental Entity<FONT STYLE="font-weight: normal">&rdquo;),
including, without limitation, those relating to environmental laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.3.&nbsp;<U>Prior
Securities Transactions</U>. Since January 1, 2022, no securities of the Company have been sold by the Company or by or on behalf of,
or for the benefit of, any person or persons controlling, controlled by or under common control with the Company, except as disclosed
in the Registration Statement, the Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.4.&nbsp;<U>Regulations</U>.
The disclosures in the Registration Statement, the Disclosure Package and the Prospectus concerning the effects of federal, state, local
and all foreign laws, rules and regulations relating to the Company&rsquo;s business as currently conducted or contemplated to be conducted
are correct and complete in all material respects and no other such laws, rules or regulations are required to be disclosed in the Registration
Statement, the Disclosure Package and the Prospectus that are not so disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.5.&nbsp;<U>No
Other Distribution of Offering Materials.</U> The Company has not, directly or indirectly, distributed and will not distribute any offering
material in connection with the Offering other than any Preliminary Prospectus, the Disclosure Package, the Prospectus and other materials,
if any, permitted under the Securities Act and consistent with <U>Section 3.2</U> below. The Company is not an &ldquo;ineligible issuer&rdquo;
in connection with the Offering pursuant to Rules 164, 405 and 433 under the Securities Act. The Company will file with the Commission
all Issuer Free General Use Writing Prospectuses and all Issuer Limited Use Free Writing Prospectuses (other than a &ldquo;road show&rdquo;
as defined in Rule 433(d) of the Securities Act Regulations, if any) in the time and manner required under Rule 433(d) of the Securities
Act Regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.5&nbsp;<U>Changes
After Dates in Registration Statement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.5.1.&nbsp;<U>No
Material Adverse Change</U>. Since the respective dates as of which information is given in the Registration Statement, the Disclosure
Package and the Prospectus, except as otherwise specifically stated therein: (i)&nbsp;there has been no material adverse change in the
financial position or results of operations of the Company and the Subsidiary, nor any change or development that, singularly or in the
aggregate, would involve a material adverse change or a prospective material adverse change, in or affecting the condition (financial
or otherwise), results of operations, business, assets, properties or prospects of the Company and the Subsidiary, taken as a whole (a
&ldquo;</FONT>Material Adverse Change<FONT STYLE="font-weight: normal">&rdquo;); (ii)&nbsp;there have been no material transactions entered
into by the Company, other than as contemplated pursuant to this Agreement; and (iii)&nbsp;no officer or director of the Company or the
Subsidiary has resigned from any position with the Company or such Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.5.2.&nbsp;<U>Recent
Securities Transactions, etc</U>. Subsequent to the respective dates as of which information is given in the Registration Statement, the
Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration
Statement, the Disclosure Package and the Prospectus, the Company has not: (i)&nbsp;issued any securities or incurred any liability or
obligation, direct or contingent, for borrowed money; or (ii)&nbsp;declared or paid any dividend or made any other distribution on or
in respect to its capital stock.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.6&nbsp;<U>Disclosures
in Commission Filings</U>. Since January 1, 2022, (i) none of the Company&rsquo;s filings with the Commission contained any untrue statement
of a material fact or omitted to state any material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading; and (ii) the Company has made all filings with the Commission required under the Exchange
Act and the rules and regulations of the Commission promulgated thereunder (the &ldquo;</FONT><FONT STYLE="font-style: normal">Exchange
Act Regulations<FONT STYLE="font-weight: normal">&rdquo;).</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.7&nbsp;<U>Independent
Accountants</U>. To the Company&rsquo;s knowledge, Farber Hass Hurley LLP (the &ldquo;</FONT><FONT STYLE="font-style: normal">Auditor<FONT STYLE="font-weight: normal">&rdquo;),
whose report is filed with the Commission as part of the Registration Statement, the Disclosure Package and the Prospectus, is an independent
registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting
Oversight Board. The Auditor has not, during the periods covered by the financial statements included in or incorporated by reference
in the Registration Statement, the Disclosure Package and the Prospectus, provided to the Company any prohibited non-audit services, as
such term is used in Section 10A(g) of the Exchange Act.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.8&nbsp;<U>Financial
Statements, etc</U>. The financial statements, including the notes thereto and supporting schedules, included or incorporated by reference
in the Registration Statement, the Disclosure Package and the Prospectus, fairly present the financial position and the results of operations
of the Company at the dates and for the periods to which they apply; and such financial statements have been prepared in conformity with
U.S. generally accepted accounting principles (&ldquo;</FONT><FONT STYLE="font-style: normal">GAAP<FONT STYLE="font-weight: normal">&rdquo;),
consistently applied throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit
adjustments that are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and the supporting
schedules, if any, included or incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus present
fairly the information required to be stated therein. Except as included therein, no historical or pro forma financial statements are
required to be included or incorporated by reference in the Registration Statement, the Disclosure Package or the Prospectus under the
Securities Act or the Securities Act Regulations. All disclosures contained in the Registration Statement, the Disclosure Package or the
Prospectus, or incorporated or deemed incorporated by reference therein, regarding &ldquo;non-GAAP financial measures&rdquo; (as such
term is defined by the rules and regulations of the Commission), if any, comply with Regulation G of the Exchange Act and Item 10 of Regulation
S-K of the Securities Act, to the extent applicable. Each of the Registration Statement, the Disclosure Package and the Prospectus discloses
all material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of
the Company with unconsolidated entities or other persons required to be disclosed under Instruction 8 to Item 303(b) of Regulation S-K
that may have a material current or future effect on the Company&rsquo;s financial condition, changes in financial condition, results
of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed
or incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus, (a) the Company has not incurred
any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the ordinary course
of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect to its capital stock,
(c) there has not been any change in the capital stock of the Company, (d) other than in the ordinary course of business and consistent
with the Company&rsquo;s prior policies, made any grants under any stock compensation plan, and (e) there has not been any material adverse
change in the Company&rsquo;s long-term or short-term debt.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.9&nbsp;<U>Authorized
Capital; Options, etc</U>. The Company had, at the date or dates indicated in the Registration Statement, the Disclosure Package and the
Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions stated in the Registration
Statement, the Disclosure Package and the Prospectus, the Company will have on the Closing Date and each Option Closing Date, if any,
the adjusted stock capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the Disclosure
Package, the Prospectus, as of the Applicable Time and on the Closing Date and any Option Closing Date, there will be no stock options,
warrants, or other rights to purchase or otherwise acquire any authorized, but unissued shares of Common Stock or any security convertible
or exercisable into shares of Common Stock, or any contracts or commitments to issue or sell shares of Common Stock or any such options,
warrants, rights or convertible securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.10&nbsp;<U>Valid
Issuance of Securities, etc.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.10.1.&nbsp;<U>Outstanding
Securities</U>. All issued and outstanding securities of the Company issued prior to the transactions contemplated by this Agreement have
been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights of rescission or the
ability to force the Company to repurchase such securities with respect thereto, and are not subject to personal liability by reason of
being such holders; and none of such securities were issued in violation of the preemptive rights, rights of first refusal or rights of
participation of any holders of any security of the Company or similar contractual rights granted by the Company. The authorized shares
of Common Stock conform in all material respects to all statements relating thereto contained in the Registration Statement, the Disclosure
Package and the Prospectus. The offers and sales of the outstanding shares of Common Stock, options, warrants and other rights to purchase
or exchange such securities for shares of Common Stock were at all relevant times either registered under the Securities Act and the applicable
state securities or &ldquo;blue sky&rdquo; laws or, based in part on the representations and warranties of the purchasers of such shares
of Common Stock, exempt from such registration requirements. The description of the Company&rsquo;s stock option, stock bonus and other
stock plans or arrangements, and the options or other rights granted thereunder, as described in the Registration Statement, the Disclosure
Package and the Prospectus, accurately and fairly present, in all material respects, the information required to be shown with respect
to such plans, arrangements, options and rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.10.2.&nbsp;<U>Securities
Sold Pursuant to this Agreement</U>. The Firm Shares and the Option Shares have been duly authorized for issuance and sale and, when issued
and paid for, will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject to personal liability
by reason of being such holders; the Public Securities and the Underwriter&rsquo;s Securities are not and will not be subject to the preemptive
rights of any holders of any security of the Company or similar contractual rights granted by the Company; and all corporate action required
to be taken for the authorization, issuance and sale of the Public Securities and the Underwriter&rsquo;s Securities has been duly and
validly taken. The Public Securities and the Underwriter&rsquo;s Securities conform in all material respects to all statements with respect
thereto contained in the Registration Statement, the Disclosure Package and the Prospectus. All corporate action required to be taken
for the authorization, issuance and sale of the Warrants and the Underwriter&rsquo;s Warrant has been duly and validly taken; the shares
of Common Stock issuable upon exercise of the Warrants and the Underwriter&rsquo;s Warrant have been duly authorized and reserved for
issuance by all necessary corporate action on the part of the Company and when paid for and issued upon exercise in accordance with the
Warrants and the Underwriter&rsquo;s Warrant, respectively, such shares of Common Stock will be validly issued, fully paid and non-assessable;
the holders thereof will not be subject to personal liability by reason of being such holders; and such shares of Common Stock will not
be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company.
</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.11&nbsp;<U>Registration
Rights of Third Parties</U>. Except as set forth in the Registration Statement, the Disclosure Package and the Prospectus, no holders
of any securities of the Company or any options, warrants, rights or other securities exercisable for or convertible or exchangeable into
securities of the Company have the right to require the Company to register the sale or resale of any such securities of the Company under
the Securities Act or to include any such securities in the Registration Statement or any other registration statement to be filed by
the Company.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.12&nbsp;<U>Validity
and Binding Effect of Agreement</U>. The execution, delivery and performance of this Agreement, the Warrants, the Underwriter&rsquo;s
Warrant and the Warrant Agency Agreement between the Company and the Company&rsquo;s transfer agent (the &ldquo;</FONT><FONT STYLE="font-style: normal">Warrant
Agency Agreement<FONT STYLE="font-weight: normal">&rdquo;) have been duly and validly authorized by the Company, and, when executed and
delivered, will constitute valid and binding agreements of the Company, enforceable against the Company in accordance with their respective
terms, except: (i)&nbsp;as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo;
rights generally; (ii)&nbsp;as enforceability of any indemnification or contribution provision may be limited under the federal or state
securities laws; and (iii)&nbsp;that the remedy of specific performance and injunctive and other forms of equitable relief may be subject
to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.13&nbsp;<U>No
Conflicts, etc</U>. The execution, delivery and performance by the Company of this Agreement, the Warrant Agency Agreement, the Warrants
and the Underwriter&rsquo;s Warrant and all ancillary documents, the consummation by the Company of the transactions herein and therein
contemplated and the compliance by the Company with the terms hereof and thereof do not and will not, with or without the giving of notice
or the lapse of time or both: (i)&nbsp;result in a material breach of, or conflict with any of the terms and provisions of, or constitute
a material default under, or result in the creation, modification, termination or imposition of any lien, charge or encumbrance upon any
property or assets of the Company or the Subsidiary pursuant to the terms of any indenture, mortgage, deed of trust, loan agreement or
any other agreement or instrument to which the Company or the Subsidiary is a party or as to which any property of the Company or the
Subsidiary is a party; (ii)&nbsp;result in any violation of the provisions of the Company&rsquo;s certificate of incorporation (as the
same may be amended or restated from time to time, the &ldquo;</FONT><FONT STYLE="font-style: normal">Charter<FONT STYLE="font-weight: normal">&rdquo;)
or the Company&rsquo;s bylaws (as the same may be amended or restated from time to time, the &ldquo;</FONT>Bylaws<FONT STYLE="font-weight: normal">&rdquo;);
or (iii)&nbsp;violate any existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity as of the date
hereof, except in the case of clauses <U>(i)</U> or <U>(iii)</U>, as would not result in a Material Adverse Change.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.14&nbsp;<U>No
Defaults; Violations</U>. No material default exists, and no event has occurred that, with the lapse of time or the giving of notice,
or both, would constitute a default, in the due performance and observance of any term, covenant or condition of any material license,
contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument evidencing an obligation
for borrowed money, or any other material agreement or instrument to which the Company or the Subsidiary is a party or by which the Company
or the Subsidiary may be bound or to which any of the properties or assets of the Company or the Subsidiary is subject. Neither the Company
nor the Subsidiary is (i) in violation of any term or provision of its Charter or Bylaws, or (ii) in violation of any franchise, license,
permit, applicable law, rule, regulation, judgment or decree of any Governmental Entity, except in the case of clause <U>(ii)</U>, such
as would not result in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.15&nbsp;<U>Corporate
Power; Licenses</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.15.1.&nbsp;<U>Corporate
Power</U>. The Company has all requisite corporate power and authority, as of the date hereof, the Applicable Time, the Closing Date and
any Option Closing Date, to conduct its business as described in the Registration Statement, the Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.15.2.&nbsp;<U>Licenses</U>.
The Company (A) possesses the licenses, permits, certificates, authorizations, consents and approvals (collectively, &ldquo;</FONT>Authorizations<FONT STYLE="font-weight: normal">&rdquo;)
issued by the appropriate Governmental Entities necessary to conduct its business as currently conducted as described in the Registration
Statement, the Disclosure Package and the Prospectus, and (B) has obtained all necessary Authorizations from other persons necessary to
conduct its business, except, in each case of <U>clauses (A)</U> and <U>(B)</U>, (i) as described in the Registration Statement, the Disclosure
Package or the Prospectus or (ii) to the extent that any failure to possess any Authorizations, provide any notice, make any filing, or
obtain any Authorizations would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.
Neither the Company nor the Subsidiary is in violation of, or in default under, any Authorizations, except as would not reasonably be
expected to result in a Material Adverse Change. All of the Authorizations are valid and in full force and effect, except when the invalidity
of such Authorizations or the failure of such Authorizations to be in full force and effect would not, individually or in the aggregate,
reasonably be expected to result in a Material Adverse Change. The Company has not received any notice of proceedings relating to the
revocation or modification of any Authorization which, individually or in the aggregate, if the subject of an unfavorable decision, ruling
or finding, would result in a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.15.3.&nbsp;<U>Transactions
Contemplated Herein</U>. The Company has all corporate power and authority to enter into this Agreement, the Warrant Agency Agreement,
the Warrants and the Underwriter&rsquo;s Warrant and to carry out the provisions and conditions hereof, and all Authorizations required
in connection therewith have been obtained. No authorization of, and no filing with, any Governmental Entity is required for the valid
issuance, sale and delivery of the Public Securities and the Underwriter&rsquo;s Securities and the consummation of the transactions and
agreements contemplated by this Agreement, the Warrant Agency Agreement and the Warrants and as contemplated by the Registration Statement,
the Disclosure Package and the Prospectus, except with respect to applicable federal and state securities laws and the rules and regulations
of the Financial Industry Regulatory Authority, Inc. (&ldquo;</FONT>FINRA<FONT STYLE="font-weight: normal">&rdquo;).</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.16&nbsp;<U>D&amp;O
Questionnaires</U>. To the Company&rsquo;s knowledge, all information contained in the FINRA questionnaires (the &ldquo;</FONT><FONT STYLE="font-style: normal">Questionnaires<FONT STYLE="font-weight: normal">&rdquo;)
completed by each of the Company&rsquo;s directors, officers, and principal shareholders immediately prior to the Offering (the &ldquo;</FONT>Insiders<FONT STYLE="font-weight: normal">&rdquo;)
as supplemented by all information concerning the Company&rsquo;s directors, officers and principal shareholders as described in the Registration
Statement, the Disclosure Package and the Prospectus, as well as in the Lock-Up Agreements (as defined in <U>Section 2.26</U>), provided
to the Underwriter is true and correct in all material respects and the Company has not become aware of any information that would cause
the information disclosed in the Questionnaires to become inaccurate and incorrect in any material respect.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.17&nbsp;<U>Litigation;
Governmental Proceedings</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding
pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or the Subsidiary, or to the Company&rsquo;s
knowledge, any executive officer or director that has not been disclosed in the Registration Statement, the Disclosure Package and the
Prospectus, which if resolved adversely to the Company is reasonably likely to result in a Material Adverse Change or is required to be
disclosed. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.18&nbsp;<U>Good
Standing</U>. Each of the Company and the Subsidiary has been duly organized and is validly existing as a corporation and is in good standing
under the laws of its jurisdiction of incorporation as of the date hereof, and is duly qualified to do business and is in good standing
in each other jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except
where the failure to qualify, singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse
Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.19&nbsp;<U>Insurance</U>.
Each of the Company and the Subsidiary carries or is entitled to the benefits of insurance (including, without limitation, as to directors
and officers insurance coverage) with reputable insurers, in such amounts and covering such risks which the Company reasonably believes
are adequate, and all such insurance is in full force and effect. Neither the Company nor the Subsidiary have any reason to believe that
it will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage
from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result
in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.20&nbsp;<U>Transactions
Affecting Disclosure to FINRA</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.1.&nbsp;<U>Finder&rsquo;s
Fees</U>. There are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder&rsquo;s, consulting
or origination fee by the Company, the Subsidiary or any Insider with respect to the sale of the Public Securities hereunder or any other
arrangements, agreements or understandings of the Company or, to the Company&rsquo;s knowledge, any of its shareholders that may affect
the Underwriter&rsquo;s compensation, as determined by FINRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.2.&nbsp;<U>Payments
Within Twelve (12) Months</U>. The Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i)&nbsp;any
person, as a finder&rsquo;s fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing
to the Company persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii)&nbsp; any person or entity that
has any direct or indirect affiliation or association with any FINRA member, within the twelve (12) months prior to the date of the Prospectus
Supplement, other than the payment to the Underwriter as provided hereunder in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.3.&nbsp;<U>Use
of Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its affiliates,
except as specifically authorized herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.4.&nbsp;<U>FINRA
Affiliation</U>. There is no officer or director of the Company or beneficial owner of 10% or more of any class of the Company&rsquo;s
securities or equity-linked securities that is an affiliate or associated person of a FINRA member participating in the Offering (as determined
in accordance with the rules and regulations of FINRA). Neither the Company nor any of its affiliates (within the meaning of FINRA&rsquo;s
Conduct Rule 5121(f)(i)) directly or indirectly controls, is controlled by, or is under common control with, or is an associated person
(within the meaning of Article 1, Section 1(ee) of the By-Laws of FINRA) of, any member of FINRA participating in the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.5.&nbsp;<U>Information</U>.
All information provided by the Company in its FINRA questionnaire to Underwriter&rsquo;s Counsel specifically for use by Underwriter&rsquo;s
Counsel in connection with its Public Offering System filings (and related disclosure) with FINRA is true, correct and complete in all
material respects.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.21&nbsp;<U>Foreign
Corrupt Practices Act</U>. Neither the Company, the Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent, employee
or affiliate of the Company, the Subsidiary nor any other person acting on behalf of the Company or the Subsidiary, has, directly or indirectly,
given or agreed to give any money, gift or similar benefit (other than legal price concessions to customers in the ordinary course of
business) to any customer, supplier, employee or agent of a customer or supplier, or official or employee of any governmental agency or
instrumentality of any government (domestic or foreign) or any political party or candidate for office (domestic or foreign) or other
person who was, is, or may be in a position to help or hinder the business of the Company or the Subsidiary (or assist it in connection
with any actual or proposed transaction) that (i)&nbsp;might subject the Company or the Subsidiary to any damage or penalty in any civil,
criminal or governmental litigation or proceeding, (ii)&nbsp;if not given in the past, might have had a Material Adverse Change or (iii)&nbsp;if
not continued in the future, might adversely affect the assets, business, operations or prospects of the Company or the Subsidiary. Each
of the Company and each Subsidiary has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to
cause the Company and the Subsidiary to comply in all material respects with the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.22&nbsp;<U>Compliance
with OFAC</U>. Neither the Company, the Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent, employee or affiliate
of the Company, the Subsidiary nor any other person acting on behalf of the Company or the Subsidiary, is currently subject to any U.S.
sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;</FONT><FONT STYLE="font-style: normal">OFAC<FONT STYLE="font-weight: normal">&rdquo;),
and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person
currently subject to any U.S. sanctions administered by OFAC.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.23&nbsp;<U>Money
Laundering Laws</U>. To the Company&rsquo;s knowledge after due inquiry, the operations of the Company and the Subsidiary are and have
been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign
Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder
and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively,
the &ldquo;</FONT><FONT STYLE="font-style: normal">Money Laundering Laws<FONT STYLE="font-weight: normal">&rdquo;); and no action, suit
or proceeding by or before any Governmental Entity involving the Company or the Subsidiary with respect to the Money Laundering Laws is
pending or, to the best knowledge of the Company, threatened.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.24&nbsp;<U>Forward-Looking
Statements</U>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) contained in either the Registration Statement, the Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable
basis or has been disclosed other than in good faith.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.25&nbsp;<U>Officers&rsquo;
Certificate</U>. Any certificate pursuant to this Agreement signed by any duly authorized officer of the Company and delivered to you
or to Underwriter&rsquo;s Counsel shall be deemed a representation and warranty by the Company to the Underwriter as to the matters covered
thereby.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.26&nbsp;<U>Lock-Up
Agreements. Schedule 2</U> hereto contains a complete and accurate list of the Company&rsquo;s executive officers and directors as well
as any stockholders deemed to be affiliates through their ownership of shares of the Company&rsquo;s Common Stock (collectively, the &ldquo;</FONT><FONT STYLE="font-style: normal">Lock-Up
Parties<FONT STYLE="font-weight: normal">&rdquo;). The Company has caused each of the Lock-Up Parties to deliver to the Underwriter an
executed Lock-Up Agreement, in the form attached hereto as <U>Exhibit B</U> (the &ldquo;</FONT>Lock-Up Agreement<FONT STYLE="font-weight: normal">&rdquo;),
prior to the execution of this Agreement. </FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.27&nbsp;<U>Subsidiaries</U>.
The Company owns all of the capital stock and/or the equity interests in Quasuras, Inc., a Delaware corporation (the &ldquo;</FONT><FONT STYLE="font-style: normal">Subsidiary<FONT STYLE="font-weight: normal">&rdquo;).
The Company has no other interest, nominal or beneficial, direct or indirect, in any other corporation, partnership, limited liability
company, joint venture or other business entity. All of the outstanding shares of capital stock and/or equity interests of the Subsidiary
have been duly authorized and validly issued, are fully paid and non-assessable and, except to the extent set forth in the Registration
Statement or the Prospectus, are owned by the Company directly or indirectly through one or more wholly-owned subsidiaries, free and clear
of any claim, lien, encumbrance, security interest, restriction upon voting or transfer or any other claim of any third party. Except
as disclosed in the Registration Statement or the Prospectus, no director, officer, or key employee of the Company named in the Prospectus
holds any direct equity, debt or other pecuniary interest in the Subsidiary or, to the best of the Company&rsquo;s knowledge, any individual
or entity with whom the Company or the Subsidiary does business or with which it is in privity of contract.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.28&nbsp;<U>Related
Party Transactions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.1.&nbsp;<U>Business
Relationships</U>. There are no business relationships or related party transactions involving the Company or the Subsidiary or any other
person required to be described in the Registration Statement, the Disclosure Package and the Prospectus that have not been described
as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.2.&nbsp;<U>No
Relationships with Customers and Suppliers</U>. No relationship, direct or indirect, exists between or among the Company or the Subsidiary
on the one hand, and the directors, officers, 5% or greater shareholders, customers or suppliers of the Company or the Subsidiary or any
of the Company&rsquo;s affiliates on the other hand, which is required to be described in the Registration Statement, the Disclosure Package
and the Prospectus or a document incorporated by reference therein and which is not so described.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.3.&nbsp;<U>No
Unconsolidated Entities</U>. There are no transactions, arrangements or other relationships between and/or among the Company or the Subsidiary,
any of the Company&rsquo;s affiliates (as such term is defined in Rule 405 of the Securities Act) and any unconsolidated entity, including,
but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially
affect the Company&rsquo;s liquidity or the availability of or requirements for its capital resources required to be described in the
Disclosure Package and the Prospectus or a document incorporated by reference therein which have not been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.4.&nbsp;<U>No
Loans or Advances to Affiliates</U>. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary
course of business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers or directors of the Company
or any of their respective family members, except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus.
All transactions by the Company with its officers or directors or control persons of the Company have been duly approved by the Board
of Directors of the Company.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.29&nbsp;<U>Board
of Directors</U>. The Board of Directors of the Company is comprised of the persons set forth in the Registration Statement, each Preliminary
Prospectus and the Prospectus. The qualifications of the persons serving as board members and the overall composition of the board comply
with the Exchange Act, the rules and regulations of the Commission under the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002
and the rules promulgated thereunder (the &ldquo;</FONT><FONT STYLE="font-style: normal">Sarbanes-Oxley Act<FONT STYLE="font-weight: normal">&rdquo;)
applicable to the Company and the listing rules of the NasdaqCM. At least one member of the Audit Committee of the Board of Directors
of the Company qualifies as an &ldquo;audit committee financial expert,&rdquo; as such term is defined under Regulation S-K and the listing
rules of the NasdaqCM. In addition, at least a majority of persons serving on the Board of Directors qualify as &ldquo;independent,&rdquo;
as defined under the listing rules of the NasdaqCM.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.30&nbsp;<U>Sarbanes-Oxley
Compliance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.30.1.&nbsp;<U>Disclosure
Controls</U>. The Company has developed and currently maintains disclosure controls and procedures that comply with Rule 13a-15 or 15d-15
under the Exchange Act Regulations, and such controls and procedures are effective to ensure that information required to be disclosed
by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within
the time periods specified in the Commission&rsquo;s rules and forms and includes, without limitation, controls and procedures designed
to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated
and communicated to the Company&rsquo;s management, including its principal executive and principal financial officers, or persons performing
similar functions, as appropriate to allow timely decisions regarding required disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.30.2.&nbsp;<U>Compliance</U>.
The Company is, or at the Applicable Time and on the Closing Date and each Option Closing Date, if any, will be, in material compliance
with the provisions of the Sarbanes-Oxley Act applicable to it, and has implemented or will implement such programs and taken reasonable
steps to ensure the Company&rsquo;s future compliance (not later than the relevant statutory and regulatory deadlines therefor) with all
of the material provisions of the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.31&nbsp;<U>Accounting
Controls</U>. The Company maintains systems of &ldquo;internal control over financial reporting&rdquo; (as defined under Rules 13a-15
and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act and have been designed by, or under
the supervision of, its principal executive and principal financial officer, or persons performing similar functions, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles and includes those policies and procedures that: (1) pertain to the maintenance of records
that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management
and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use or disposition of the Company&rsquo;s assets that could have a material effect on the financial statements. Except as disclosed in
the Registration Statement, the Disclosure Package and the Prospectus, the Company is not aware of any material weaknesses in its internal
controls. The Company&rsquo;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all
significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are known
to the Company&rsquo;s management and that have adversely affected or are reasonably likely to adversely affect the Company&rsquo;s ability
to record, process, summarize and report financial information; and (ii) any fraud known to the Company&rsquo;s management, whether or
not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal controls over financial
reporting.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.32&nbsp;<U>No
Investment Company Status</U>. The Company is not and, after giving effect to the Offering and the application of the proceeds thereof
as described in the Registration Statement, the Disclosure Package and the Prospectus, will not be, required to register as an &ldquo;investment
company,&rdquo; as defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.33&nbsp;<U>No
Labor Disputes</U>. No labor dispute with the employees of the Company or the Subsidiary exists or, to the knowledge of the Company or
the Subsidiary, is imminent. The Company is not aware that any key employee or significant group of employees of the Company or the Subsidiary
plans to terminate employment with the Company or the Subsidiary.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.34&nbsp;<U>Intellectual
Property Rights</U>. The Company owns or possesses or has valid rights to use all patents, patent applications, trademarks, service marks,
trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade secrets software, databases,
know-how, internet domain names, other unpatented and/or unpatentable proprietary confidential information systems, processes or procedures
and similar rights (&ldquo;</FONT><FONT STYLE="font-style: normal">Intellectual Property Rights<FONT STYLE="font-weight: normal">&rdquo;)
necessary for the conduct of the business of the Company and the Subsidiary as currently carried on and as described in the Registration
Statement, the Disclosure Package and the Prospectus. The Intellectual Property Rights licenses described in the Registration Statement,
Disclosure Package and the Prospectus are valid, binding upon and enforceable against the parties thereto in accordance with their respective
terms. To the knowledge of the Company, no action or use by the Company or the Subsidiary necessary for the conduct of its business as
currently carried on and as described in the Registration Statement, the Disclosure Package and the Prospectus will involve or give rise
to any infringement of, or license or similar fees for, any Intellectual Property Rights of others. None of the Company nor the Subsidiary
has received any notice alleging any such infringement, fee or conflict with asserted Intellectual Property Rights of others. Except as
would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change (A) to the knowledge of the
Company, there is no infringement, misappropriation or violation by third parties of any of the Intellectual Property Rights owned by
the Company or the Subsidiary; (B) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim
by others challenging the rights of the Company or the Subsidiary in or to any such Intellectual Property Rights, and the Company is unaware
of any facts which would form a reasonable basis for any such claim, that would, individually or in the aggregate, together with any other
claims in this <U>Section 2.34</U>, reasonably be expected to result in a Material Adverse Change; (C) the Intellectual Property Rights
owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company or the Subsidiary
have not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or,
to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such
Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim that would,
individually or in the aggregate, together with any other claims in this <U>Section 2.34</U>, reasonably be expected to result in a Material
Adverse Change; (D) there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others that
the Company or the Subsidiary infringes, misappropriates or otherwise violates any Intellectual Property Rights or other proprietary rights
of others, none of the Company nor the Subsidiary has received any written notice of such claim and the Company is unaware of any other
facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together with any other claims
in this <U>Section 2.34</U>, reasonably be expected to result in a Material Adverse Change; and (E) to the Company&rsquo;s knowledge,
no employee of the Company or the Subsidiary is in or has ever been in violation in any material respect of any term of any employment
contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure
agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&rsquo;s
employment with the Company or the Subsidiary, or actions undertaken by the employee while employed with the Company or the Subsidiary
and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change. To the Company&rsquo;s knowledge,
all material technical information developed by and belonging to the Company or the Subsidiary which has not been patented has been kept
confidential. None of the Company nor the Subsidiary is a party to or bound by any options, licenses or agreements with respect to the
Intellectual Property Rights of any other person or entity that are required to be set forth in the Registration Statement, the Disclosure
Package and the Prospectus and are not described therein. The Registration Statement, the Disclosure Package and the Prospectus contain
in all material respects the same description of the matters set forth in the preceding sentence. None of the technology employed by the
Company or the Subsidiary has been obtained or is being used by the Company in violation of any contractual obligation binding on the
Company or the Subsidiary or, to the Company&rsquo;s knowledge, any of their officers, directors or employees, or otherwise in violation
of the rights of any persons. </FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.35&nbsp;<U>Taxes</U>.
Each of the Company and the Subsidiary has filed all returns (as hereinafter defined) required to be filed with taxing authorities prior
to the date hereof or has duly obtained extensions of time for the filing thereof. Each of the Company and the Subsidiary has paid all
taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against the
Company or the Subsidiary. The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Registration
Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of
such consolidated financial statements. Except as disclosed in writing to the Underwriter, (i) no issues have been raised (and are currently
pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company or the Subsidiary, and
(ii) no waivers of statutes of limitation with respect to the returns or collection of taxes have been given by or requested from the
Company or the Subsidiary. There are no tax liens against the assets, properties or business of the Company or the Subsidiary. The term
&ldquo;</FONT><FONT STYLE="font-style: normal">taxes<FONT STYLE="font-weight: normal">&rdquo; means all federal, state, local, foreign
and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service
use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other
taxes, fees, assessments or charges of any kind whatever, together with any interest and any penalties, additions to tax or additional
amounts with respect thereto. The term &ldquo;</FONT>returns<FONT STYLE="font-weight: normal">&rdquo; means all returns, declarations,
reports, statements and other documents required to be filed in respect to taxes.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.36&nbsp;<U>Compliance
with Environmental Laws</U>. Except as described in the Registration Statement, the Disclosure Package and the Prospectus and except as
would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Change, (i) none of the Company nor the
Subsidiary n is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of
common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or
judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water,
groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release
or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products
(collectively, &ldquo;</FONT><FONT STYLE="font-style: normal">Hazardous Materials<FONT STYLE="font-weight: normal">&rdquo;) or to the
manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively,
&ldquo;</FONT>Environmental Laws<FONT STYLE="font-weight: normal">&rdquo;), (ii) each of the Company and the Subsidiary has all material
permits, authorizations and approvals required under any applicable Environmental Laws and is in compliance with their requirements, (iii)
there are no pending or, to the Company&rsquo;s knowledge, threatened administrative, regulatory or judicial actions, suits, demands,
demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against
the Company or the Subsidiary and (iv) to the Company&rsquo;s knowledge, there are no events, conditions, incidents or circumstances that
might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private
party or governmental body or agency, against or affecting the Company or the Subsidiary relating to Hazardous Materials or any Environmental
Laws.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.37&nbsp;<U>ERISA
Compliance</U>. The Company, each Subsidiary and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement Income
Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;</FONT><FONT STYLE="font-style: normal">ERISA<FONT STYLE="font-weight: normal">&rdquo;))
established or maintained by the Company or its &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance in all material respects
with ERISA. &ldquo;</FONT>ERISA Affiliate<FONT STYLE="font-weight: normal">&rdquo; means, with respect to the Company, any member of any
group of organizations described in Sections 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations
and published interpretations thereunder (the &ldquo;</FONT>Code<FONT STYLE="font-weight: normal">&rdquo;) of which the Company is a member.
No &ldquo;reportable event&rdquo; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any &ldquo;employee
benefit plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates. No &ldquo;employee benefit plan&rdquo; established
or maintained by the Company or any of its ERISA Affiliates, if such &ldquo;employee benefit plan&rdquo; were terminated, would have any
&ldquo;amount of unfunded benefit liabilities&rdquo; (as defined under ERISA). Neither the Company nor any of its ERISA Affiliates has
incurred or reasonably expects to incur any material liability under (i) Title IV of ERISA with respect to termination of, or withdrawal
from, any &ldquo;employee benefit plan&rdquo; or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each &ldquo;employee benefit plan&rdquo;
established or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code
is so qualified and, to the knowledge of the Company, nothing has occurred, whether by action or failure to act, which would cause the
loss of such qualification. The execution of this Agreement, or consummation of the Offering does not constitute a triggering event under
any employee benefit plan or any other employment contract, whether or not legally enforceable, which (either alone or upon the occurrence
of any additional or subsequent event) will or may result in any payment (of severance pay or otherwise), acceleration, increase in vesting,
or increase in benefits to any current or former participant, employee or director of the Company other than an event that is not material
to the financial condition or business of the Company and the Subsidiary taken as a whole.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.38&nbsp;<U>Compliance
with Laws</U>. Each of the Company and the Subsidiary: (A) is and at all times has been in material compliance with all statutes, rules,
or regulations applicable to the conduct of the business of the Company or the Subsidiary (collectively, the &ldquo;</FONT><FONT STYLE="font-style: normal">Applicable
Laws<FONT STYLE="font-weight: normal">&rdquo;), except as could not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Change; (B) has not received any warning letter, untitled letter or other correspondence or notice from any other Governmental
Entity alleging or asserting noncompliance with any Applicable Laws or any Authorizations; (C) possesses all material Authorizations and
such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations;
(D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from
any Governmental Entity or third party alleging that any of the Company&rsquo;s activities is in violation of any Applicable Laws or Authorizations
and has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action,
suit, investigation or proceeding; (E) has not received notice that any Governmental Entity has taken, is taking or intends to take action
to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such governmental authority is considering such action;
and (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected
or supplemented by a subsequent submission).</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.39&nbsp;<U>Company
IT Systems</U>. Except as described in the Registration Statement, the Disclosure Package and the Prospectus, the Company owns or has
a valid right to access and use all computer systems, networks, hardware, software, databases, websites and equipment used to process,
store, maintain and operate data, information and functions necessary for the conduct of its business (the &ldquo;</FONT><FONT STYLE="font-style: normal">Company
IT Systems<FONT STYLE="font-weight: normal">&rdquo;), except where the failure to own or have the right to access the Company IT Systems
would not reasonably be expected to have a Material Adverse Change. The Company IT Systems are adequate for, and operate and perform in
all material respects as required in connection with, the operation of the business of the Company as currently conducted except as would
not be reasonably expected, individually or in the aggregate, to have a Material Adverse Change.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.40&nbsp;<U>Health
Care Authorizations</U>. The Company currently complies in all material respects with applicable laws and regulations governing its business
and, to the extent any valid and current registrations, listings, approvals, clearances, licenses, certificates, authorizations or permits
and supplements or amendments thereto (collectively, &ldquo;</FONT><FONT STYLE="font-style: normal">Health Care Authorizations<FONT STYLE="font-weight: normal">&rdquo;)
become necessary to conduct its business as described in the Registration Statement, the Disclosure Package and the Prospectus, the Company
either had obtained or will obtain such Health Care Authorizations from the appropriate local, state, federal, national, supranational
or other foreign regulatory agencies or bodies (collectively, &ldquo;</FONT>Health Regulatory Agencies<FONT STYLE="font-weight: normal">&rdquo;),
including, without limitation, all such Health Care Authorizations required by the U.S. Food and Drug Administration (the &ldquo;</FONT>FDA<FONT STYLE="font-weight: normal">&rdquo;),
the Department of Health and Human Services, the European Commission, the EMA or any other Health Regulatory Agencies engaged in the regulation
of Biologics (as defined in the Public Health Service Act of 1944, as amended (42 U.S.C. 6A et seq.)), except as would not be reasonably
expected to result in a Material Adverse Change. The Company has not received any notice of proceedings, or have any knowledge of any
threatened proceedings, relating to the revocation or modification of, or non-compliance with, any such Health Care Authorization, except
where such revocation, modification or non-compliance would not result in a Material Adverse Change.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.41&nbsp;<U>Compliance
with Health Care Laws</U>. The Company is, and has been, in compliance in all material respects with all applicable Health Care Laws,
and has not engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive
exclusion from Medicare, Medicaid or any other state, federal or national health care program. For purposes of this Agreement, &ldquo;</FONT><FONT STYLE="font-style: normal">Health
Care Laws<FONT STYLE="font-weight: normal">&rdquo; means all health care laws and regulations applicable to the Company, including, but
not limited to: the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), the Anti-Kickback Statute (42 U.S.C. Section
1320a-7b(b)), the Civil Monetary Penalties Law (42 U.S.C. &sect; 1320a-7a), the Physician Payments Sunshine Act (42 U.S.C. &sect; 1320a-7h),
the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal
laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal
provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&ldquo;</FONT>HIPAA<FONT STYLE="font-weight: normal">&rdquo;)
(42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C. &sect; 1320a-7), Basic Health and Human Services Policy for Protection
of Human Research Subjects &ldquo;Common Rule&rdquo; as codified and enforced by the Department of Health and Human Services in 45 C.F.R.
part 46 and enforced by FDA under 21 C.F.R. part 50, Laboratory Animal Welfare Act of 1966, HIPAA, as amended by the Health Information
Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.), the Controlled Substances Act (2 U.S.C. &sect; 801,
et seq.), Good Manufacturing Practices (21 C.F.R. &sect;&sect;210 &amp; 211), Medicare (Title XVIII of the Social Security Act), Medicaid
(Title XIX of the Social Security Act), any and all other applicable comparable local, state, federal, national, supranational and foreign
health care laws and the regulations promulgated pursuant to such laws, each as amended from time to time. The Company has not received
written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court
or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in material violation
of any Health Care Laws, and, to the knowledge of the Company, no such claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action is threatened. The Company has not received any written notice of adverse filing, warning letter, untitled
letter or other correspondence or notice from the FDA, the European Commission, the EMA, or any other Health Regulatory Agencies, or any
other court or arbitrator, alleging or asserting material noncompliance with the Health Care Laws. The Company is not a party to and has
no ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements,
consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental or regulatory authority.
Additionally, neither the Company, nor, to the knowledge of the Company, any of its employees, officers or directors has been excluded,
suspended or debarred from participation in any U.S. federal health care program or human research study or trial or, to the knowledge
of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected
to result in debarment, suspension or exclusion.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.42&nbsp;<U>Research
Studies and Trials</U>. (A) The research studies and trials conducted by or, to the Company&rsquo;s knowledge, on behalf of, or sponsored
by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Disclosure Package or
the Prospectus, or the results of which are referred to in the Registration Statement, the Disclosure Package or the Prospectus, as applicable,
were and, if still pending, are being, conducted in all material respects in accordance with applicable experimental protocols, procedures
and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable
to those being developed by the Company and all applicable statutes, rules and other regulations of the FDA, National Institute of Health
Department of Health and Human Services, the European Commission, the EMA, and any other Health Regulatory Agencies to which it is subject;
(B) the descriptions of the results of such studies and trials contained in the Registration Statement, the Disclosure Package and the
Prospectus do not contain any misstatement of a material fact or omit to state a material fact necessary to make such statements not misleading;
(C) the Company has no knowledge of any research studies or trials not described in the Registration Statement, the Disclosure Package
or the Prospectus the results of which reasonably call into question in any material respect the results of the research studies and trials
described in the Registration Statement, the Disclosure Package or the Prospectus or that suggest a reasonable possibility of any adverse
side effects not described in the Registration Statement, the Disclosure Package and the Prospectus; (D) the Company has not received
any notices or correspondence from the FDA, the European Commission, the EMA, or any Health Regulatory Agency or any institutional review
board or comparable authority requiring or threatening the premature termination, suspension, material modification or clinical hold of
any research studies or trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated that
are described in the Registration Statement, the Disclosure Package or the Prospectus, and, to the Company&rsquo;s knowledge, there are
no reasonable grounds for the same; (E) there has not been any violation of applicable law or regulation by the Company in any of its
product development efforts, submissions or reports to the FDA, the European Commission, the EMA, or any other Health Regulatory Agency
that could reasonably be expected to require investigation, corrective action or result in enforcement action, except where such violation
would not, singly or in the aggregate, result in a Material Adverse Change; and (F) the research studies and clinical trials of Company
are being conducted in an ethical and humane manner under state, national or supra-national applicable laws that are either equal or more
stringent than applicable laws and regulations enforced by the Department of Health and Human Services and FDA governing human, animal
or non-human primate research participants and test subjects and such studies and the clinical trials are conducted under the auspices
of a neutral and independent Institutional Animal Care and Use Committee or Institutional Review Board and applicable state, national,
or supra national agencies responsible for oversight</FONT><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.43&nbsp;<U>Health
Care Products Manufacturing</U>. The manufacture of the Company&rsquo;s products by the Company or, to the knowledge of the Company, on
behalf of the Company, is being conducted in compliance with all applicable Health Care Laws pertaining to the manufacture and post market
surveillance of Drugs, Devices, and Biologics, including, without limitation, the FDA&rsquo;s current good manufacturing practice regulations
pertaining to drugs (21 CFR Parts 210 and 211 et seq.), and, to the extent applicable, the respective counterparts governing manufacturing
operations promulgated by other Health Regulatory Agencies. Except as disclosed in the Registration Statement, the Disclosure Package
and the Prospectus, the Company has not had any manufacturing site (whether owned by the Company or, to the knowledge of the Company,
that of a third party manufacturer of the Company&rsquo;s products) subject to an FDA or other Health Regulatory Agency consent decree,
seizure, import alert, or export prohibition, nor received any FDA or other Health Regulatory Agency &ldquo;warning letters,&rdquo; or
&ldquo;untitled letters&rdquo; alleging or asserting material noncompliance with any applicable Health Care Laws, requests to make material
changes to the Company&rsquo;s products, processes or operations from the FDA or other Health Regulatory Agency, other than those that
have been satisfactorily addressed and/or closed with the FDA or other Health Regulatory Agency. To the knowledge of the Company, none
of the FDA or any other Health Regulatory Agency is considering such action.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.44&nbsp;<U>Smaller
Reporting Company</U>.&nbsp; As of the time of filing of the Registration Statement and the date of this Agreement, the Company was a
&ldquo;smaller reporting company,&rdquo; as defined in Rule&nbsp;12b-2 of the Exchange Act Regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.45&nbsp;<U>Industry
Data</U>.&nbsp; The statistical and market-related data included in each of the Registration Statement, the Disclosure Package and the
Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate or represent
the Company&rsquo;s good faith estimates that are made on the basis of data derived from such sources.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.46&nbsp;<U>Margin
Securities</U>. None of the Company nor the Subsidiary owns any &ldquo;margin securities&rdquo; as that term is defined in Regulation
U of the Board of Governors of the Federal Reserve System (the &ldquo;</FONT><FONT STYLE="font-style: normal">Federal Reserve Board<FONT STYLE="font-weight: normal">&rdquo;),
and none of the proceeds of the Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security,
for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for
any other purpose which might cause any of the shares of Common Stock to be considered a &ldquo;purpose credit&rdquo; within the meanings
of Regulation T, U or X of the Federal Reserve Board.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.47&nbsp;<U>Integration</U>.
None of the Company nor the Subsidiary or affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any
offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering to be integrated
with prior offerings by the Company for purposes of the Securities Act that would require the registration of the offering of any such
securities under the Securities Act.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.48&nbsp;<U>Title
to Real and Personal Property</U>. Each of the Company and the Subsidiary has good and marketable title in fee simple to, or has valid
rights to lease or otherwise use, all items of real or personal property that are material to the business of the Company and the Subsidiary
taken as a whole, free and clear of all liens, encumbrances, security interests, claims and defects that do not, singularly or in the
aggregate, result in a Material Adverse Change and do not interfere with the use made of such property by the Company or the Subsidiary;
and all of the leases and subleases material to the business of the Company and the Subsidiary taken as a whole, and under which the Company
or the Subsidiary holds properties described in the Registration Statement, the Disclosure Package and the Prospectus, are, to the Company&rsquo;s
knowledge in full force and effect, and neither the Company nor the Subsidiary has received any notice of any material claim of any sort
that has been asserted by anyone adverse to the rights of the Company or the Subsidiary under any of the leases or subleases mentioned
above, or affecting or questioning the rights of the Company or the Subsidiary to the continued possession of the leased or subleased
premises under any such lease or sublease, which would result in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.49&nbsp;<U>Confidentiality
and Non-Competition Agreements</U>. To the Company&rsquo;s knowledge, no director, officer, key employee or consultant of the Company
or the Subsidiary is subject to any confidentiality, non-disclosure, non-competition agreement or non-solicitation agreement with any
employer or prior employer that could materially affect his ability to be and act in his respective capacity of the Company or the Subsidiary
or be expected to result in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.50&nbsp;<U>Corporate
Records</U>. The minute books of the Company and each Subsidiary have been made available to the Underwriter and the Underwriter&rsquo;s
Counsel, and such books (i) contain a summary of all meetings and actions of the board of directors (including each board committee) and
shareholders of the Company, and (ii) reflect all material transactions referred to in such minutes.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.51&nbsp;<U>Diligence
Materials</U>. The Company has provided to the Company and the Underwriter&rsquo;s Counsel all materials responsive in all material respects
to the diligence requests, if any, submitted to the Company or its counsel by the Underwriter.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.52&nbsp;<U>Nasdaq
Marketplace Rules</U></FONT><FONT STYLE="font-weight: normal">.<FONT STYLE="font-style: normal">&nbsp;Except as set forth in the Registration
Statement, the Disclosure Package and the Prospectus, the Company is, and after giving effect to the Offering will be, in compliance
in all material respects with all applicable corporate governance requirements set forth in the Nasdaq Marketplace Rules.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-weight: normal">3.<U></U>&nbsp;<U>Covenants
of the Company</U>. The Company covenants and agrees as follows:</FONT></P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.1&nbsp;<U>Amendments
to Registration Statement</U>. The Company shall deliver to the Underwriter, prior to filing, any amendment or supplement to the Registration
Statement, any Preliminary Prospectus, any issuer Free Writing Prospectus, the Disclosure Package or the Prospectus proposed to be filed
after the date of this Agreement and not file any such amendment, supplement or document to which the Underwriter shall reasonably object
in writing. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.2&nbsp;<U>Federal
Securities Laws</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.1.&nbsp;<U>Compliance</U>.
The Company, subject to <U>Section 3.2.2</U>, shall comply with the requirements of Rule 424(b) and Rule 430B of the Securities Act Regulations,
and will notify the Underwriter promptly, and confirm the notice in writing, (i)&nbsp;when any post-effective amendment to the Registration
Statement or any amendment or supplement to any Preliminary Prospectus, the Disclosure Package or the Prospectus shall have been filed
and when any post-effective amendment to the Registration Statement shall become effective; (ii)&nbsp;of the receipt of any comments from
the Commission; (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement
to any Preliminary Prospectus, the Disclosure Package or the Prospectus or for additional information; (iv)&nbsp;of the issuance by the
Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order
preventing or suspending the use of any Preliminary Prospectus or the Prospectus, or of the suspension of the qualification of the Public
Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or
of any examination pursuant to Section&nbsp;8(d) or 8(e) of the Securities Act concerning the Registration Statement; and (v)&nbsp;if
the Company becomes the subject of a proceeding under Section 8A of the Securities Act in connection with the Offering of the Public Securities.
The Company shall effect all filings required under Rule 424(b) of the Securities Act Regulations, in the manner and within the time period
required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps as it deems necessary to ascertain promptly whether
the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was
not, it will promptly file such prospectus. The Company shall use its commercially reasonable efforts to prevent the issuance of any stop
order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.2.&nbsp;<U>Continued
Compliance</U>. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the Exchange Act
Regulations so as to permit the completion of the distribution of the Public Securities as contemplated in this Agreement and in the Registration
Statement, the Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Public Securities is (or, but for
the exception afforded by Rule 172 of the Securities Act Regulations (&ldquo;</FONT>Rule 172<FONT STYLE="font-weight: normal">&rdquo;),
would be) required by the Securities Act to be delivered in connection with sales of the Public Securities, any event shall occur or condition
shall exist as a result of which it is necessary, in the opinion of Underwriter&rsquo;s Counsel or Company Counsel (as defined below),
to (i)&nbsp;amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii)&nbsp;amend
or supplement the Disclosure Package or the Prospectus in order that the Disclosure Package or the Prospectus, as the case may be, will
not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein
not misleading in the light of the circumstances existing at the time it is delivered to a purchaser; or (iii)&nbsp;amend the Registration
Statement or amend or supplement the Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements
of the Securities Act or the Securities Act Regulations, the Company will promptly (A)&nbsp;give the Underwriter notice of such event;
(B)&nbsp;prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration Statement,
the Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or
use, furnish the Underwriter with copies of any such amendment or supplement; and (C)&nbsp;file with the Commission any such amendment
or supplement; <I>provided, however</I>, that the Company shall not file or use any such amendment or supplement to which the Underwriter
or Underwriter&rsquo;s Counsel shall reasonably object. The Company will furnish to the Underwriter such number of copies of such amendment
or supplement as the Underwriter may reasonably request. The Company will give the Underwriter notice of its intention to make any such
filing from the Applicable Time until the earlier of the last Option Closing Date, if any, and the expiration date of the Over-allotment
Option and will furnish the Underwriter with copies of the related document(s) a reasonable amount of time prior to such proposed filing,
as the case may be, and will not file or use any such document to which the Underwriter or Underwriter&rsquo;s Counsel shall reasonably
object. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.3.&nbsp;<U>Exchange
Act Registration</U>. For a period of two (2) years after the date of this Agreement, the Company shall use its commercially reasonable
efforts to maintain the registration of the Common Stock under the Exchange Act. The Company shall not deregister the Common Stock under
the Exchange Act without the prior written consent of the Underwriter, which consent shall not unreasonably be withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.3.1.&nbsp;<U>Free
Writing Prospectuses.</U>&nbsp;The Company agrees that, unless it obtains the prior written consent of the Underwriter, it shall not make
any offer relating to the Public Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute
a &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission or retained by
the Company under Rule 433; <I><U>provided</U></I> that the Underwriter shall be deemed to have consented to each Issuer General Use Free
Writing Prospectus listed in <U>Schedule 1-B</U> and any &ldquo;road show that is a written communication&rdquo; within the meaning of
Rule 433(d)(8)(i) that has been reviewed by the Underwriter. The Company represents that it has treated or agrees that it will treat each
such free writing prospectus consented to, or deemed consented to, by the Underwriter as an &ldquo;issuer free writing prospectus,&rdquo;
as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including
timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing
Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would
conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact
or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
existing at that subsequent time, not misleading, the Company will promptly notify the Underwriter and will promptly amend or supplement,
at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.3&nbsp;<U>Delivery
to the Underwriter of Registration Statements</U>. The Company has delivered or made available or shall deliver or make available to the
Underwriter and Underwriter&rsquo;s Counsel, without charge, signed copies of the Registration Statement as originally filed and each
amendment thereto (including exhibits filed therewith or incorporated by reference therein and documents incorporated or deemed incorporated
by reference therein) and signed copies of all consents and certificates of experts, and will also deliver to the Underwriter, without
charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) for the Underwriter.
The copies of the Registration Statement and each amendment thereto furnished to the Underwriter will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.4&nbsp;<U>Delivery
to the Underwriter of Prospectuses</U>. The Company has delivered or made available or will deliver or make available to the Underwriter,
without charge, as many copies of each Preliminary Prospectus and the Disclosure Package as the Underwriter reasonably requests, and the
Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to the Underwriter,
without charge, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172
of the Securities Act Regulations, would be) required to be delivered under the Securities Act, such number of copies of the Prospectus
(as amended or supplemented) as the Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished
to the Underwriter will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except
to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.5&nbsp;<U>Effectiveness
and Events Requiring Notice to the Underwriter</U>. The Company shall use commercially reasonable efforts to cause the Registration Statement
(or another registration statement registering the offer and sale of the Public Securities and the Underwriter&rsquo;s Securities under
the Securities Act) to remain effective with a current prospectus until the latest of (a) nine (9) months after the Applicable Time, (b)
the date that the Warrants have been exercised in full or expired by their terms and (c) the date that the Underwriter&rsquo;s Warrant
has been exercised in full or expired by its terms. The Company shall notify the Underwriter immediately and confirm the notice in writing:
(i)&nbsp;of the effectiveness of the Registration Statement and any amendment thereto; (ii)&nbsp;of the issuance by the Commission of
any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii)&nbsp;of the issuance by any state securities
commission of any proceedings for the suspension of the qualification of the Public Securities for offering or sale in any jurisdiction
or of the initiation, or the threatening, of any proceeding for that purpose; (iv)&nbsp;of the mailing and delivery to the Commission
for filing of any amendment or supplement to the Registration Statement or Prospectus; (v)&nbsp;of the receipt of any comments or request
for any additional information from the Commission; and (vi)&nbsp;of the happening of any event during the period described in this <U>Section
3.5</U> that, in the judgment of the Company, makes any statement of a material fact made in the Registration Statement, the Disclosure
Package or the Prospectus untrue or that requires the making of any changes in (a) the Registration Statement in order to make the statements
therein not misleading, or (b) in the Disclosure Package or the Prospectus in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. If the Commission or any state securities commission shall enter a stop order or suspend such
qualification at any time, the Company shall make every reasonable effort to obtain promptly the lifting of such order.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.6&nbsp;<U>Review
of Financial Statements.</U> For a period of five (5) years after the date of this Agreement, the Company, at its expense, shall cause
its regularly engaged independent registered public accounting firm to review (but not audit) the Company&rsquo;s financial statements
for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.7&nbsp;<U>Listing</U>.
The Company shall use its commercially reasonable efforts to maintain the listing of the Common Stock (including the Public Securities)
on the NasdaqCM for at least two (2) years from the date of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.8&nbsp;<U>Reports
to the Underwriter</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.8.1.&nbsp;<U>Periodic
Reports</U>. For a period of two (2) years after the date of this Agreement, the Company shall furnish or make available to the Underwriter
copies of such financial statements and other periodic and special reports as the Company from time to time furnishes generally to holders
of any class of its securities and also promptly furnish to the Underwriter: (i) a copy of each periodic report the Company shall be required
to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every press release and every news
item and article with respect to the Company and its affairs which was released by the Company; (iii) a copy of each Form 8-K prepared
and filed by the Company; (iv) five copies of each registration statement filed by the Company under the Securities Act; (v) a copy of
each report or other communication furnished to shareholders; and (vi) such additional documents and information with respect to the Company
and the affairs of any future subsidiaries of the Company as the Underwriter may from time to time reasonably request; provided the Underwriter
shall sign, if requested by the Company, a Regulation FD compliant confidentiality agreement which is reasonably acceptable to the Underwriter
and Underwriter&rsquo;s Counsel in connection with the Underwriter&rsquo;s receipt of such information. Documents filed with the Commission
pursuant to its EDGAR system shall be deemed to have been delivered to the Underwriter pursuant to this <U>Section 3.8.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.8.2.&nbsp;<U>Transfer
Agent; Transfer Sheets</U>. For a period of two (2) years after the date of this Agreement, the Company shall retain a transfer agent
and registrar acceptable to the Underwriter (the&nbsp;&ldquo;</FONT>Transfer Agent<FONT STYLE="font-weight: normal">&rdquo;). Colonial
Stock Transfer, Inc. is acceptable to the Underwriter to act as Transfer Agent for the Common Stock. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.8.3.&nbsp;[Reserved.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.8.4.&nbsp;<U>Payment
of Expenses</U>. The Company hereby agrees to pay on the Closing Date and each Option Closing Date, if any, to the extent not paid at
the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement, including, but not
limited to: (a) all filing fees and communication expenses relating to the registration of the Public Securities and the Underwriter&rsquo;s
Securities to be sold in the Offering (including the Option Securities) with the Commission, (b) all filing fees and other expenses (including
the reasonable fees and disbursements of Underwriter&rsquo;s Counsel) incurred in connection with qualification of the Public Securities
and the Underwriter&rsquo;s Securities for sale under the laws of such jurisdictions as the Underwriter designates, (c) costs and expenses
related to the review of the Offering by FINRA, including all filing fees and the reasonable fees and disbursements of counsel to the
Underwriter relating to such review, (d) costs and reasonable expenses relating to investor presentations or any &ldquo;road show&rdquo;
in connection with the Offering, including, without limitation, the costs of recording and hosting on the Internet of the Company&rsquo;s
road show presentation and any reasonable travel expenses of the Company&rsquo;s officers and employees and any other expenses of the
Company, (e) fees and expenses incident to listing or continued listing of the Public Securities and the Underwriter&rsquo;s Securities
on the NasdaqCM and on such other stock exchanges as the Company and the Underwriter together determine, (f) the fees, disbursements and
expenses of the Company&rsquo;s counsel, accountants and other advisors in connection with the Offering, (g) expenses incurred in preparing,
printing and distributing each Preliminary Prospectus and the Prospectus (including any amendments and supplements thereto) to the Underwriter
and for expenses incurred for preparing, printing and distributing any issuer free writing prospectuses to investors or prospective investors,
(h) reasonable fees, disbursements and expenses of the Underwriter&rsquo;s counsel, (i) the costs and expenses of a public relations firm
selected by the Company, if any, (i) the costs of preparing, printing and delivering certificates representing the Public Securities and
the Underwriter&rsquo;s Securities, (j) fees and expenses of the transfer agent for the delivery of the Public Securities and the Underwriter&rsquo;s
Securities, (k) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the Underwriter,
and (l) fees, expenses and disbursements relating to background checks of the Company&rsquo;s officers and directors in connection with
the Offering; <U>provided</U>, <U>however</U>, that the maximum amount of fees, costs and expenses incurred by the Underwriter with respect
to subparagraphs <U>(a)</U> through <U>(l)</U> above, including, without limitation, the fees, disbursements and expenses of Underwriter&rsquo;s
Counsel, that the Company shall be required to pay under this <U>Section 3.8.4</U> shall not exceed $85,000. The Underwriter may deduct
from the net proceeds of the Offering payable to the Company on the Closing Date or any Option Closing Date, the expenses set forth herein
to be paid by the Company to the Underwriter.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.9&nbsp;<U>Application
of Net Proceeds</U>. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with the application
thereof described under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.10&nbsp;<U>[Reserved</U>.]</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.11&nbsp;<U>Stabilization</U>.
Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Underwriter), has
taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause
or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of the Public Securities or the Underwriter&rsquo;s Securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.12&nbsp;<U>Internal
Controls</U>. The Company shall use commercially reasonable efforts to maintain a system of internal accounting controls sufficient to
provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: (1) pertain to the
maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the
Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance
with authorizations of management and directors of the issuer; and (3) provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use or disposition of the Company&rsquo;s assets that could have a material effect on the financial statements.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.13&nbsp;<U>Accountants</U>.
The Company shall retain an independent registered public accounting firm, as required by the Securities Act and the Securities Act Regulations
and the Public Company Accounting Oversight Board, reasonably acceptable to the Underwriter, and the Company shall continue to retain
an independent registered public accounting firm for a period of at least three (3) years after the date of this Agreement. The Underwriter
acknowledges that the Auditor is acceptable to the Underwriter.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.14&nbsp;<U>FINRA</U>.
For a period of 90 days from the later of the Closing Date or the last Option Closing Date, if any, the Company shall advise the Underwriter
(who shall make an appropriate filing with FINRA) if it is or becomes aware that any officer or director of the Company or any beneficial
owner of 10% or more of any class of the Company&rsquo;s securities or equity-linked securities is or becomes an affiliate or associated
person of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.15&nbsp;<U>No
Fiduciary Duties</U>. The Company acknowledges and agrees that the Underwriter&rsquo;s responsibility to the Company is solely contractual
in nature and that none of the Underwriter or its affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity,
or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions
contemplated by this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.16&nbsp;<U>Company
Lock-Up Agreements</U>. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of the
Underwriter, it will not, for a period of three (3) months after the date of this Agreement (the &ldquo;</FONT><FONT STYLE="font-style: normal">Lock-Up
Period<FONT STYLE="font-weight: normal">&rdquo;), (a) offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly
or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares
of capital stock of the Company, (b) file or cause to be filed any registration statement with the Commission relating to the offering
of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital
stock of the Company or (c) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of capital stock of the Company, whether any such transaction described in <U>clause (a)</U>, <U>(b)</U> or
<U>(c)</U> above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise.
The restrictions contained in this <U>Section 3.16</U> shall not apply to (i)&nbsp;sales of shares of capital stock of the Company under
any trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, existing as of the date of the Underwriting
Agreement, (ii) the Public Securities to be sold hereunder, (iii) the issuance by the Company of shares of capital stock of the Company
upon the exercise of a stock option or warrant or the conversion or vesting of a security outstanding on the date hereof, (iv) the issuance
by the Company of equity awards of the Company under any equity compensation plan of the Company, (v) the issuance by the Company of shares
of capital stock of the Company or securities convertible into, exchangeable for or that represent the right to receive shares of capital
stock of the Company in connection with the acquisition by the Company of the securities, business, technology, property or other assets
of another person or entity, (vi) the sale of shares of capital stock of the Company to cover the payment of exercise prices or the payment
of taxes associated with the exercise or vesting of equity awards under any equity compensation plan of the Company, (vii) sales pursuant
to that certain Sales Agreement (the &ldquo;</FONT>ATM Agreement<FONT STYLE="font-weight: normal">&rdquo;) dated November 22, 2023 between
the Company and Leerink Partners LLC, as sales agent; provided, that, the securities sold pursuant to the ATM Agreement are sold at a
price that is no less than 125% of the purchase price per Firm Share in Section 1.1.1(ii) above, or (viii) the filing of the resale registration
statement with the Commission relating to the inducement offer letter agreements the Company entered into with certain warrant holders
on September 22, 2025.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.17&nbsp;<U>[Reserved</U>.]</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.18&nbsp;<U>Blue
Sky Qualifications</U>. The Company shall use commercially reasonable efforts, in cooperation with the Underwriter, if necessary, to qualify
the Public Securities and the Underwriter&rsquo;s Securities for offering and sale under the applicable securities laws of such states
and other jurisdictions (domestic or foreign) as the Underwriter may designate and to maintain such qualifications in effect so long as
required to complete the distribution of the Public Securities; </FONT><FONT STYLE="font-weight: normal">provided, however, <FONT STYLE="font-style: normal">that
the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer
in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any
jurisdiction in which it is not otherwise so subject.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.19&nbsp;<U>Reporting
Requirements</U>. The Company, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded
by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed with the Commission
pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.20&nbsp;<U>Press
Releases</U>. Prior to the Closing Date and any Option Closing Date, the Company shall not issue any press release or other communication
directly or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business
affairs or business prospects (except for routine oral marketing communications in the ordinary course of business and consistent with
the past practices of the Company and of which the Underwriter is notified), without the prior written consent of the Underwriter, which
consent shall not be unreasonably withheld, unless in the reasonable judgment of the Company and its counsel, and after notification to
the Underwriter, such press release or communication is required by law or applicable NasdaqCM rules.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.21&nbsp;<U>Sarbanes-Oxley</U>.
The Company shall use commercially reasonable efforts to comply with all applicable provisions of the Sarbanes-Oxley Act in effect from
time to time.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.22&nbsp;<U>IRS
Forms</U>. The Company shall deliver to the Underwriter (or its agent), prior to or at the Closing Date, a properly completed and executed
Internal Revenue Service (&ldquo;</FONT><FONT STYLE="font-style: normal">IRS<FONT STYLE="font-weight: normal">&rdquo;) Form W-9 or an
IRS Form W-8, as appropriate, together with all required attachments to such form.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">4.&nbsp;<U>Conditions
of Underwriter&rsquo;s Obligations</U>. The obligations of the Underwriter to purchase and pay for the Public Securities, as provided
herein, shall be subject to (i) the continuing accuracy of the representations and warranties of the Company as of the date hereof, as
of the Closing Date and each Option Closing Date, as applicable; (ii) the accuracy of the statements of officers of the Company made pursuant
to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the following conditions:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.1&nbsp;<U>Regulatory
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.1.&nbsp;<U>Absence
of Certain Commission Actions; Required Filings</U>. The Registration Statement is effective under the Securities Act, no stop order suspending
the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the Securities Act, no order
preventing or suspending the use of any Preliminary Prospectus, the Prospectus or any part thereof shall have been issued and no proceedings
for that purpose or pursuant to Section 8A under the Securities Act shall have been initiated or threatened by the Commission, and all
requests for additional information on the part of the Commission (to be included or incorporated by reference in the Registration Statement
or the Prospectus or otherwise) shall have been complied with to the reasonable satisfaction of the Underwriter. The Prospectus containing
the Rule 430B Information shall have been filed with the Commission in the manner and within the time frame required by Rule 424(b) of
the Securities Act Regulations (without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information shall have
been filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430B under the Securities Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.2.&nbsp;<U>FINRA
Clearance</U>. The non-objection letter issued by FINRA with respect to the Registration Statement shall not have been rescinded, withdrawn
or suspended, nor shall FINRA have raised any subsequent objection to, or issued comments with respect to, the amount of compensation
allowable or payable to the Underwriter as described in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.3.&nbsp;<U>NasdaqCM
Market Clearance</U>. The Company shall have submitted the Listing of Additional Shares Notification Form to the NasdaqCM with respect
to the Offering of the Public Securities and the NasdaqCM shall not have raised any objection to the submission prior to the Closing Date
or each Option Closing Date, as applicable. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.2&nbsp;<U>Counsel
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.1.&nbsp;<U>Closing
Date Opinion of Counsel to the Company</U>. On the Closing Date and each Option Closing Date, if any, the Underwriter shall have received
the favorable opinion and negative assurance letter of Lucosky Brookman LLP, counsel to the Company (&ldquo;</FONT>Company Counsel<FONT STYLE="font-weight: normal">&rdquo;),
dated the Closing Date and each Option Closing Date, as applicable, and addressed to the Underwriter in form and substance reasonably
satisfactory to the Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.2.&nbsp;<U>Opinion
of Underwriter&rsquo;s Counsel</U>. On the Closing Date and each Option Closing Date, if any, the Underwriter shall have received from
Underwriter&rsquo;s Counsel negative assurance letter of Underwriter&rsquo;s Counsel, dated the Closing Date and each Option Closing Date,
as applicable. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.3.&nbsp;<U>Reliance</U>.
In rendering such opinion, Company Counsel may rely: (i)&nbsp;as to matters involving the application of laws other than the laws of the
United States and jurisdictions in which it is admitted, to the extent such counsel deems proper and to the extent specified in such opinion,
if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Underwriter) of other counsel reasonably
acceptable to the Underwriter, familiar with the applicable laws; and (ii)&nbsp;as to matters of fact, to the extent it deems proper,
on certificates or other written statements of officers of the Company and officers of departments of various jurisdictions having custody
of documents respecting the corporate existence or good standing of the Company, provided that copies of any such statements or certificates
shall be delivered to Underwriter&rsquo;s Counsel if requested. The opinion of counsel referred to in <U>Sections 4.2.1</U> above shall
include a statement to the effect that it may be relied upon by Underwriter&rsquo;s Counsel in its opinion delivered to the Underwriter.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.3&nbsp;<U>Comfort
Letters</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.3.1.&nbsp;<U>Cold
Comfort Letter</U>. At the time this Agreement is executed you shall have received a cold comfort letter containing statements and information
of the type customarily included in accountants&rsquo; comfort letters with respect to the financial statements and certain financial
information contained or incorporated by reference or deemed incorporated by reference in the Registration Statement, the Disclosure Package
and the Prospectus, addressed to the Underwriter and in form and substance satisfactory in all respects to you and to the Auditor, dated
as of the date of this Agreement, from the Auditor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.3.2.&nbsp;<U>Bring-down
Comfort Letter</U>. At the Closing Date and each Option Closing Date, if any, the Underwriter shall have received from the Auditor a letter,
dated as of the Closing Date or such Option Closing Date, as applicable, to the effect that the Auditor reaffirms the statements made
in the letter furnished pursuant to <U>Section 4.3.1</U>, except that the specified date referred to shall be a date not more than three
(3) Business Days prior to the Closing Date or Option Closing Date, as applicable. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.4&nbsp;<U>Company
Certificates</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.4.1.&nbsp;<U>Officers&rsquo;
Certificate</U>. The Company shall have furnished to the Underwriter a certificate, dated the Closing Date and such Option Closing Date,
as applicable, of its Chief Executive Officer and its Chief Financial Officer stating that (i) such officers have carefully examined the
Registration Statement, the Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus and, in their opinion, the Registration
Statement and each amendment thereto, as of the Applicable Time and as of the Closing Date or such Option Closing Date, as applicable,
did not include any untrue statement of a material fact and did not omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading, and the Disclosure Package, as of the Applicable Time and as of the Closing Date and such
Option Closing Date, as applicable, any Issuer Free Writing Prospectus as of its date and as of the Closing Date and such Option Closing
Date, as applicable, the Prospectus and each amendment or supplement thereto, as of the respective date thereof and as of the Closing
Date or Option Closing Date, as applicable, did not include any untrue statement of a material fact and did not omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances in which they were made, not misleading, (ii)
since the effective date of the Registration Statement, no event has occurred which should have been set forth in a supplement or amendment
to the Registration Statement, the Disclosure Package or the Prospectus, (iii) to the best of their knowledge after reasonable investigation,
as of the Closing Date or such Option Closing Date, as applicable, the representations and warranties of the Company in this Agreement
are true and correct in all material respects, except for such representations and warranties qualified by materiality or material adverse
change which shall be true and correct in all respects and the Company has complied in all material respects with all agreements and satisfied
all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or such Option Closing Date, as applicable,
and (iv) there has not been, subsequent to the date of the most recent audited financial statements included or incorporated by reference
in the Disclosure Package, any material adverse change in the financial position or results of operations of the Company, or any change
or development that, singularly or in the aggregate, would involve a material adverse change or a prospective material adverse change,
in or affecting the condition (financial or otherwise), results of operations, business, assets or prospects of the Company, except as
set forth in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.4.2.&nbsp;<U>Secretary&rsquo;s
Certificate</U>. At the Closing Date and each Option Closing Date, if any, the Underwriter shall have received a certificate of the Company
signed by the Secretary of the Company, dated the Closing Date or each Option Closing Date, as applicable, certifying: (i)&nbsp;that each
of the Charter and the Bylaws is true and complete, has not been modified and is in full force and effect; (ii)&nbsp;that the resolutions
of the Company&rsquo;s Board of Directors and/or any committee thereof relating to the Offering are in full force and effect and have
not been modified; (iii) as to the accuracy and completeness of all correspondence between the Company or Company Counsel and the Commission;
and (iv)&nbsp;as to the incumbency of the officers of the Company. The documents referred to in such certificate shall be attached to
such certificate.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.5&nbsp;<U>No
Material Changes</U>. Prior to and on the Closing Date and each Option Closing Date: (i)&nbsp;there shall have been no Material Adverse
Change or development involving a prospective material adverse change in the condition or prospects or the business activities, financial
or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement, the Disclosure
Package and the Prospectus; (ii)&nbsp;no action, suit or proceeding, at law or in equity, shall have been pending or threatened against
the Company or any Insider before or by any court or federal or state commission, board or other administrative agency wherein an unfavorable
decision, ruling or finding may materially adversely affect the business, operations, prospects or financial condition or income of the
Company, except as set forth in the Registration Statement, the Disclosure Package and the Prospectus; (iii)&nbsp;no stop order shall
have been issued under the Securities Act and no proceedings therefor shall have been initiated or threatened by the Commission; (iv)&nbsp;no
action shall have been taken and no law, statute, rule, regulation or order shall have been enacted, adopted or issued by any Governmental
Entity which would prevent the issuance or sale of the Public Securities or materially and adversely affect or potentially materially
and adversely affect the business or operations of the Company or the Subsidiary; (v) no injunction, restraining order or order of any
other nature by any federal or state court of competent jurisdiction shall have been issued which would prevent the issuance or sale of
the Public Securities or materially and adversely affect or potentially materially and adversely affect the business or operations of
the Company or the Subsidiary; and (vi) the Registration Statement, the Disclosure Package and the Prospectus and any amendments or supplements
thereto shall contain all material statements which are required to be stated therein in accordance with the Securities Act and the Securities
Act Regulations and shall conform in all material respects to the requirements of the Securities Act and the Securities Act Regulations,
and neither the Registration Statement, the Disclosure Package, the Prospectus nor any Issuer Free Writing Prospectus nor any amendment
or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.6&nbsp;<U>Corporate
Proceedings</U>. All corporate proceedings and other legal matters incident to the authorization, form and validity of each of this Agreement,
the Public Securities, the Registration Statement, the Disclosure Package, each Issuer Free Writing Prospectus, if any, and the Prospectus
and all other legal matters relating to this Agreement and the transactions contemplated hereby and thereby shall be reasonably satisfactory
in all material respects to Underwriter&rsquo;s Counsel and the Company shall have furnished to such counsel all documents and information
that they may reasonably request to enable them to pass upon such matters.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.7&nbsp;<U>Delivery
of Agreements</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.7.1.&nbsp;On
or before the date of this Agreement, the Company shall have delivered to the Underwriter executed copies of the Lock-Up Agreements from
each of the persons listed in <U>Schedule 2</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.7.2.&nbsp;On
the Closing Date, the Company shall have delivered to the Underwriter the Firm Shares and the Firm Warrants, and on each Option Closing
Date, if any, the Company shall have delivered to the Underwriter the applicable Option Shares and/or Option Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.7.3.&nbsp;No
later than five (5) Business Days of the expiration of the Over-allotment Option, the Company shall have delivered to the Underwriter
an executed copy or copies of the Underwriter&rsquo;s Warrant.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.8&nbsp;<U>Representations
and Warranties</U>. The representations and warranties of the Company contained herein shall be true and correct on the date hereof and
on and as of the Closing Date or each Option Closing Date, if any, as the case may be; and the statements of the Company and its officers
made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or each Option Closing
Date, if any, as the case may be.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.9&nbsp;<U>Additional
Documents</U>. At the Closing Date and each Option Closing Date, if any, Underwriter&rsquo;s Counsel shall have been furnished with such
documents and opinions as they may require for the purpose of enabling Underwriter&rsquo;s Counsel to deliver an opinion to the Underwriter,
or in order to evidence the accuracy of any of the representations or warranties, or the fulfilment of any of the conditions, herein contained;
and all proceedings taken by the Company in connection with the issuance and sale of the Public Securities as herein contemplated shall
be satisfactory in form and substance to the Underwriter and Underwriter&rsquo;s Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">5.&nbsp;</FONT> <FONT STYLE="font-weight: normal"><U>Indemnification</U>.</FONT></P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.1&nbsp;<U>Indemnification
by the Company</U>. The Company shall indemnify, defend and hold harmless the Underwriter, its affiliates and each of its and their respective
directors, officers, members, employees, representatives and agents and each person, if any, who controls the Underwriter within the meaning
of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the &ldquo;</FONT><FONT STYLE="font-style: normal">Underwriter
Indemnified Parties<FONT STYLE="font-weight: normal">,&rdquo; and each an &ldquo;</FONT>Underwriter Indemnified Party<FONT STYLE="font-weight: normal">&rdquo;)
against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding in respect thereof), to which
such Underwriter Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense,
liability, action, investigation or proceeding arises out of or is based upon (A) any untrue statement or alleged untrue statement of
a material fact contained in any Preliminary Prospectus, the Disclosure Package, any Issuer Free Writing Prospectus, any &ldquo;issuer
information&rdquo; filed or required to be filed pursuant to Rule 433(d) of the Securities Act Regulations, any Registration Statement
or the Prospectus, or in any amendment or supplement thereto or document incorporated by reference therein, (B) the omission or alleged
omission to state in any Preliminary Prospectus, the Disclosure Package, any Issuer Free Writing Prospectus, any &ldquo;issuer information&rdquo;
filed or required to be filed pursuant to Rule 433(d) of the Securities Act Regulations, any Registration Statement or the Prospectus,
or in any amendment or supplement thereto or document incorporated by reference therein, a material fact required to be stated therein
or necessary to make the statements therein not misleading or (C) any breach of the representations and warranties of the Company contained
herein or any certificate delivered pursuant to this Agreement or failure of the Company to perform its obligations hereunder or pursuant
to any law, any act or failure to act, or any alleged act or failure to act, by the Company in connection with, or relating in any manner
to, this Agreement, the Public Securities or the Offering, and which is included as part of or referred to in any loss, claim, damage,
expense, liability, action, investigation or proceeding arising out of or based upon matters covered by <U>subclause (A)</U>, <U>(B)</U>
or <U>(C)</U> above of this <U>Section 5.1</U> (provided&nbsp;that the Company shall not be liable in the case of any matter covered by
this <U>subclause (C)</U> to the extent that it is determined in a final judgment by a court of competent jurisdiction that such loss,
claim, damage, expense or liability resulted directly from any such act or failure to act undertaken or omitted to be taken by the Underwriter
through its gross negligence or willful misconduct), and shall reimburse the Underwriter Indemnified Party promptly upon demand for any
legal fees or other expenses reasonably incurred by that Underwriter Indemnified Party in connection with investigating, or preparing
to defend, or defending against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such
loss, claim, damage, expense, liability, action, investigation or proceeding, as such fees and expenses are incurred;&nbsp;</FONT></FONT><FONT STYLE="font-weight: normal"><U>provided</U><FONT STYLE="font-style: normal">,
</FONT><U>however</U><FONT STYLE="font-style: normal">,&nbsp;that the Company shall not be liable in any such case to the extent that
any such loss, claim, damage, expense or liability arises out of or is based upon an untrue statement in, or omission from any Preliminary
Prospectus, the Disclosure Package, any Registration Statement or the Prospectus, or any such amendment or supplement thereto, or any
Issuer Free Writing Prospectus made in reliance upon and in conformity with written information furnished to the Company by or on behalf
of the Underwriter specifically for use therein, which information the parties hereto agree is limited to the Underwriter&rsquo;s Information.
This indemnity agreement is not exclusive and will be in addition to any liability, which the Company might otherwise have and shall not
limit any rights or remedies which may otherwise be available at law or in equity to each Underwriter Indemnified Party.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.2&nbsp;<U>Indemnification
by the Underwriter</U>. The Underwriter shall indemnify, defend and hold harmless the Company, the Company&rsquo;s directors, its officers
who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act (collectively the &ldquo;</FONT><FONT STYLE="font-style: normal">Company Indemnified Parties<FONT STYLE="font-weight: normal">&rdquo;
and each a </FONT>&ldquo;Company Indemnified Party<FONT STYLE="font-weight: normal">&rdquo;) against any loss, claim, damage, expense
or liability whatsoever (or any action, investigation or proceeding in respect thereof), to which such Company Indemnified Party may become
subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding
arises out of or is based upon (i) any untrue statement of a material fact contained in any Preliminary Prospectus, any Issuer Free Writing
Prospectus, any &ldquo;issuer information&rdquo; filed or required to be filed pursuant to Rule 433(d) of the Securities Act Regulations,
any Registration Statement, the Disclosure Package, or the Prospectus, or in any amendment or supplement thereto, or (ii) the omission
to state in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &ldquo;issuer information&rdquo; filed or required to
be filed pursuant to Rule 433(d) of the Securities Act Regulations, any Registration Statement, the Disclosure Package, or the Prospectus,
or in any amendment or supplement thereto, a material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading, but in each case only to the extent that the untrue statement
or omission was made in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Underwriter
specifically for use therein, which information the parties hereto agree is limited to the Underwriter&rsquo;s Information and shall reimburse
the Company Indemnified Parties for any legal or other expenses reasonably incurred by any Company Indemnified Party in connection with
investigating or preparing to defend or defending against or appearing as third party witness in connection with any such loss, claim,
damage, liability, action, investigation or proceeding, as such fees and expenses are incurred. Notwithstanding the provisions of this
<U>Section 5.2</U>, in no event shall any indemnity by the Underwriter under this <U>Section 5.2</U> exceed the total discount and commission
received by the Underwriter in connection with this Offering.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.3&nbsp;<U>Procedure</U>.
Promptly after receipt by an indemnified party under this <U>Section 5</U> of notice of the commencement of any action, the indemnified
party shall, if a claim in respect thereof is to be made against an indemnifying party under this <U>Section 5</U>, notify such indemnifying
party in writing of the commencement of that action; </FONT><FONT STYLE="font-weight: normal"><U>provided</U><FONT STYLE="font-style: normal">,
</FONT><U>however</U><FONT STYLE="font-style: normal">, that the failure to notify the indemnifying party shall not relieve it from any
liability which it may have under this <U>Section 5</U> except to the extent it has been materially adversely prejudiced by such failure;
and, provided, further, that the failure to notify an indemnifying party shall not relieve it from any liability which it may have to
an indemnified party otherwise than under this <U>Section 5</U>. If any such action shall be brought against an indemnified party, and
it shall notify the indemnifying party thereof, the indemnifying party shall assume the defense of such action with counsel reasonably
satisfactory to the indemnified party (which counsel shall not, except with the written consent of the indemnified party, be counsel to
the indemnifying party). After notice from the indemnifying party to the indemnified party of its assumption of the defense of such action,
except as provided herein, the indemnifying party shall not be liable to the indemnified party under <U>Section 5</U> for any legal or
other expenses subsequently incurred by the indemnified party in connection with the defense of such action other than reasonable costs
of investigation; </FONT><U>provided</U><FONT STYLE="font-style: normal">, </FONT><U>however</U><FONT STYLE="font-style: normal">, that
any indemnified party shall have the right to employ separate counsel in any such action and to participate in the defense of such action
but the fees and expenses of such counsel (other than reasonable costs of investigation) shall be at the expense of such indemnified party
unless (i) the employment thereof has been specifically authorized in writing by the Company in the case of a claim for indemnification
under <U>Section 5.1</U> or the Underwriter in the case of a claim for indemnification under <U>Section 5.2</U>, (ii) such indemnified
party shall have been advised by its counsel that there may be one or more legal defenses available to it which are different from or
additional to those available to the indemnifying party, or (iii) the indemnifying party has failed to assume the defense of such action
and employ counsel reasonably satisfactory to the indemnified party within a reasonable period of time after notice of the commencement
of the action or the indemnifying party does not diligently defend the action after assumption of the defense, in which case, if such
indemnified party notifies the indemnifying party in writing that it elects to employ separate counsel at the expense of the indemnifying
party, the indemnifying party shall not have the right to assume the defense of (or, in the case of a failure to diligently defend the
action after assumption of the defense, to continue to defend) such action on behalf of such indemnified party and the indemnifying party
shall be responsible for legal or other expenses subsequently incurred by such indemnified party in connection with the defense of such
action; </FONT><U>provided</U><FONT STYLE="font-style: normal">, </FONT><U>however</U><FONT STYLE="font-style: normal">, that the indemnifying
party shall not, in connection with any one such action or separate but substantially similar or related actions in the same jurisdiction
arising out of the same general allegations or circumstances, be liable for the reasonable fees and expenses of more than one separate
firm of attorneys at any time any such indemnified party (in addition to any local counsel), which firm shall be designated in writing
by the Underwriter if the indemnified party under this <U>Section 5</U> is an Underwriter Indemnified Party or by the Company if an indemnified
party under this <U>Section 5</U> is a Company Indemnified Party. Subject to this <U>Section 5.3</U>, the amount payable by an indemnifying
party under <U>Section 5</U> shall include, but not be limited to, (x) reasonable legal fees and expenses of counsel to the indemnified
party and any other expenses in investigating, or preparing to defend or defending against, or appearing as a third party witness in respect
of, or otherwise incurred in connection with, any action, investigation, proceeding or claim, and (y) all amounts paid in settlement of
any of the foregoing. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise
or consent to the entry of judgment with respect to any pending or threatened action or any claim whatsoever, in respect of which indemnification
or contribution could be sought under this <U>Section 5</U> (whether or not the indemnified parties are actual or potential parties thereto),
unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party in form and substance reasonably
satisfactory to such indemnified party from all liability arising out of such action or claim and (ii) does not include a statement as
to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. Subject to the provisions of the
following sentence, no indemnifying party shall be liable for settlement of any pending or threatened action or any claim whatsoever that
is effected without its written consent (which consent shall not be unreasonably withheld or delayed), but if settled with its written
consent, if its consent has been unreasonably withheld or delayed or if there be a judgment for the plaintiff in any such matter, the
indemnifying party agrees to indemnify and hold harmless any indemnified party from and against any loss or liability by reason of such
settlement or judgment. In addition, if at any time an indemnified party shall have requested that an indemnifying party reimburse the
indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature
contemplated herein effected without its written consent if (i) such settlement is entered into more than forty-five (45) days after receipt
by such indemnifying party of the request for reimbursement, (ii) such indemnifying party shall have received notice of the terms of such
settlement at least thirty (30) days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed
such indemnified party in accordance with such request prior to the date of such settlement.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.4&nbsp;<U>Contribution</U>.
If the indemnification provided for in this <U>Section 5</U> is unavailable or insufficient to hold harmless an indemnified party under
<U>Section 5.1</U> or <U>Section 5.2</U>, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute
to the amount paid, payable or otherwise incurred by such indemnified party as a result of such loss, claim, damage, expense or liability
(or any action, investigation or proceeding in respect thereof), as incurred, (i) in such proportion as shall be appropriate to reflect
the relative benefits received by the Company on the one hand and the Underwriter on the other hand from the Offering, or (ii) if the
allocation provided by <U>clause (i)</U> of this <U>Section 5.4</U> is not permitted by applicable law, in such proportion as is appropriate
to reflect not only the relative benefits referred to in <U>clause (i)</U> of this <U>Section 5.4</U> but also the relative fault of the
Company on the one hand and the Underwriter on the other with respect to the statements, omissions, acts or failures to act which resulted
in such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof) as well as any other
relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriter on the other with
respect to such offering shall be deemed to be in the same proportion as the total proceeds from the Offering purchased under this Agreement
(before deducting expenses) received by the Company bear to the total underwriting discount and commissions received by the Underwriter
in connection with the Offering, in each case as set forth in the table on the cover page of the Prospectus. The relative fault of the
Company on the one hand and the Underwriter on the other shall be determined by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied
by the Company on the one hand or the Underwriter on the other, the intent of the parties and their relative knowledge, access to information
and opportunity to correct or prevent such untrue statement, omission, act or failure to act; provided that the parties hereto agree that
the written information furnished to the Company by or on behalf of the Underwriter for use in any Preliminary Prospectus, any Registration
Statement, the Disclosure Package or the Prospectus, or in any amendment or supplement thereto, consists solely of the Underwriter&rsquo;s
Information. The Company and the Underwriter agree that it would not be just and equitable if contributions pursuant to this <U>Section
5.4</U> be determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations
referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage, expense, liability, action,
investigation or proceeding referred to above in this <U>Section 5.4</U> shall be deemed to include, for purposes of this <U>Section 5.4</U>,
any legal or other expenses reasonably incurred by such indemnified party in connection with investigating, preparing to defend or defending
against or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense,
liability, action, investigation or proceeding. Notwithstanding the provisions of this <U>Section 5.4</U>, the Underwriter shall not be
required to contribute any amount in excess of the total discount and commission received by the Underwriter in connection with the Offering
less the amount of any damages which the Underwriter has otherwise paid or become liable to pay by reason of any untrue or alleged untrue
statement, omission or alleged omission, act or alleged act or failure to act or alleged failure to act. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-weight: normal">6. &nbsp;<U>Additional
Covenants</U>.</FONT></P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">6.1&nbsp;<U>Board
Composition and Board Designations</U>. The Company shall ensure that: (i)&nbsp;the qualifications of the persons serving as members of
the Board of Directors and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act, the Exchange Act and
the listing rules of the NasdaqCM or any other national securities exchange, as the case may be, in the event the Company seeks to have
its Common Stock listed on another exchange or quoted on an automated quotation system, subject to any applicable cure period, and (ii)&nbsp;if
applicable, at least one member of the Audit Committee of the Board of Directors qualifies as an &ldquo;audit committee financial expert,&rdquo;
as such term is defined under Regulation S-K and the listing rules of the NasdaqCM.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-weight: normal">7. <U></U>&nbsp;<U>Effective
Date of this Agreement and Termination Thereof</U>.</FONT></P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.1&nbsp;<U>Effective
Date</U>. This Agreement shall become effective when both the Company and the Underwriter have executed the same and delivered counterparts
of such signatures to the other party.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.2&nbsp;<U>Termination</U>.
The Underwriter shall have the right to terminate this Agreement at any time prior to the Closing Date, (i)&nbsp;if any domestic or international
event or act or occurrence has materially disrupted, or in your opinion will in the immediate future materially disrupt, general securities
markets in the United States; or (ii)&nbsp;if trading on the New York Stock Exchange or Nasdaq Stock Market LLC shall have been suspended
or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall
have been required by FINRA or by order of the Commission or any other government authority having jurisdiction; or (iii)&nbsp;if the
United States shall have become involved in a new war or an increase in major hostilities; or (iv)&nbsp;if a banking moratorium has been
declared by a New York State or federal authority; or (v)&nbsp;if a moratorium on foreign exchange trading has been declared which materially
adversely impacts the United States securities markets; or (vi)&nbsp;if the Company shall have sustained a material loss by fire, flood,
accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured,
will, in your opinion, make it inadvisable to proceed with the delivery of the Firm Securities or the Option Securities; or (vii)&nbsp;if
the Company is in material breach of any of its representations, warranties or covenants hereunder; or (viii)&nbsp;if the Underwriter
shall have become aware after the date hereof of such a material adverse change in the conditions or prospects of the Company, or such
adverse material change in general market conditions as in the Underwriter&rsquo;s judgment would make it impracticable to proceed with
the offering, sale and/or delivery of the Public Securities or to enforce contracts made by the Underwriter for the sale of the Public
Securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.3&nbsp;<U>Expenses</U>.
Notwithstanding anything to the contrary in this Agreement, in the event that this Agreement shall not be carried out for any reason whatsoever,
within the time specified herein or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the
Underwriter its reasonable accountable out-of-pocket expenses actually incurred related to the transactions contemplated herein then due
and payable (including the fees and disbursements of Underwriter&rsquo;s Counsel) up to $50,000 and upon demand the Company shall pay
the full amount thereof to the Underwriter on behalf of the Underwriter; </FONT><FONT STYLE="font-weight: normal">provided, however, <FONT STYLE="font-style: normal">that
such expense cap in no way limits or impairs the indemnification and contribution provisions of this Agreement. Notwithstanding the foregoing,
any advance received by the Underwriter will be reimbursed to the Company to the extent not actually incurred in compliance with FINRA
Rule 5110(g)(4).</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.4&nbsp;<U>Survival
of Indemnification</U>. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination
of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of <U>Section 5</U> shall remain in full
force and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this Agreement
or any part hereof.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.5&nbsp;<U>Representations,
Warranties, Agreements to Survive</U>. All representations, warranties and agreements contained in this Agreement or in certificates of
officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i)&nbsp;any investigation
made by or on behalf of the Underwriter or its affiliates or selling agents, any person controlling the Underwriter, its officers or directors
or any person controlling the Company or (ii)&nbsp;delivery of and payment for the Public Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">8.&nbsp;</FONT> <FONT STYLE="font-weight: normal"><U>Miscellaneous</U>.</FONT></P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.1&nbsp;<U>Notices</U>.
All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered or
certified mail, return receipt requested), personally delivered or sent by facsimile transmission and confirmed and shall be deemed given
when so delivered or faxed and confirmed or if mailed, two (2) days after such mailing.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to the Underwriter:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Newbridge Securities Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1200 North Federal Highway, Suite 400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Boca Raton, Florida 33432</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.75in">Attn:</TD><TD>Chad D. Champion, Senior Managing Director</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>Email:</TD><TD></TD></TR>
                                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>Tel. No:</TD><TD></TD></TR>
                                                                                                                       </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">McGuireWoods LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1251 Avenue of the Americas, 20<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">New York, NY 10020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.75in">Attention:</TD><TD>Stephen Older, Esq.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD></TD><TD>Andrew J. Terjesen, Esq.</TD></TR>
                                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>Email:</TD><TD></TD></TR>
                                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD></TD></TR>
                                                                                                                       </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Modular Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">10740 Thornmint Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">San Diego, CA 92127</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.75in">Attention:</TD><TD>James Besser</TD></TR>
                                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>Email:</TD><TD></TD></TR>
                                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>Tel. No:</TD><TD></TD></TR>
                                                                                                                       </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Lucosky Brookman LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">101 Wood Avenue South</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Woodbridge, NJ 08830</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.75in">Attention:</TD><TD>Lawrence Metelitsa</TD></TR>
                                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>Email:</TD><TD></TD></TR>
                                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>Tel. No:</TD><TD></TD></TR>
                                                                                                                       </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.2&nbsp;<U>Headings</U>.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning
or interpretation of any of the terms or provisions of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.3&nbsp;<U>Absence
of Fiduciary Relationship</U>. The Company acknowledges and agrees that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.7pt">(i) the Underwriter&rsquo;s
responsibility to the Company is solely contractual in nature, the Underwriter has been retained solely to act as an underwriter in connection
with the Offering and no fiduciary, advisory or agency relationship between the Company and the Underwriter has been created in respect
of any of the transactions contemplated by this Agreement, irrespective of whether either the Underwriter has advised or is advising the
Company on other matters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.7pt">(ii) the price of the Public
Securities set forth in this Agreement was established by the Company following discussions and arms-length negotiations with the Underwriter,
and the Company is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions
contemplated by this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.7pt">(iii) it has been advised
that the Underwriter and its respective affiliates are engaged in a broad range of transactions which may involve interests that differ
from those of the Company and that the Underwriter has no obligation to disclose such interests and transactions to the Company by virtue
of any fiduciary, advisory or agency relationship.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.4&nbsp;<U>Research
Analyst Independence</U>. The Company acknowledges that the Underwriter&rsquo;s research analysts and research departments are required
to be independent from its investment banking division and are subject to certain regulations and internal policies, and that the Underwriter&rsquo;s
research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the
Company and/or the offering that differ from the views of their investment banking division. The Company acknowledges that the Underwriter
is a full service securities firm and as such from time to time, subject to applicable securities laws, rules and regulations, may effect
transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the
Company; provided, however, that nothing in this <U>Section 8.4</U> shall relieve the Underwriter of any responsibility or liability it
may otherwise bear in connection with activities in violation of applicable securities laws, rules or regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.5&nbsp;<U>Amendment</U>.
This Agreement may only be amended by a written instrument executed by each of the parties hereto.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.6&nbsp;<U>Entire
Agreement</U>. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with this
Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and supersedes
all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.7&nbsp;<U>Binding
Effect</U>. This Agreement shall inure solely to the benefit of and shall be binding upon the Underwriter, the Company and the controlling
persons, directors and officers referred to in <U>Section 5</U>, and their respective successors, legal representative, heirs and assigns,
and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect of or by virtue
of this Agreement or any provisions herein contained. The term &ldquo;successors and assigns&rdquo; shall not include a purchaser, in
its capacity as such, of securities from the Underwriter.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.8&nbsp;<U>Governing
Law; Consent to Jurisdiction; Trial by Jury</U>. This Agreement shall be governed by and construed and enforced in accordance with the
laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action,
proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in state and federal
courts located in the Borough of Manhattan in the City of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall
be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum.
Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail,
return receipt requested, postage prepaid, addressed to it at the address set forth in <U>Section 9.1</U>. Such mailing shall be deemed
personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company agrees that the prevailing
party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys&rsquo; fees and expenses
relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to
the extent permitted by applicable law, on behalf of its shareholders and affiliates) and the Underwriter hereby irrevocably waives, to
the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating
to this Agreement or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.9&nbsp;<U>Execution
in Counterparts</U>. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts,
each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall
become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties
hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient
delivery thereof.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.10&nbsp;<U>Waiver,
etc</U>. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed or
construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof or the
right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non-compliance
or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by
the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment
shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[Signature Page Follows]</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>




<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">If
the foregoing correctly sets forth the understanding between the Underwriter and the Company, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement between us.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase">MODULAR MEDICAL,
</FONT>INC.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:
    <TD STYLE="border-bottom: Black 1.5pt solid"><I>/s/ James Besser</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD>James Besser, Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3">Confirmed as of the date first written above mentioned:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3">NEWBRIDGE SECURITIES CORPORATION</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>By: </TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><I>/s/ Chad D. Champion</I></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 5%">Name: </TD>
    <TD STYLE="width: 31%">Chad D. Champion</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Title: </TD>
    <TD>Senior Managing Director</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">[Signature
Page]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Modular
Medical, Inc. &ndash; Underwriting Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 1-A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Pricing Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%">Number of Firm Shares:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12,173,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Number of shares underlying Firm Warrants:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,086,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Number of Option Shares:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,825,950</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Number of shares underlying Option Warrants:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">912,975</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Combined Public Offering Price per two Firm Shares and one Firm Warrant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7700</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Underwriting Discount per two Firm Shares and one Firm Warrant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0539</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds to Company per two Firm Shares and one Firm Warrant (before expenses)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.7161</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Sch. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-A</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 1-B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issuer General Use Free Writing Prospectuses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Sch. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-B</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>List of Lock-Up Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>JEB Partners, L.P.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Manchester Explorer, L.P.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Manchester Management LLC</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>James E. Besser</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD>Paul DiPerna</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD>Duane DeSisto</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">7.</TD><TD>Steven Felsher</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">8.</TD><TD>Morgan C. Frank</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">9.</TD><TD>Ellen O&rsquo;Connor Vos</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">10.</TD><TD>Philip Sheibley</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">11.</TD><TD>Carmen Volkart</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">12.</TD><TD>Jeffrey Goldberg</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">13.</TD><TD><FONT STYLE="background-color: white">Kevin Schmid</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Sch. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Warrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(See attached.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 41; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Modular Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10740 Thornmint Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Diego, California 91927</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Underwriting Agreement, dated as of December __, 2025 (the &ldquo;<U>Underwriting Agreement</U>&rdquo;), between Modular Medical, Inc. (the &ldquo;<U>Company</U>&rdquo;) and Newbridge Securities Corporation (the &ldquo;<U>Representative</U>&rdquo;)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">Defined terms not otherwise defined in this letter
agreement (the &ldquo;<U>Letter Agreement</U>&rdquo;) shall have the meanings set forth in the Underwriting Agreement. In satisfaction
of a condition of the Company&rsquo;s obligations under the Underwriting Agreement, the undersigned irrevocably agrees with the Company
that, from the date hereof until sixty (60) days after the date of the final Prospectus for the Offering (such period, the &ldquo;<U>Restriction
Period</U>&rdquo;), the undersigned will not offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into
any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or
effective economic disposition due to cash settlement or otherwise) by the undersigned or any Affiliate of the undersigned to the extent
such Affiliate transaction would be required to be reported by the undersigned during the Restriction Period with the Securities and Exchange
Commission in accordance with Section 13 or Section 16 of the Exchange Act ), directly or indirectly, or establish or increase a put equivalent
position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934,
as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), with respect to, any shares of Common Stock of the Company or securities convertible,
exchangeable or exercisable into, shares of Common Stock of the Company beneficially owned, held or hereafter acquired by the undersigned
(the &ldquo;<U>Securities</U>&rdquo;), other than Securities acquired in the Offering, or make any demand for or exercise any right or
cause to be filed a registration, including any amendments thereto, with respect to the registration of any shares of Common Stock or
Common Stock Equivalents or publicly disclose the intention to do any of the foregoing. Beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act. The undersigned acknowledges that the Company shall provide written notice to the transfer agent
of the Company to inform them of the Restriction Period, which written notice shall include notification by email. In order to enforce
this covenant, the Company shall impose irrevocable stop-transfer instructions preventing the transfer agent of the Company from effecting
any actions in violation of this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">Notwithstanding the foregoing, and subject to
the conditions below, the undersigned may transfer the Securities provided that (1) the Company receives a signed lock-up letter agreement
(in the form of this Letter Agreement) for the balance of the Restriction Period from each donee, trustee, distributee, or transferee,
as the case may be, prior to such transfer (2) any such transfer shall not involve a disposition for value, (3) such transfer is not required
to be reported with the Securities and Exchange Commission in accordance with the Exchange Act and no report of such transfer shall be
made voluntarily during the Restricted Period, and (4) neither the undersigned nor any donee, trustee, distributee or transferee, as the
case may be, otherwise voluntarily effects any public filing or report regarding such transfers during the Restricted Period, with respect
to transfer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 33.75pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">as a bona fide gift or gifts;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 69.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 33.75pt"></TD><TD STYLE="text-align: justify; width: 36pt">(ii)</TD><TD STYLE="text-align: justify">to any immediate family member or to any trust for the direct or indirect benefit of the undersigned or
the immediate family of the undersigned (for purposes of this Letter Agreement, &ldquo;immediate family&rdquo; shall mean any relationship
by blood, marriage or adoption, not more remote than first cousin);</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 42; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 33.75pt"></TD><TD STYLE="text-align: justify; width: 36pt">(iii)</TD><TD STYLE="text-align: justify">to any corporation, partnership, limited liability company, or other business entity all of the equity
holders of which consist of the undersigned and/or the immediate family of the undersigned;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 33.75pt"></TD><TD STYLE="text-align: justify; width: 36pt">(iv)</TD><TD STYLE="text-align: justify">if the undersigned is a corporation, partnership, limited liability company, trust or other business entity
(a) to another corporation, partnership, limited liability company, trust or other business entity that is an Affiliate of the undersigned
or (b) in the form of a distribution to limited partners, limited liability company members or stockholders of the undersigned;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 33.75pt"></TD><TD STYLE="text-align: justify; width: 36pt">(v)</TD><TD STYLE="text-align: justify">if the undersigned is a trust, to the beneficiary of such trust;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 33.75pt"></TD><TD STYLE="text-align: justify; width: 36pt">(vi)</TD><TD STYLE="text-align: justify">by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree,
separation agreement or other court order;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 33.75pt"></TD><TD STYLE="text-align: justify; width: 36pt">(vii)</TD><TD STYLE="text-align: justify">to a charity or educational institution;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 33.75pt"></TD><TD STYLE="text-align: justify; width: 36pt">(viii)</TD><TD STYLE="text-align: justify">by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary
or a member of the immediate family of the undersigned; or</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 33.75pt"></TD><TD STYLE="text-align: justify; width: 36pt">(ix)</TD><TD STYLE="text-align: justify">sales of Common Stock made pursuant to and in accordance with a trading plan pursuant to Rule 10b5-1 under
the Exchange Act existing on the date hereof.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.35pt; text-indent: 33.75pt">In addition, notwithstanding the foregoing,
this Letter Agreement shall not restrict (i) the delivery of shares of Common Stock to the undersigned upon exercise of any options or
settlement of restricted stock units or other equity awards granted under any employee benefit plan of the Company, or the exercise of
warrants; provided in each case that any shares of Common Stock or Securities acquired in connection with any such exercise or settlement
will be subject to the restrictions set forth in this Letter Agreement, (ii) the withholding of shares of Common Stock to cover the payment
of the exercise prices or the payment of taxes associated with the exercise or settlement of equity set forth in (i) above, or (iii) the
issuance to the undersigned of awards by the Company under its equity incentive plans or the issuance of warrants.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">Furthermore, the undersigned may enter into any
new plan established in compliance with Rule 10b5-1 of the Exchange Act; provided that (i) such plan may only be established if no public
announcement or filing with the Securities and Exchange Commission, or other applicable regulatory authority, is made in connection with
the establishment of such plan during the Restriction Period and (ii) no sale of shares of Common Stock are made pursuant to such plan
during the Restriction Period.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 33.75pt"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">The undersigned acknowledges that the execution,
delivery and performance of this Letter Agreement is a material inducement to the Representative to complete the transactions contemplated
by the Underwriting Agreement and the Company shall be entitled to specific performance of the undersigned&rsquo;s obligations hereunder.
The undersigned hereby represents that the undersigned has the power and authority to execute, deliver and perform this Letter Agreement,
that the undersigned has received adequate consideration therefor and that the undersigned will indirectly benefit from the closing of
the transactions contemplated by the Underwriting Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">The undersigned understands that, if the Agreement
does not become effective, or if the Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated
prior to payment for and delivery of the Common Stock to be sold thereunder, the undersigned shall be released from all obligations under
this Letter Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">This Letter Agreement may not be amended or otherwise
modified in any respect without the written consent of each of the Company and the undersigned. This Letter Agreement shall be construed
and enforced in accordance with the laws of the State of New York without regard to the principles of conflict of laws. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. The undersigned agrees and understands
that this Letter Agreement does not intend to create any relationship between the undersigned and the Representative and that the Representative
is not entitled to cast any votes on the matters herein contemplated and that no issuance or sale of the Securities is created or intended
by virtue of this Letter Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">This Letter Agreement shall be binding on successors
and assigns of the undersigned with respect to the Securities and any such successor or assign shall enter into a similar agreement for
the benefit of the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: center">*** SIGNATURE PAGE FOLLOWS***</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: center"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Letter Agreement may be executed in two or
more counterparts, all of which when taken together may be considered one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Print Name</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Position in Company</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Address for Notice:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">By signing below, the Company agrees to enforce
the restrictions on transfer set forth in this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Modular Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 37%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form of Underwriter&rsquo;s Warrant</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I><U>(See attached.)</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 46; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Ex. C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ea026926401ex4-1_modular.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>MODULAR
MEDICAL, inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Warrant Shares: _______</TD>
    <TD STYLE="text-align: right; width: 50%; padding-left: 18.25pt; font-size: 10pt">Initial Issue Date: _________, 2025</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS COMMON STOCK PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
__________________ (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on _______, 20[30]
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Modular Medical, Inc., a company incorporated
under the laws of the State of Nevada (the &ldquo;<U>Company</U>&rdquo;), up to ___ shares of Common Stock (as subject to adjustment hereunder,
the &ldquo;<U>Warrant Shares</U>&rdquo;). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in <U>Section 2(b)</U>. This Warrant shall initially be issued and maintained in the form of a security held in book-entry
form and The Depository Trust Company or its nominee (&ldquo;<U>DTC</U>&rdquo;) shall initially be the sole registered holder of this
Warrant, subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agency
Agreement, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this <U>Section 1</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)
in all other cases, the fair market value of a share of Common Stock as determined in good faith by an independent appraiser selected
in good faith by the Board of Directors, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-3, as amended and supplemented (File No. 333-287313).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Colonial Stock Transfer, Inc., the current transfer agent of the Company, with a mailing address of 7840 S 700
E, Sandy, UT 8407018, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price per share of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price per share of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the
Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink
Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share
of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent
appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to
the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Agency Agreement</U>&rdquo; means that certain warrant agency agreement, dated on or about the Initial Exercise Date, between the Company
and the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Agent</U>&rdquo; means the Transfer Agent and any successor warrant agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise of
Warrant</U>. Subject to the provisions of <U>Section 2(e)</U> herein, exercise of the purchase rights represented by this Warrant may
be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery
to the Warrant Agent (with a copy to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice
of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;), and, unless the cashless exercise procedure specified
in <U>Section 2(c)</U> below is specified in the applicable Notice of Exercise, delivery of the aggregate Exercise Price of the Warrant
Shares specified in the applicable Notice of Exercise as specified in this <U>Section 2(a)</U>. Within the earlier of (i) two (2) Trading
Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in <U>Section 2(d)(i)</U> herein) following
the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable
Notice of Exercise by wire transfer of immediately available funds or cashier&rsquo;s check drawn on a United States bank unless the cashless
exercise procedure specified in <U>Section 2(c)</U> below is specified in the applicable Notice of Exercise. No ink-original Notice of
Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be
required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the
Warrant Agent until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Warrant Agent for cancellation within three (3) Trading Days of the date
on which the final Notice of Exercise is delivered to the Warrant Agent. Partial exercises of this Warrant resulting in purchases of a
portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Company and the Warrant Agent
shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Notwithstanding the foregoing in this
<U>Section 2(a)</U>, a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this Warrant held
in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect exercises made
pursuant to this <U>Section 2(a)</U> by delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction
form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation, as applicable),
subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agency Agreement,
in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise Price</U>.
The exercise price per share of Common Stock under this Warrant shall be $[&#9679;], subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless Exercise</U>.
The Company shall use commercially reasonable best efforts to cause the Registration Statement to remain effective with a current prospectus
and to maintain the registration of the shares of Common Stock under the Exchange Act for as long as this Warrant remains outstanding.
If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not
available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such
time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to
the quotient obtained by dividing ((A-B)(X)) by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">(A)</TD>
    <TD STYLE="width: 0.15in; font-size: 10pt; text-align: left">=</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">as applicable: (i) the VWAP on the Trading Day
    immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant
    to <U>Section 2(a)</U> hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to <U>Section 2(a)</U> hereof
    on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(68) of Regulation NMS promulgated
    under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately
    preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported
    by Bloomberg L.P. as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed
    during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2)
    hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to <U>Section 2(a)</U> hereof or (iii) the VWAP
    on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is
    both executed and delivered pursuant to <U>Section 2(a)</U> hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading
    Day;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">(B)</TD>
    <TD STYLE="width: 0.15in; font-size: 10pt; text-align: justify">=</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">(X)</TD>
    <TD STYLE="width: 0.15in; font-size: 10pt; text-align: justify">=</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act,
the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position
contrary to this <U>Section 2(c)</U>. Upon receipt of an Election to Purchase for a cashless exercise, the Warrant Agent will promptly
deliver a copy of the Election to Purchase to the Company to confirm the number of Warrant Shares issuable in connection with the cashless
exercise. The Company shall calculate and transmit to the Warrant Agent in a written notice, and the Warrant Agent shall have no duty,
responsibility or obligation under this section to calculate, the number of Warrant Shares issuable in connection with any cashless exercise.
The Warrant Agent shall be entitled to rely conclusively on any such written notice provided by the Company, and the Warrant Agent shall
not be liable for any action taken, suffered or omitted to be taken by it in accordance with such written instructions or pursuant to
the Warrant Agency Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Delivery of
Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent
to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered
in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder
is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest
of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the
aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the
number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the fifth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until
such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to <U>Section 2(d)(i)</U>
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of <U>Section
2(d)(i)</U> above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v. <U>No Fractional
Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As
to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to <U>Section 2</U> or otherwise, to the extent that after giving effect to such issuance after
exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons
acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties to the extent such issuance would exceed such limitation. Except as set forth in the preceding sentence,
for purposes of this <U>Section 2(e)</U>, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the
Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules
required to be filed in accordance therewith. To the extent that the limitation contained in this <U>Section 2(e)</U> applies, the determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice
of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each
case subject to the Beneficial Ownership Limitation, and neither the Company nor the Warrant Agent shall have any obligation to verify
or confirm the accuracy of such determination and neither of them shall have any liability for any error made by the Holder or any other
Person. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d)
of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this <U>Section 2(e)</U>, in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)
the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement
by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock
outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the
Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise
of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
<U>Section 2(e)</U>, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the
Holder and the provisions of this <U>Section 2(e)</U> shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61<FONT STYLE="font-size: 10pt"><SUP>st</SUP></FONT> day after such notice is delivered to the Company. The
provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
<U>Section 2(e)</U> to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial
Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.
The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock Dividends
and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which,
for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides
outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding
shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of
capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise
of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment
made pursuant to this <U>Section 3(a)</U> shall become effective immediately after the record date for the determination of stockholders
entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to <U>Section 3(a)</U> above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Pro Rata Distributions</U>.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, to the extent that the
Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares
of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation). To the extent this Warrant has not been partially or completely exercised at the time of such Distribution, such portion
of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power
of the then outstanding common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common
Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other
Person or group acquires more than 50% of the outstanding shares of Common Stock or 50% or more of the voting power of the then outstanding
common equity of the Company (not including any shares of Common Stock held by the other Person or other Persons making or party to, or
associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)
(each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction (without regard to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant), the number of shares of Common
Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(together, the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the
number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard
to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this <U>Section 3(d)</U> pursuant to written agreements in form and substance reasonably satisfactory to the Warrant
Agent and the holders of Warrants representing at least a majority of the shares of Common Stock underlying the Warrants then outstanding
(the &ldquo;<U>Required Holders</U>&rdquo;) and approved by the Required Holders (without unreasonable delay) prior to such Fundamental
Transaction and shall deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock
of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares
of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital
stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any
such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental
Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may
exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same
effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Calculations</U>.
All calculations under this <U>Section 3</U> shall be made by the Company to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this <U>Section 3</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Notice to
Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 3</U>, the Company shall promptly
deliver to the Warrant Agent pursuant to the Warrant Agency Agreement and to the Holder by email a notice setting forth the Exercise Price
after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring
such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice to
Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock,
(B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize
the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class
or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the
Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets
of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E)
the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in
each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant
Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a
record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in
the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that
any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain
entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Voluntary
Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of
this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of
the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days
of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New Warrants</U>.
If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be divided or combined with other
Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations
in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with <U>Section 4(a)</U>,
as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants
in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or
exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of
Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Warrant Register</U>.
The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No Rights
as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends or
other rights as a stockholder of the Company prior to the exercise hereof as set forth in <U>Section 2(d)(i)</U>, except as expressly
set forth in <U>Section 3</U>. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo;
pursuant to <U>Section 2(c)</U> or to receive cash payments pursuant to <U>Section 2(d)(i)</U> and <U>Section 2(d)(iv)</U> herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss, Theft,
Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to
it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of any Warrant held in book
entry form through DTC, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in
lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in
such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding. Notwithstanding the foregoing, nothing
in this paragraph shall limit or restrict the federal district court in which a Holder may bring a claim under the U.S. securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. No provision of this Warrant shall be construed
as a waiver by the Holder of any rights that the Holder may have under U.S. federal securities laws and the rules and regulation of the
Commission thereunder. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as
shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of
appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder to the Warrant Agent including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, or sent by a nationally recognized overnight courier
service, first-class mail, postage prepaid, addressed to the Warrant Agent, at <B>[</B>&#9679;<B>]</B>, Attention: [&#9679;], email address:
[&#9679;], or such other email address or address as the Company may specify for such purposes <FONT STYLE="background-color: white">by
notice to the Holders and the Company. Any and all notices or other communications or deliveries to be provided to the Company shall be
in writing and delivered personally, or e-mail, or sent by a nationally recognized overnight courier service, at 10740 Thornmint Road,
San Diego, CA 92127, Attention: James Besser, chief executive officer, email address: IR@modular-medical.com, or such other email address
or address as the Company may specify for such purposes by notice to the Warrant Agent Holders. Any and all notices or other communications
or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally
recognized overnight courier service addressed to each Holder at the </FONT>e-mail address or address of such Holder appearing on the
books of the Warrant Agent. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest
of (i) the date of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this <U>Section
5(h)</U> prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice
or communication is delivered via e-mail at the e-mail address set forth in this <U>Section 5(h)</U> on a day that is not a Trading Day
or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by
U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.
To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any
subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment
and Waiver</U>. Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action
herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent
of the Required Holders. Any such amendment shall apply to all Warrants outstanding and be binding upon all registered holders of such
Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">o) <U>Warrant Agency
Agreement.</U> If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued subject to the
Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the Warrant Agency Agreement,
the provisions of this Warrant shall govern and be controlling with respect to the rights and obligations between the Holders and the
Company, provided that, with respect to the rights, duties, obligations, protections, immunities and liability of the Warrant Agent, the
Warrant Agency Agreement shall govern and control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="text-transform: uppercase"><B>MODULAR MEDICAL, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%; font-size: 10pt">Name: </TD>
    <TD STYLE="width: 32%; font-size: 10pt">James Besser</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title: </TD>
    <TD STYLE="font-size: 10pt">Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><B>MODULAR MEDICAL,
INC.</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1) The undersigned hereby elects
to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) Payment shall take the form
of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: _______________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _______________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify">Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%; font-size: 10pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Phone Number:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Email Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Dated: _______________ __, ______</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Holder&rsquo;s Signature:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Holder&rsquo;s Address:</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>ea026926401ex4-2_modular.htm
<DESCRIPTION>FORM OF UNDERWRITER WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Underwriter&rsquo;s Warrant Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS PURCHASE WARRANT NOR THE SHARES OF
COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
OR ANY OTHER SECURITIES LAWS. THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER
OR ASSIGN THIS PURCHASE WARRANT EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT COVERING THIS PURCHASE WARRANT OR PURSUANT TO AN
EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT AND OTHERWISE AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT
AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING
THE DATE OF THE UNDERWRITING AGREEMENT (DEFINED BELOW) TO ANYONE OTHER THAN (I) NEWBRIDGE SECURITIES CORPORATION OR AN UNDERWRITER OR
A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF NEWBRIDGE SECURITIES CORPORATION OR OF ANY
SUCH UNDERWRITER OR SELECTED DEALER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR
TO JUNE 11, 2026. VOID AFTER 5:00 P.M., EASTERN TIME, DECEMBER 10, 2030.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">COMMON STOCK PURCHASE
WARRANT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">MODULAR MEDICAL,
Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; text-align: justify">Warrant Shares: _______</TD>
    <TD STYLE="width: 33%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: justify">Initial Issue Date: ___________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Initial Exercise Date: June 11, 2026</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<B>Warrant</B>&rdquo;) certifies that, for value received, [Newbridge Securities Corporation] [other designee] or its assigns
(the &ldquo;<B>Holder</B>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after June 11, 2026 (the &ldquo;<B>Initial Exercise Date</B>&rdquo;) and, in accordance with FINRA Rule 5110(g)(8)(A),
prior to 5:00 p.m. (New York City time) on the date that is five (5) years following the date of the Underwriting Agreement (the &ldquo;<B>Termination
Date</B>&rdquo;) but not thereafter, to subscribe for and purchase from Modular Medical, Inc., a company incorporated under the laws of
the State of Nevada (the &ldquo;<B>Company</B>&rdquo;), up to ___ shares of Common Stock (as subject to adjustment hereunder, the &ldquo;<B>Warrant
Shares</B>&rdquo;). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in <U>Section 2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this <U>Section 1</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Bid Price</B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined in good faith by an independent appraiser
selected in good faith by the Board of Directors of the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business
Day</B>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commission</B>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common
Stock</B>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common
Stock Equivalents</B>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exchange
Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Rule 144</B>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities
Act</B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trading
Day</B>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trading
Market</B>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer
Agent</B>&rdquo; means Colonial Stock Transfer, Inc., the current transfer agent of the Company, with a mailing address of 7840 S 700
E, Sandy UT 84070, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Underwriting
Agreement</B>&rdquo; means the underwriting agreement, dated as of December 10, 2025 between the Company and Newbridge Securities Corporation,
as amended, modified or supplemented from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>VWAP</B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price per share of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price per share of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the
Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink
Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share
of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Warrants</B>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company as underwriting compensation pursuant to the Underwriting
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a)&nbsp;<U>Exercise
of Warrant</U>. Subject to the provisions of <U>Section 2(e)</U> herein, exercise of the purchase rights represented by this Warrant may
be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery
to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the
address of the Holder appearing on the books of the Company) of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail
attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<B>Notice of Exercise</B>&rdquo;), and, unless the cashless
exercise procedure specified in <U>Section 2(c)</U> below is specified in the applicable Notice of Exercise, delivery of the aggregate
Exercise Price of the Warrant Shares specified in the applicable Notice of Exercise as specified in this <U>Section 2(a)</U>. Within the
earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in <U>Section
2(d)(i)</U> herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant
Shares specified in the applicable Notice of Exercise by wire transfer of immediately available funds or cashier&rsquo;s check drawn on
a United States bank unless the cashless exercise procedure specified in <U>Section 2(c)</U> below is specified in the applicable Notice
of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b)&nbsp;<U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $0.462, subject to adjustment hereunder (the &ldquo;<B>Exercise
Price</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c)&nbsp;<U>Cashless
Exercise</U>. This Warrant may be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which
the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing ((A-B)(X)) by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
<TD STYLE="width: 0.25in">(A)</TD><TD STYLE="width: 0.15in"> =</TD><TD STYLE="text-align: justify">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to <U>Section 2(a)</U> hereof on a day that is not
a Trading Day or (2) both executed and delivered pursuant to <U>Section 2(a)</U> hereof on a Trading Day prior to the opening of &ldquo;regular
trading hours&rdquo; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day,
(ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading
hours&rdquo; on a Trading Day) pursuant to <U>Section 2(a)</U> hereof or (iii) the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to <U>Section
2(a)</U> hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
<TD STYLE="width: 0.25in">(B)</TD><TD STYLE="width: 0.15in"> =</TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
<TD STYLE="width: 0.25in">(X)</TD><TD STYLE="width: 0.15in"> =</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the
terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this <U>Section 2(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d)&nbsp;<U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&nbsp;<U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<B>DWAC</B>&rdquo;) if the Company is then a participant in such system
and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by Holder, or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant
to Rule 144, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the
Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified
by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2)&nbsp;Trading Days after the delivery to the Company
of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company
of the Notice of Exercise (such date, the &ldquo;<B>Warrant Share Delivery Date</B>&rdquo;). Upon delivery of the Notice of Exercise,
the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which
this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of
Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason
to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, then the Company shall
pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the fifth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until
such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<B>Standard Settlement Period</B>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.&nbsp;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to <U>Section 2(d)(i)</U>
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of <U>Section
2(d)(i)</U> above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <I><U>provided</U></I>, <I><U>however</U></I>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">viii&nbsp;<U>Signature</U>.
This <U>Section 2</U> and the exercise form attached hereto set forth the totality of the procedures required of the Holder in order to
exercise this Warrant. Without limiting the preceding sentences, no ink-original exercise form shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any exercise form be required in order to exercise this Warrant. No additional
legal opinion, other information or instructions shall be required of the Holder to exercise this Warrant. The Company shall honor exercises
of this Warrant and shall deliver Shares underlying this Warrant in accordance with the terms, conditions and time periods set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e)&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to <U>Section 2</U> or otherwise, to the extent that after giving effect to such issuance after
exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons
acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties to the extent such issuance would exceed such limitation.&nbsp; Except as set forth in the preceding
sentence, for purposes of this <U>Section 2(e)</U>, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to
the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this <U>Section 2(e)</U> applies,
the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall not have any obligation to verify or confirm the accuracy
of such determination and neither of them shall have any liability for any error made by the Holder or any other Person. In addition,
a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder. For purposes of this <U>Section 2(e)</U>, in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;
Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the
number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise
of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
<U>Section 2(e)</U>, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the
Holder and the provisions of this <U>Section 2(e)</U> shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be
construed and implemented in a manner otherwise than in strict conformity with the terms of this <U>Section 2(e)</U> to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a)&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this <U>Section 3(a)</U> shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b)&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to <U>Section 3(a)</U> above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<B>Purchase Rights</B>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights; <I><U>provided</U></I>, <I><U>however</U></I>, to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c)&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other than
cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
return of capital or otherwise (including, without limitation, any distribution of stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<B>Distribution</B>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<I><U>provided</U></I>,
<I><U>however</U></I>, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the Beneficial Ownership Limitation). To the extent this Warrant has not been partially or completely exercised at
the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder
has exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d)&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power
of the then outstanding common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common
Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other
Person or group acquires more than 50% of the outstanding shares of Common Stock or 50% or more of the voting power of the then outstanding
common equity of the Company (not including any shares of Common Stock held by the other Person or other Persons making or party to, or
associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)
(each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction (without regard to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant), the number of shares of Common
Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(together, the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the
number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard
to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this <U>Section 3(d)</U> pursuant to written agreements in form and substance reasonably satisfactory to the Company
and the holders of Warrants representing at least a majority of the shares of Common Stock underlying the Warrants then outstanding (the
&ldquo;<B>Required Holders</B>&rdquo;) and approved by the Required Holders (without unreasonable delay) prior to such Fundamental Transaction
and shall deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e)&nbsp;<U>Calculations</U>.
All calculations under this <U>Section 3</U> shall be made by the Company to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this <U>Section 3</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">f)&nbsp;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 3</U>, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property,
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a)&nbsp;<U>Transferability</U>.
Pursuant to FINRA Rule 5110(g)(1), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred,
assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result
in the effective economic disposition of the securities by any person for a period of 180 days immediately following the commencement
of sales of the offering pursuant to which this Warrant is being issued, except the transfer of any security:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i.&nbsp;by
operation of law or by reason of reorganization of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii.&nbsp;to
any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject
to the lock-up restriction in this <U>Section 4(a)</U> for the remainder of the time period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iii.&nbsp;if
the aggregate amount of securities of the Company held by the Holder or related person do not exceed 1% of the securities being offered;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iv.&nbsp;that
is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or
otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the fund;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">v.&nbsp;the
exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this <U>Section 4(a)</U>
for the remainder of the time period.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the foregoing restriction,
the Securities Act and any other applicable securities laws, and the conditions set forth in <U>Section 4(d)</U>, this Warrant and all
rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers
an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b)&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with <U>Section 4(a)</U>, as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c)&nbsp;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<B>Warrant
Register</B>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d)&nbsp;<U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Registration
Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a)&nbsp;<U>Piggyback
Registration</U>. To the extent the Company does not maintain an effective registration statement for the Warrant Shares and in the further
event that the Company files a registration statement with the Securities and Exchange Commission covering the sale of its shares of Common
Stock (other than a registration statement on Form S-4 or S-8, or on another form, or in another context, in which such &ldquo;piggyback&rdquo;
registration would be inappropriate), then, for a period of five (5) years from the commencement of sales of the offering, the Company
shall give written notice of such proposed filing to the Holder as soon as practicable but in no event less than ten (10) days before
the anticipated filing date, which notice shall describe the amount and type of securities to be included in such offering, the intended
method(s) of distribution, and the name of the proposed managing underwriter or underwriters, if any, of the offering, and offer to the
Holder in such notice the opportunity to register the sale of such number of shares of Warrant Shares as such Holder may request in writing
within five (5) days following receipt of such notice (a &ldquo;<U>Piggyback Registration</U>&rdquo;). The Company shall cause such Warrant
Shares to be included in such registration and shall use its commercially reasonable efforts to cause the managing underwriter or underwriters
of a proposed underwritten offering to permit the Warrant Shares requested to be included in a Piggyback Registration on the same terms
and conditions as any similar securities of the Company and to permit the sale or other disposition of such Warrant Shares in accordance
with the intended method(s) of distribution thereof. All Holders proposing to distribute their securities through a Piggyback Registration
that involves an underwriter or underwriters shall enter into an underwriting agreement in customary form with the underwriter or underwriters
selected for such Piggyback Registration. Furthermore, each Holder must provide such information as reasonably requested by the Company
(which information shall be limited to that which is required for disclosure under the Securities Act and the forms, rules and regulations
promulgated thereunder) to be included in the registration statement timely or the Company may elect to exclude such Holder from the registration
statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b)&nbsp;<U>Confirmation
of Effective Registration Statement</U>. Upon the written or oral request of a Holder, the Company shall within two Trading Days of such
request confirm orally and in writing to the Holder whether (i) the Commission or any state authority has issued any order preventing
or suspending the effectiveness of the registration statement filed pursuant to Section 5(a) or the use of the prospectus included in
such registration statement and any prospectus supplement filed with respect to the Warrant Shares, or instituted or, to the Company&rsquo;s
knowledge, threatened to institute, any proceedings with respect to such order, (ii) the Company at the time of such request and, to the
Company&rsquo;s knowledge, for at least the five (5) Trading Days following such request, satisfies the conditions for use of Form S-3
and the prospectus, as supplemented by a prospectus supplement related to the Warrant Shares, is still a valid prospectus for purposes
of Section 10(a) of the Securities Act and (iii) the Company is aware of any reason why Warrant Shares issued upon the exercise of the
Warrant within five Trading Days of such request would be issued subject to a restrictive legend or otherwise not freely tradable.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 6</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a)&nbsp;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in <U>Section 2(d)(i)</U>, except as expressly
set forth in <U>Section 3</U>. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo;
pursuant to <U>Section 2(c)</U> or to receive cash payments pursuant to <U>Section 2(d)(i)</U> and <U>Section 2(d)(iv)</U> herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b)&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c)&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d)&nbsp;<U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">The Company covenants that,
during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares
to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants
that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary
Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be
necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or
of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which
may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Except and to the extent as
waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times
in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to
protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company
will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such
increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally
issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain
all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable
the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company
shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or
bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e)&nbsp;<U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">f)&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">g)&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. No provision of this Warrant shall be construed
as a waiver by the Holder of any rights that the Holder may have under U.S. federal securities laws and the rules and regulation of the
Commission thereunder. Without limiting any other provision of this Warrant or the Underwriting Agreement, if the Company willfully and
knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay
to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo;
fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing
any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">h)&nbsp;<U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">i)&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">j)&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">k)&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">l)&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Required Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">m)&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">n)&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="text-transform: uppercase">MODULAR MEDICAL, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 37%"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name: James Besser</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Title: Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left">&nbsp;</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">[Signature
Page]</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">Modular
Medical, Inc. &ndash; Underwriter&rsquo;s Warrant</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase">TO:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase">modular medical, inc.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">_________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1)&nbsp;The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2)&nbsp;Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">[ ]</TD><TD STYLE="text-align: justify">in lawful money of the United States; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">[ ]</TD><TD STYLE="text-align: justify">if permitted the cancellation of such number of Warrant
Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum
number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3)&nbsp;Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Warrant Shares shall be delivered to the following DWAC Account
Number or by physical delivery of a certificate to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(4)&nbsp;<U>Accredited
Investor</U>. If the Warrant is being exercised via cash exercise and the registration statement registering the issue of the shares under
the Warrant is no longer effective, the undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under
the Securities Act of 1933, as amended</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: _______________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%; text-align: justify"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">Address:&nbsp;</P></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone Number:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Dated: ________________ __, ______</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Signature:___________________________</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Address:____________________________</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>ea026926401ex5-1_modular.htm
<DESCRIPTION>OPINION OF LUCOSKY BROOKMAN, LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">December 11, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Modular Medical, Inc.<BR>
10740 Thornmint Road<BR>
San Diego, CA 92127</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RE: Registration Statement on Form S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as counsel to Modular Medical, Inc.,
a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), in connection with the above-referenced registration statement (the &ldquo;<B>Registration
Statement</B>&rdquo;), the base prospectus dated May 22, 2025 (the &ldquo;<B>Base Prospectus</B>&rdquo;) and the prospectus supplement
dated December 10, 2025 (the &ldquo;<B>Prospectus Supplement</B>,&rdquo; and together with the Base Prospectus, the &ldquo;<B>Prospectus</B>&rdquo;),
relating to the offering and sale by the Company of 12,173,000 shares (the &ldquo;<B>Shares</B>&rdquo;) of common stock of the Company,
par value $0.001 per share (the &ldquo;<B>Common Stock</B>&rdquo;), and accompanying warrants (the &ldquo;<B>Warrants</B>&rdquo;) exercisable
to purchase up to 6,086,500 shares of Common Stock (the &ldquo;<B>Warrant Shares</B>&rdquo;), having an aggregate offering price of $4,686,605,
pursuant to that certain Underwriting Agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;) dated December 10, 2025, between the
Company and Newbridge Securities Corporation. The Shares and Warrant Shares are covered by the Registration Statement, and we understand
that the Shares, the Warrants, and the Warrant Shares are to be offered and sold in the manner described in the Prospectus. This opinion
is being delivered at the request of the Company and in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated
by the U.S. Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this opinion, we have examined
such documents and reviewed such questions of law as we have considered necessary and appropriate for the purposes of our opinion set
forth below. In rendering our opinion, we have assumed the authenticity of all documents submitted to us as originals, the genuineness
of all signatures and the conformity to authentic originals of all documents submitted to us as copies. We have also assumed the legal
capacity for all purposes relevant hereto of all natural persons and, with respect to all parties to agreements or instruments relevant
hereto other than the Company, that such parties had the requisite power and authority (corporate or otherwise) to execute, deliver and
perform such agreements or instruments, that such agreements or instruments have been duly authorized by all requisite action (corporate
or otherwise), executed and delivered by such parties and that such agreements or instruments are the valid, binding and enforceable obligations
of such parties. As to questions of fact material to our opinions, we have relied upon certificates of officers of the Company and of
public officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon and subject to the foregoing, we are
of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">the Shares have been duly authorized and, when issued and sold by the Company and delivered by the Company
against receipt of the purchase price therefor, in the manner contemplated by the Prospectus and the Underwriting Agreement, will be validly
issued, fully paid and non-assessable; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">upon due exercise of the Warrants and payment to the Company of the applicable aggregate exercise price
in accordance with the terms of the Warrants, and when certificates or book-entry evidence of ownership for the Warrant Shares have been
duly executed and countersigned and delivered in accordance with and pursuant to the terms of the Warrants, the Warrant Shares issuable
upon such exercise will be duly and validly issued, fully paid and non-assessable shares of Common Stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The opinions expressed herein are limited to the
laws of the Nevada Revised Statutes of the State of Nevada and the laws of the State of New York, as currently in effect, and no opinion
is expressed with respect to any other laws or any effect that such other laws may have on the opinions expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the filing of this opinion with
the SEC as Exhibit 5.1 to the Company&rsquo;s Current Report on Form 8-K filed on December 11, 2025, which is incorporated by reference
in the Prospectus. We also consent to the reference of our firm under the caption &ldquo;Legal Matters&rdquo; in the Prospectus and in
each case in any amendment or supplement thereto. In giving this consent, we do not thereby admit that we are in the category of persons
whose consent is required under Section 7 and Section 11 of the Securities Act of 1933, as amended, or the rules and regulations of the
SEC promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ea026926401ex99-1_modular.htm
<DESCRIPTION>PRESS RELEASE DATED DECEMBER 9, 2025, REGARDING THE LAUNCH OF THE OFFERING
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: right"><B>Exhibit
99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Modular Medical Announces Proposed Public Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO, CA/ACCESSWIRE/ December 9, 2025 --
Modular Medical, Inc. (Nasdaq: MODD) (&ldquo;Modular Medical&rdquo;), an insulin delivery technology company with the first FDA-cleared
patch pump designed specifically to target all adult &ldquo;almost-pumpers&rdquo; with its user-friendly and affordable design, today
announced that it has commenced an underwritten public offering (the &ldquo;offering&rdquo;) of shares of its common stock and warrants
to purchase shares of its common stock. The shares of the common stock and the accompanying warrants are immediately separable and will
be issued separately but can only be purchased together in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modular Medical expects to grant the underwriter
a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock and /or warrants sold in the
offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may
be completed or as to the actual size or terms of the offering. All shares of common stock and warrants to be sold in the proposed offering
will be sold by Modular Medical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Newbridge Securities Corporation is acting as
the sole bookrunner for the proposed offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering is being made pursuant to an effective
&ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-287313) previously filed with the Securities and Exchange Commission
(the &ldquo;SEC&rdquo;) on May 15, 2025 and declared effective by the SEC on May 22, 2025. The securities may be offered only by means
of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering
will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and accompanying prospectus and, when available,
copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by visiting the SEC&rsquo;s
website at www.sec.gov or by contacting Newbridge Securities Corporation, Attn: Equity Syndicate Department, 1200 North Federal Highway,
Suite 400, Boca Raton, Florida 33432, by email at syndicate@newbridgesecurities.com
or by telephone at (877) 447-9625.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release does not constitute an offer
to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities
laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Modular Medical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modular Medical, Inc. (Nasdaq: MODD) is a medical
device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company
seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple
to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes, taking it beyond &ldquo;superusers&rdquo;
and providing &ldquo;diabetes care for the rest of us.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modular Medical was founded by Paul DiPerna, a
seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005)
of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All trademarks mentioned herein are the property
of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking statements
that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements
can be identified through the use of words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;intend,&rdquo; &ldquo;should,&rdquo;
&ldquo;could,&rdquo; &ldquo;can,&rdquo; &ldquo;would,&rdquo; &ldquo;continue,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;outlook,&rdquo; &ldquo;potential,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo;
and similar expressions and variations or the negatives of these terms or other comparable terminology. Such forward-looking statements
are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements
contained in this press release, including whether or when the offering may be completed, as well as other risk factors and business considerations
described in Modular Medical&rsquo;s SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press
release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press
release represent Modular Medical&rsquo;s views only as of the date of its publication and should not be relied upon as representing its
views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contact Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Jeb Besser</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Modular Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (617) 399-1741</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IR@modular-medical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>7
<FILENAME>ea026926401ex99-2_modular.htm
<DESCRIPTION>PRESS RELEASE DATED DECEMBER 10, 2025, REGARDING THE PRICING OF THE OFFERING
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: right"><B>Exhibit
99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex99-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Modular Medical Announces Pricing of $4.68 Million
Public Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO, CA/ACCESSWIRE/ December 10, 2025 --
Modular Medical, Inc. (Nasdaq: MODD) (&ldquo;Modular Medical&rdquo; or the &ldquo;Company&rdquo;), an insulin delivery technology company
with the first FDA-cleared patch pump designed specifically to target all adult &ldquo;almost-pumpers&rdquo; with its user-friendly and
affordable design, today announced that it has priced an underwritten public offering (the &ldquo;offering&rdquo;) of 12,173,000 shares
of its common stock and accompanying warrants to purchase 6,086,500 shares of its common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each two shares of common stock are being offered
and sold together with one accompanying warrant at a combined offering at a price of $0.77, yielding an effective price of $0.38 per share
and $0.01 per warrant. The warrants will have an exercise price of $0.45 per share, are exercisable immediately upon issuance and will
expire five years following the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the offering, Modular Medical
has granted the underwriter a 30-day option to purchase up to an additional 15% of common shares and/or warrants at the public offering
price, less underwriting discounts and commissions. The over-allotment option may be elected with respect to, at the underwriter&rsquo;s
sole discretion, shares and warrants together, solely shares, solely warrants, or any combination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Newbridge Securities Corporation is acting as
the sole bookrunner for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming no exercise of the over-allotment option,
the gross proceeds to the Company from the offering are expected to be approximately $4.68 million, before deducting underwriting discounts,
commissions, and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to
fund operations and for working capital and general corporate purposes, including capital expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering is expected to close on or about
December 11, 2025, subject to the satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities described above were offered by
Modular Medical pursuant to an effective &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-287313) previously filed
with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on May 15, 2025 and declared effective by the SEC on May 22, 2025.
The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating
to and describing the terms of the offering have been filed with the SEC. The final prospectus supplement relating to the offering will
be filed with the SEC. Electronic copies of the preliminary prospectus and, when available, copies of the final prospectus supplement
and the accompanying prospectus relating to the offering may be obtained by visiting the SEC&rsquo;s website at www.sec.gov or by contacting
Newbridge Securities Corporation, Attn: Equity Syndicate Department, 1200 North Federal Highway, Suite 400, Boca Raton, Florida 33432,
by email at syndicate@newbridgesecurities.com or by telephone at (877) 447-9625.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release does not constitute an offer
to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities
laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Modular Medical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modular Medical, Inc. (Nasdaq: MODD) is a medical
device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company
seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple
to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond &ldquo;superusers&rdquo;
and providing &ldquo;diabetes care for the rest of us.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modular Medical was founded by Paul DiPerna, a
seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005)
of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All trademarks mentioned herein are the property
of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This press release contains
forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified through the use of words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo;
&ldquo;intend,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;can,&rdquo; &ldquo;would,&rdquo; &ldquo;continue,&rdquo; &ldquo;expect,&rdquo;
&ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;outlook,&rdquo; &ldquo;potential,&rdquo;
&ldquo;plan,&rdquo; &ldquo;seek,&rdquo; and similar expressions and variations or the negatives of these terms or other comparable terminology.
Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different
from the forward-looking statements contained in this press release, including the satisfaction of customary closing conditions related
to the offering, the expected closing date of the offering and the expected use of proceeds, as well as other risk factors and business
considerations described in Modular Medical&rsquo;s SEC filings, including its annual report on Form 10-K. Any forward-looking statements
in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included
in this press release represent Modular Medical&rsquo;s views only as of the date of its publication and should not be relied upon as
representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except
as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contact Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Jeb Besser</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Modular Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (617) 399-1741</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IR@modular-medical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  > )X# 2(  A$! Q$!_\0
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I]G67_/']#_A4\$5O;H(H@ J]NI_EQ5FBDVWJVV^[;;^]MC_7?S]3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !* )8# 2(  A$! Q$!_\0
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MZOQ-@.'L\E7Q4/:9OD]2MCL'@Z\7BEA%'$X7#SPBA]6YJD93<7[6G%R_R_\
M%GQ]\9> /I+<95,KS7&YMX2>&E'@/-^-.$:>%P%2-'AGB6C@LJS+,L-.. >8
M.>#Q^.ACG5^O<E"K"BJB6'KS4/[!M=T31O%&AZSX<\1:99ZSH'B#2=1T/7='
MU*!+G3M6T?5K.:PU33+^VE#17-E?V-Q/:W,$BLDT$TD;J58U_FW:_9>./^#;
M;_@MC::KIJ:]<?LH>/+E[JVC5[NXA\;?LE_$?6XQJVC'_H+^+_@3XBMXY+<.
MOVBZU'PEILS"*S\3[YO]#_\ 9[^-?AC]H3X0>"OBSX6FC%CXITF*:_T_S4DG
MT/7K8_9M=T&]"L0EUI>IQW%JVY5:6-8IT'E21L?R1_X. O\ @FQ#_P %"/V)
M?$&H^ ]#BOOVD/V<X=8^*/P6EMX$;4_$UM9Z?O\ 'GPL$J1O<3P>.?#]F3I%
MFO!\9Z1X9DRD8N"?P/A3'RX>SS,>'.(:,Z.6YI*OD.?8.NG!X3$0K5,-3Q4H
M22Y*V!Q*5YV5J<E-2Y5%O_1'$5\'Q-D.4\3<.XJCC:=;"83/<CQ^'FITL;@L
M7AZ6+I\DXN2E#$X:HO=N^6K&=.4>>$XK]&_VI_VTO@O^RK^R!X^_;.\6>(M/
MUGX7>%?AU;^//"USIE];C_A8L_B.PMI?A[X>\*SRNB7M_P"/=3U/1].T41AL
MC45NI$%M!,Z?P]?\$$_V4/B-_P %5_\ @I)\7/\ @IE^U7:?\)+X+^$WQ);X
MF7_]H0+/H/B[]H76BM]\//!&EVMVLL,GA'X,^'H]/UI;*'?#ITFF> M-E5H+
MJX2OQ=/[8/[9G[;'[.7[&O\ P2=T);OQ3H7P_P#BW>:/\*O#T,M_#XC\9:_X
MNOTTOX>>%?&R32)!_87P;CU+Q4NB/<1I)I6CZE<MJ;QQ^'+ Q?ZA?_!/+]BS
MP)_P3[_9&^$/[+W@3R+P>!]#%YXV\416Y@G\=_$K72NI>._&EXK9DWZSK<EP
M-/@E9CI^BVVE:5&1;V$*I]'F> 7AQD.98/V]*OQ#Q-6KX2AB*,XRGA.&Z,W'
MVR<=:57,5*$9<KLG.48R:IW.?"8E<49AAJ_LZD,MRJ,*U2G4BX*MFLTKTW%_
M%'"M2WOJE=:Z_;'0$D9^OJ3^( SCO]>E?A5^U1_P5Q\0_"?XV>*_AI\(O _@
MGQIX>\%31:%JOB77[[65:]\56X<Z[:Z:-*N(K=M.TF9H]-,S^8\U];WNUA&B
M"ON;_@H3^U''^S%\ ]7U/1KN./XD^.Q<>#_AW;,P,T&IWEN?[2\2%"&S!X8T
MZ1]0#.IA>_-A;-S<*I_FPA_9QO\ 2_V-M?\ VH?%T5TUWXP^*'AGP;\/%NVG
M6>\TGS]:G\6^*YA(JFZ;6M5M1865T[.)([/4;H9-U&Z_8>"'AYPUFE'_ %HX
M^P7UO)<TSC \(\,994G6H_VMGF/KI8C%0]A7PU6IALLI4VISC4<%*5><U/V<
M8/\ CSZ7GCEQ]P_C5X=^#&:2R[BKA_AG-/$CQ!S_  ]/"XC_ %<X3RG#/ZGE
M]1XK"X[#4L9G.(Q$*D:<Z/MYTU@Z--P]O4FOZ??V(/VB_$O[4'P*T[XJ^*_#
M^A^&]7N_$7B+17TS0);Z73T@T:[6V@F1M0DEN?-F5MTRLY0' 0 <U]A\_P"?
M\_X?3U_+?_@D*?\ C#C1/^QZ\<C_ ,J2?UYK]1\XSD]_Y@?U-?CO'^78+)^.
M.+,JRW#QPF7Y?G^9X/!8:#G*%##T,1R4J49U)U*C4(Z)SG.3ZR;U/ZG\$<]S
M?B?PA\->(L^QM3,<ZSK@[),RS7'U8TH5,9C<5A95,1B)PHTJ-&,JD[2<:5*G
M!6M&$5H+12$C@Y')P.^<\X'Y=:,]/?MW_P CO7R-_P"OE<_4KBT4F1ZCKCKW
MY&/J",$=J,^O'\NN!STY].#[4N;;S]5;[TOQL,6BC(Z9Y]*0\8 QR>Y//X\_
MY_"JN M%)G].O(XZ_P"%+G\?R]/K^'_UN:3=KZ %% Y]OK10G?R _ [_ (+C
M\Z#^SIG.?[;^(@&"/^@;X>[=O0\_GSCZ?^!GP+\/_M,_\$P?A5\*M?\ +CFU
MKX:+)X=U9D+3:!XJTG4]4DT#68&QO7[%?QQI<HI!GL9;JU;Y)FQ\O_\ !<4X
MT3]G(\<Z[\0L8[C^S/#QSD=SCK]?:OT'_P"";#E_V(/V?N=VWPKJ2Y;)/R^)
M]<"@XYPO"C'![<5_2.<8W%Y9]'_PHS3 5IX?'9=QWGF,PF)IMJ=+$4:F(JTI
MQEI\,Z2YHWM.#E!IQG)/^ .%<IRSB+Z:GTD.&\ZPE+'91GWA#POEF98*O%2I
MXG!8K#Y9A\13E&2DDW3KN4)I<U*K"E5@U.G&2_(W_@EW\>?$?[.?Q_\ %G[)
MWQ8,FB:?XO\ $EYHUI8W[NL7ASXLZ.QLQ;0[LI'8^,[*!(8)5 CN;NWT>:-M
MU\S/_2R,D#@<>AZ=\XXY/'7(R.F,U_/O_P %@OV9+O1=5\.?M:?#ZWFL+J*]
MTC0OB3/I<;QW.GZK9S1_\(5X\1XE/DW%O/#!HE_>'85D31)'8E7+?IY^PK^T
MS:_M0_ 'PWXQNYX/^$Z\/[/"?Q)T^)E5[;Q3I<$2OJ2PC#1V7B&R-OK=FZHJ
M 74UL/GMI57R/%G X3B[(\B\8LDHTZ=//53RCC3!8>/NY9Q9@Z,*4Z\XQUC0
MS6E256%222G/V3YG.<K_ %'T:<WS/PPXOXP^BYQ=BJU>MPA*OQ-X59KBY-2S
M_P /,SQ-7$PP5"527[S$Y#6KRA4HTW)TJ7UR$80ITHI<[\,/^"8G[ 7P8^/%
MU^T[\+/V5OA7X)^/%WJ_BS7F^(^BZ9?QZK;ZSXY^V?\ "5ZEIUE/J$VBZ5=:
MRNHW\<\VEZ99M%#>W<-IY$,\JM]S7=U;V5O/=W<\5M:VL,MS=7,SK';V]O;H
MTDTTTKL$CBAC1I)&<JBH"[$ '%L9Z'KR>.G6OR%_X*V_M4_\*C^$47P5\*:I
M]F\>?%^TNHM8N+2=X[OP_P##F!S#K=V9(7$EO<>(I0-"L2Q!DM'U:5"#;JP_
M+N&,BSGCOB;)>'L-6KXG&YC7HX15L15JXA8/!4_?Q.(J2J3J.&&P6%C7KN/-
M"'N4Z:2=5']*>)O'N0>$W /$_'><JE2P&0Y?6Q=/#4_9T:F99G63H99EM!)1
M<\5F685,-A86C.<82KU6N6@S\ROBWXB\4?\ !37]NC2_!/A"YO%^&>C7MSX=
M\/7UN ;?1/AGH-XLOC'QP_6$7OB:Y!?3'EVR2FYT"RSF,@_HS_P5J\+Z!X _
M8I^'G@GPKIUOHWASPW\2O 'A_1--M8DBAL],TO0/$,-O"$0 ;@D 9W/S2R%I
M&.YF)[C_ ()1_LK_ /"DO@P?BIXJTP6?Q%^,EK8ZJ(+F+9=>'? ,0\[PQH@4
MEC!/J*2G7M2C7:P:ZL[25-]@N.<_X+12[/V7O"$>/]=\9/#1]SY>A^)#GU.-
MQ]^M?T!+B3 9EXS>&/!'#,TN$. <\P&3Y6H27)F&84'B'G&<57'W:M7%8NE7
MIPK:N5.%6<9<M6+/X8CP%G61?14\?/%WCV$JGB=XS\*YGQ1GTJT)*KDV1XZK
M@O\ 5OANA&HG5PU#!X#$8;$UL,I05.=3"4IP4J$HKNO^"0W_ "9QH?OXZ\<?
M^G-!_3\Z_44# &?53W&.%'I]<C_(_+K_ ()#?\F<:)R"/^$[\<X(_P"PFA_/
MU_*OU&.,C/TZGV[?B#Z]#]/Q#Q2O_P 1&XY[OB?.+^OUM6WVW_#J?V!]'-?\
M:&\(?+@'ASO_ - 4OGMWU/Y4O@G^TW\6/V$OB5^W!\=;[1OB?\</A+^TU^WE
M^V;\&?!WPY@_X2#Q/<>#OVR? WQ%FTG]G#PAX9@9KN7PQ\/_ -I#0;R7P1K%
M^D</ASPEXI\#Z#JD]S9V>O.@\Z\/^!_V@O@?\/\ ]O+P!XZ^)WQ>\>1#_@H3
M^PKXB_;U^('A#7?'-SJ\/P;^+?PX^&?CW]KV;X<OX>D/BKP?\*-.OO$E[H-S
MI_@%+._T#X2VFI^1Y;1W;K^IO[*/_!2_6?%/QQ_;@^&/[56F> /AEX*^"WQ4
M_::UW]GOXC:1;WUAI/C3X&?LN>+AX/\ C0?&#7U[J$:?$CX47T_AWQ'X@>P^
MS+J_A7QKH^KV6EVZ6-\S?(&G?\%8_P!K_5_@5^TE\3]8\"?#'X0^(-'_ &S_
M -C_ .%OPCTB^^'GC7QWX@\)?L[_ +6D7P[UOPIK7Q-\%Z!XAM]=\7_&*Q^'
MWCFP\07OAGPR;+[+J]VGAJWT^^N+8F87]H3K8B$<MPD:DWE,<14>)I.%=25)
MY>J36'=YTJ2J?6'1C>-:-*IB(N=!0J_HE\,H47]=KR@HXSV=-4Y<T$HR>(<U
M[1-*4^3V:FW[KG"G)1FY1]&N)O@/H?[3NG:=_P $W==TJ]^#U]^QM^U-J/[7
MUI\"O$NI>(_@;IKV_@W0+G]F[6-8N],O]3\$Z+\<KGQ-<^*8M'.B7=G\0=1\
M)R>)9O$L-QIMEILL'S7^S%J?P:M?@#_P2EO?V(?$4>J?MQ:YJ_[*0^/VG_"?
MQ1XC\2+J_P 'K[1K"3]J&Y_:SL[/4]2\-VVC6OA=-;U&'4OB&EMXQL_B5!X=
M7P5)_;<S6LWW;\7_ -J/]I7X%?LQ>+?B/X.^*'PY\;>)]9_:)_9-^"'AAO$W
M[$WQC_9VT/PA-\?/CYX#^%/B[Q-J7A/X@^+M(U3XC26^@>,_[0TXZ+=Z;96.
MJ::EOJ5]<^>;>/TOQE^U)^T)^RO\0/'?P/\ B[;_  9^(/B+Q)^R)^T9^TW\
M$_BQ\-O!.M_#J"X\1?LZ6&D3>)_!7Q9^&UYXI\5)):S'QIX6U'0/%/AWQA;)
MJ%O!K6C7NCV5VMMJDW!&IB)4:5.G2A6M*7*ZF)O5QBP]*5"L\9&6%@JU.G+,
MZ,N7GA+DI04.;EE-=3C3YY2G.4$TKN-/W*+K3C4I^P<:TG"4EA*D5)IKFG)N
MR:C+X*O_ (Z^%O ?_!+[_@HQ^S/XS^)>H^&_VL[WXE_\%"?!G@;X+ZSK>OP_
MM :_K?QB^,?Q8U7X"6WPY\)>8_CKQ/8>-O#WBCPE?> M<\$VVH^'X]*OK5K3
M4;*VTV\%C]'?LS?'_P"&O[/O[>O[;GAK]H_XU^$_A-/_ ,,U_P#!-N+1-&^+
M?Q&L/#-O)J>D_"KXMVWC:70+;Q/J]O837=IJ36*>)[G2 \DEV]D^IRR.8''H
M?PQ_:O\ VB_VJ_&G[/?PH^%4GP:^$_Q%U#]@#]G?]LOXV?&CQ?\ #O5/B.;&
M^_:#BU/3?#OPX^$W@.+Q=X3:ST\ZSX5\;:IX@U[Q%XRO?[,TIM"TC3M*U"]O
M;W5+/U3XV_M*?&?]FS]DOQ7XW_:7\"_ >;]I6\^*2_L_?L^+HVK+!\-/C9XW
M\?\ B&'PS\$O&.I6OB:>35/AMI.IPWDGC'XH>#M1\2:N_@[P_P"$_%US9>*-
M0LHK*Z.=>527ML'/"T56QU2<Y4HXFG[:G/$5,/252FOJ_+'#1_LJM4;E)SIT
MZDZDU&"7-5-1BH5HU9NGAH)1G*E-PE&DJLY1G:KS.N_K=.$;1Y93BHQ;D_=^
M'OVV?%/QR_;A^/WB;0/V4= ^-?B[P)^P]X7TSQE\)OB9\#O&/PXT3P)XI_X*
M#ZYIWA_Q]\/M.^(%[XO^*OP_A\=_"#X;_"R]T[2O%^C:1'XAT;4+WXRZM!J-
MN^I^%[)(O+_BG\1M;_;X_:^_8#^('@/X$> /BU'XQ_X)_P#[7'B3Q=^SY^T#
MXZ\8?#WP7X)^+7@+XU_L^>#_ !SX=U:XT/PEXRB/Q,^'/CA?$?P[LYM5\->2
M-.O==U2WU&"T>$W7V)/_ ,%(/'MM_P $]O%GQMT6R^$#?M+? S]H3X8_LR?'
MOPUX<>37_A=:?$34?CU\-_AEXL\1^$4TS7%OI?"/CSX?^-+#XE_#6YN-7N)K
M72O$FBVVIRW]WIFHP-^V$=K:1R>9':V\<H,S>8D,22;IW$MPV]4!S/(%DF.<
MR2 ,^6 -8U,95R^%&G/ T8NA'&8/"S5>;G[U"E3Q4YRA&FYQK5*]'&4JD)0N
MI1]FXPDT:4Z4<1.<XXBI+VGL:]:+II12YZCHQ@I.2C*$(3H5(24G>+Y[RU/R
MT_X(\76I3?LF:S;>(?$6M1^+K#X\_&JW\6_ [7KWQ1J5[^R%K?\ PEDC3?LI
MV>J>-+V]\3:[X>^%,)A'AGQ->&VTSQ1H>M66O^%K2W\)ZAHB K]4$BBC:5HX
MHXWF823.B*K3.$6,/*P ,CB-$0,Y+!$5<[5 !7B8BM]8KUJZA[-5JDJGLTTU
M#F4?=3M%M+ELFUS-*\W*;G.?H4:;HTJ=+FYO9P4>9J5Y6<M7J[-W5TG9/2*4
M5&,?E#]J']CSX4?M96O@VU^*%QXK@C\#W6L7>C'PQK$>E,9-;@LX+P7A>UN_
M.14L8O) ""-O,)W!ACU_X*?"+PM\"/A?X2^$W@J35)/"_@VRGL-)?6KQ;[5&
M@GOKK4)#=W:Q0K,YGNYL,(DQ'L3!VY/ITO8=OEX_''\JD7[H_P ]Z]"MGV=8
MC*,)P]7S3&ULDR_$5<5@LJJ5G+!87$UU-UJ]"CRKDJ5/:3YY<[OS/1'S6#X(
MX2P'%6:<<8+A[*\-Q=G6!H9;FW$-'#\N:9A@,+[)8?"8K$>UE[2A1]A1]G#V
M4;>SA[SMKR/C[P+X9^)G@SQ/X!\9Z;#J_A?Q=HU]H6MZ?/@K<6%_"\,FQ]NZ
M&>+>)K:=#YEO<1Q31G>BD?+?[,7[#GPF_90U_P 1Z[\+M=^(;#Q3I-OI6MZ/
MXD\2)K&CW8LKDW%AJ+6?V*W*ZK9^9<00WH;>;6YGA<,C+L^TSU'U_H?\!42?
M>'OG/Y4L-GV<X'*\PR3"YGC*&49M.C/,LMIU?]BQM3#ZT*E>A*$X2J4N5<E2
M/LYJR]^R*S+@GA/-^(\CXNS+A_+,9Q/PW3Q-'(L^JX=_VIE='%\WUFAA<73J
MTJD:%?GG[2C45>C+GE^Z7-*\FT' ))Q^'N.GI^O?-? /Q1_X)S? 7XS?&B;X
MV?$?4/B#XC\2W&J:)>OH]SXCB3PLMCX>:"33?#T>DI8;ET!3"?M-B+C-T;B\
M>65GN92?O\=_J?T)Q^51G[_XC^E/)\]SG(*];%Y'F>+RK%8C"U\%6Q&!J^QK
MSPF(7+7H>U4)3A3JQ]V:IRIMK3G22L^*N"^%.-\%A,NXNR#+>(LOP.8X;-L+
M@LUH/%86EF6"DI83&?5Y5:=*I6P\GS4G6A6A%MM4VVVV1V\4$:10QI%%$BQP
MQ1J$CCC10B1HJ[0JJJJJ*H"HH51P,5\]?M*_LR_#S]J;P1IG@+XE3^(8-$TG
MQ'9^)[5_#6I)I5[_ &E96EY9Q++<R6]QOMO)OIR\00;G$;;QM(/T;3).GX_T
M-<F S+'91C\-FF68O$8',<%6CB,)C<-/V>)P]=<\55I5&IN-1*<[2LW[SW;N
M>AGO#^2\39+F'#N?Y9@\VR/-<*\%F.5XVDJF"QF$DZ;>'KT5*FI46Z5+W%*"
M7LX6LHI'AO[/'[/W@;]FOX<VWPQ^'LNN3>&[35M4U>-_$&H+J6HF[U:83W0:
MYC@MU,0D $2>7\BY&XDYKW,Y]^"#@<D^V/;CH<=^M"?='X_SH7[H_'^9J<;C
M<7F>+Q.89AB*V,QV-KU,3B\5B)N=?$5ZLN:I6JSLN:I.6LI65WT-<GR?+.'\
MJR[),DP.&RS*,JPM' Y=E^#I^RPN#P="+A1P^'I\T^2E3B^6,>:5EI=GYV^/
M_P#@EG^Q[\3_  O-X/\ '7@SQ'X@T2X_:I\:_M@W23^,M;MKR[^*/Q(U6XU3
MX@Z!<W]E+;7=Q\*?&Z7,VD>+/AE+,_AG7]",>DZI:W5M%$J]+\4/^"=?[/OQ
M6?XS7FL77Q,\/ZW\<OC3\$OV@?%7B+P=X\O=#UO1OBE^SUIOA72_A=KW@ZX:
MUN[;P_#HD7@S0;BYTQ;2ZL-3N[:6:\@E%Q)&?N^BA9ECEMB\1[CE*/[QM1DY
M4Y-I--7<J=.3O%W<(Z65CK>$PSWH4MK? MK2C:Z:>TI+?9OU7P/XU_X)]^"/
MBA\-/$GPK^*WQY_:C^)GA_7?%WPI\>Z5J'BOXHZ0?$7@7QI\&/'^D?$SP-XC
M\#ZMH?@O1#I-_:^+M T:^OTO8-4L]1ATZ"TFM1 TRR[WA[]@GX+Z;<_$W7O%
MVO?%CXP?$'XK_";Q#\"_$?Q2^+OQ$U+Q?X[TGX2^*(+B/7/ _@:Y2WTSP_X!
MTC4;NY;5]17PEX=TJXU?68+'4-:GU&;3K#[-]M45$<9B4HP5>I&.LDH<L+-R
MA*5N2$+*4J-)R2:C)TX.49.*+="DW=TXMV6KO+922^*3O93FHMIN/,^5QO<^
M%-1_X)\?!=+?X,77@#Q5\8_@SXU^!/P5\/?LZ^#OB=\)_B#+H'CK5O@MX6M-
M.MM$\ ^/;C5M+U_P]X]TG3[G2[;6;"7Q-X=O]0TC79=0U31+S3+C5-1-U%X<
M_P""<?[,&A7_ ,,-0UG0?%?Q)D^%OB;XM^/]/M?BYXQU?XEZ;XO^*WQO@M++
MQ]\7/B)IOBM]1L?&'Q"FTN"\T?PYJM_;QZ?X.TC6M:T[PMI6D6UXB0?>%)W'
MT/\ -:/KV+;E_M%9-QG[RG:5FZO,G-)5+-UJS2YTHNK4<%!SDVOJ]#_GU!K3
M2WNWCRV?*VXW]R%WRW?)'F<N56_/WXE?\$S?V5OB*OQH@A\/>)?AI8?'S1?@
MQIOQ#T7X/^(!\.] N]:^ 'CE?B!\+O'VD:!H]B-'T;X@Z%JT5MIEYXIL[);G
M7/#=CIV@ZW%?V6FV"VWT/\&_@7>?""]UV]NOCE\>_BX-<MK&V6S^,OC/0O%-
MEHALYKB4W.@Q:/X2\-O975YYXBO9)I;M)HH+=$CB*,S>^8 Z#%%%3%8FI&%*
MK7J58+X54:G;2$=)34IKW:<(Z3NU"";:BK.%&E"3E"G"$GNXKEOK)ZI-1>LY
//X;)RDTDVPHHHK(U/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex99-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !* )8# 2(  A$! Q$!_\0
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MZOQ-@.'L\E7Q4/:9OD]2MCL'@Z\7BEA%'$X7#SPBA]6YJD93<7[6G%R_R_\
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//X;)RDTDVPHHHK(U/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>modd-20251210.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qRZo7xRiXhun8uNbXQsSaKImaPtypR1WYkxs2t0HVnqPywnvaxbaSl/FYYW0VAO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:MODD="http://modularmedical.com/20251210" elementFormDefault="qualified" targetNamespace="http://modularmedical.com/20251210">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://modularmedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="modd-20251210_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="modd-20251210_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>modd-20251210_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>modd-20251210_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="modd-20251210.xsd#Cover" roleURI="http://modularmedical.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://modularmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 10,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MODULAR MEDICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001074871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0620495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10740 Thornmint Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">800-3500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MODD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0269264-8k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modularmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0269264-8k_modular.htm">ea0269264-8k_modular.htm</File>
    <File>modd-20251210.xsd</File>
    <File>modd-20251210_lab.xml</File>
    <File>modd-20251210_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0269264-8k_modular.htm": {
   "nsprefix": "MODD",
   "nsuri": "http://modularmedical.com/20251210",
   "dts": {
    "inline": {
     "local": [
      "ea0269264-8k_modular.htm"
     ]
    },
    "schema": {
     "local": [
      "modd-20251210.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "modd-20251210_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "modd-20251210_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://modularmedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0269264-8k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0269264-8k_modular.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001213900-25-120759-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-120759-xbrl.zip
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M0O%;R!,S^*YEZ"K,B3DX!C,'MLY(EG!%J75FE0]=Z?!%)#Q60ES&Z97%>XX
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MA;P)?1RX+W19@_51TN1<;>S^+,G!-@8^IRRP**!BMT,=GLSU\.GK5R#;0-?
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MN^,YK<F18!C6H[0-@,(!X(&98V6U_"11N1$"JI8@WY0#,=WD],^!Q>0K!)?
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MM=Q".7J5HEU,>720HB!C339PKXQ [\71:@1&>!:7&&99F7 'J3,\"K4 S7!
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M80J<C]WPY8:->(=%\[<1!SA6Y!P?=!87O':#3Z(C?/#^H![6??$9W.#LG,2
MY%S;,MSNVZVJ3LU=RHMD-C6^0*'W3&GV#*JKE^BLOM\_"?9>(BS@=7X0G)R<
M[!\_>GAR=#)"7]2DCEE@S2B#L' &&^@E]Q?./'EO8'&16)K,(K(&K6WI4LCF
MU>'_7H%J.C[FZKS0)FZ\03N2*36;IVP0'_U\<D+R"O1CAIP$+;.ITSMPV?;L
M%-;-)$TM_$)DO-914\:![9CT*V)/2!81N3"UE#HH=K0!Y@A%0/]94L^EV+,8
M6DBKE=M?J-#3(K%XOY8),FY6 =X:;T 8V'(FA@)?PS0'LB"=4[UV6ND7[]R=
MMYAAR8@C'TI)$#KRL^03?S[L-(KCBBZKS$$L&!3Z2<P^5$H5A9@!+&+R[NS$
M=4Q2;9OH%SK @XNI+[&M<'P@.<BN(@?E"B, ,IB0[;/N<X=R0B69W.Q3_&2%
M(*%$BEC1#C2'D-V?%>]T,P\<8<*LGDEL@>/"D29>\!(C4;3\YL<Z"P:.8SY9
M\LU8?.%18GB7\88I$F6XWW#?:H39&;Q6<'1,;$1&G'1NHD;^C9Q!.P"V;G&?
M\Z2YF8V1Z\TL,@^/$L9J?#!):N7U$"E4<>_D\&G'(5'KW+;-W>5G;FS;B&4#
MMZ(WT0/;,!9_G=+2BR3)>[;&D3JLA-[A(RZM;;^+0271$J889DA!R<(YQ7SM
M!)T5)^^W&/*9Q SU0Y'%9^NQ(P9)"U7<U*7HK];SV-PI#X[WQJ/F7FD(!<H(
M9Q)VHI6:DJ7F,L7F)=NGTD\9RQ9>*SOHA/KG3PU9@-U./>N8=&HJBE+60C5;
M10DA+WKB?K%AA7"Q#;U55TGU4TP N'C/%HOZ CT64)RS%-U<\,[56Y8JIBV'
MJO8@#8)K^QKQ8KFZ3Q*/6,/$23DITK&\3$/96Q'V1ML'X(E7C-/"0]0F/.2Z
MB%=B69)1I?"HO(W,#ISB\6I_8>]XV=4VD3:0DM%Y$2W (&LL3E2'?ZNYO=8*
MP47S187H<AN%32P9/H$?+,T#O1>,R%)X^K W,@#$2*(KN]7EVKGIV MDQC+@
M*.^[K!UV!/%@E<:4<DN-U_-?Q_=:14E=U!_ 06+YT?TZV^]A/RG5?>"5.!D.
M]+@[]7B/LWZM371*8AKCH3#/PX$\HWTA0Q+J[?O6D+6J3VQ\S9D2%J3#=@>+
M7]\B\>V>L1I=JZ6QG3%DC783#B?1[U;_(#@U4")\HLASI,&U)\?,3;N""642
MVJ8HK$^0I"&L<<EPYEI WLHD$YX.2;:X.=73.,D7#9^X?=M1'N:%@R0_CZHH
M^"W"*29]>@K'8H4TBW2RDJI(DTLX*.]7)4XXCWPX@.F#62IQW/R%,7AKJ>T7
MSW\[?;<%/]RM!4QN@13ZJ"^FZF0'GZK#ITZ^$_C4][>A%6VX'T!7Q-W# =?O
M/_CEI)-.RL]=:A/FX,>1#FXRGZ<ED@PLP4Y["^<6ME3+?*+6.,.<5H$4^X1%
M_PB*_"7F//\4Z+-20X:MLN+@HK**:TNW3KG1(L66_6LX^%G8OXQEIZ,,-G:0
M<[FJQ$N"HWUF8V4E$E(LBL@X8R$79"C'#[GRLJ!Z$8<#9?(IWGRW"^3RE*^=
MXK4&^^Z,'E=A[9$>BG%]LMF6'@[VW#C-97ZK 6=)HUV2+ZL ]U!E?#,[THXA
MFA'NM0WQ\+X-JW:/<62]D*#3"3'@+HSZU:*<W3:5'U$.">6@\@)%'F&F.;^R
M=X_H_:HD(XS9,L.*#KB1>46IT,1[XCJ*5VIF=2\>[3T:P0 QZLVX)LQ4YU7K
M@!40PXTX%"P&O"2XB^!!<MFC>,";S$8]D/LX$(I!+4N*3)FH,E*JD!^_$"P+
M>^;-&<]M]8MU_#@*8,K3P!2?44F7]<JIJHO\+,JI8GNB%J>+\",])P1^3&G8
MKEGTG3J03)'9?VKA+5*A2-!K+=LG[7ST(\LNI8R&@PYMU"['6H2?UCWF:*59
MQ1DIS&F=R]-B=-/2\=*6*<MU%"[-+I.RR@NBM7*H)Q>J.7MBX4K85U 7<=J3
MO4%^CBA7EB!]-]BF%@,W3@B!ITL!E2H<#H[VGRI=^"-OFS]04\ ,?;5M@P<?
M5KV_R70+J_$]9?*//42_@[FB.+79>M#?Q EL$#P:#*RQ@5K.6N*%X\Y8FKZ_
M)+/OZ60V"()F9$U?M"W+O:U+P"1,] G4?I8' @Z5@@+4-J259^DG+!;'Q$UT
MF;#2Y-Q.@/!45'T$.9. I)>R<. G-U-N!O0;A#A2'H\'CIHD(!)C.CA8CSP5
MPP2'(1DHG;(H.2,[7QBK2@VND5#YRI5T=P/2]/7.UA?BFAQ+FH#_[6[X U8(
M%JS[H,WPF)&?AM^^CLHX^G?P+%K@*P>OHN)3THI3V##2?SSA.SU[M16)1(V/
M^!I'*JB=*,R0E/8\>2]ON4#,4.VQX7.Y\=P$]MB8._0X-#*<T-3]DDEA,F)B
M<7:D ]D[;P8(K ?NZ:^_@8SP;IS*NS?Z+=B6[^U"OO60[[WO).1[9[?GMWVX
MCE5A[NN<NE(M@C>X_;&RLYHP*OQUDHJWYQDUF63D"/YA<'M(I2' _XIUCFWO
MLQ(&CT5!= =2YU(N0<QF-FV\5+1B74G#K?*J8KP9?EJ*=H0U*BL;COB4Y5=4
M)(7J 8X .,A":&.OY\>#6SQ)$AQUZ='P6* ;UJWBVS;-V@G\>Y::^!B%90S9
MQA[#VT<>"Z>9;CB*H-0=?:4*$?\0!N/=&_WQP3U7I6,MB9)*8[J!\-\\OOUV
M'>)[NL3]&9VEB, 8=)S\D/9C&.MX_W[@E\*P4+N5E[REKK=?8X@]F^<@,&Z#
M0.?"'ZHP+:M]A\YT2(_*IKA\;&<#T*DP2"18!?=A?S <Q,S#YDOLJE;/U '.
MU3#9+M3,R,EWJIIBL#A\TH#/(P&JX.>O@YA? ]8BE:-8W#"^NY2&K(+Z"1VU
MFZWD,Z&\,U!UQ5(JJ^W4VYEU!$<S"37BURT7!V<'3P\>,.20[ <U)%.K8:B]
M,)_!+NN&Z@7R2\?(L\SL73#1!XR^[+ (FOZ<OXUHGSC *2I90]/7F<:R=VC/
MM?.&EB!0_VI+NW&DR& X:-\XP5?=-^W3B(T9"![IUJQ.H[7DU%(3F@M3X^%/
M:P8:SKTIJ\#R4I1#V-?=DI_:) *"N,$88SI(A+ B@BLUA0/PVOVP7 2OLC$#
M2[%:$=@:0PR5]"EP<P-'YL.M-J+\KA1'/\TA7H? E-LU1]8 !6I5@8DCIQL8
M)--9JAH*06GCT!KT7AL+G&J4;+.YC1(A+%H"F9CH&ALDE;'G&2D(2;OPU@OI
M'^Y&^!?Y%7@Y)LO]"]=7&&&^.T'48<0<A_/HDW VZ&(E_BW*=#@PLR2*.<SY
MG>SWKYC&V6+3;]%]M1F67+MQFT#=.GR]:U]7FGW:^S9.P>^%#1$Z=(&U9_ /
M@Z/=;G?;;=SX@=NDJ7C.9K>R &AN5PLTF!&+M"'@28O)<LX$GZ58:5Q7 M^N
M@BNDDD$VA+"VVQ\[Y=Q,I%)F<SAH28H*@-?.$99!PN)43@EI))<5%VW!Z7ZP
M:#)0&O:,&3J%'CK&WY*9I:VC(?FH]4A%4YZ@V3_"P_-;L[ZQ(6'S_'V;9#A8
M(]-N>I/\>O8$W$[37YSKVL^>A/+Y17Z5@(UD/[;)0$K":A]44RIH*E3D(EW9
M">!78?*.0G\DF@)?#G<)57T0V9/P;]2J<<&D%1"5WHW399&EY86SZ%R!RWKW
MJ(5'-?F,;U?"V)4I>)WT2VL KT7%<UFEQO\+](-KS**""V4F-J+G:*5D5>BL
MZ/FP7>/'U/P*T6H)+,RTC4%'FIZ7IMF&+3LPM4VQ>[7&J9?LG[T?_-YB4DNQ
MG1OD0[^PRX($>TS\;JNGE"]ZP?NT[0D6=U,[*.[B<CF6ZV&&T@I-:;G/6R(O
M@\4;I[/T/Q$W*GE/Y$YOA8*)':VW21;-8-,]36.+0K1D9>N?&?B/=,46I XM
M)LEB&W7'D+9.-M?N.'NM(MK'Y+Q^-Q;3[0YQBY3?_5W*KY[RN_^=I/QVQV2C
M3W&YO2.M%&O3>6[5J#JH*JDO&[H!];-(BI%Q0=!K90+9F"):.LXFW(!3X0KJ
MAYR6\M1UCGD'3Y343-A_.7>Z892"TKT!QWP+CZ;+5K61V)LS5IVE*E:J-5'Q
M[R[KE".QZ\Q3>#1OO0T:]/L)(MSR6>]WU"EZT%X=''C%P3W\SU[8*"JLR'@G
MUK,QS):#VW-=(%WX:K P@7LJA,9[88.Y/?(M7DF/N+?QEWU,)T)8K=<:]J(A
MTI**3JSI[(6^;N;JH]WT.\.?.I5L)VR48(&+OU+([\9%CDGE@6])D0,W&65N
M^'NXF+U]8]KQW-3.K"V)-"MR46%4(FMW*-$5-K:HB? :ZI(OWZ4MP&-_DSI$
MY_:[-/2#=RXTO;I68(;[[7VM/;E=R(9.]YH]>:L:Z-L(8O>'7FA:6GL(*0YH
M@\VJR4!D/V."%7L*UX)TKW7:S5DD^;'V,*I2.Y<X=)*ZQB46M%%J6'TAM.2(
MIW:O:F "6A';PR&A,__TAQL2LVW208Y9WYED'=AO*KFB>6T9)Y9H&0ZW#0P?
M]FYKJ$JNMPL:H4(Q: DBD%%?*50 N9HD[#)I*AZ[QR.  KNFKA]E2N@&IKL1
M2SJ -2E  ":VU[U]W C?W.I-&UZ5<;]?CLLT3LE!,)1V*[*9L$V:H<)*:3VD
MV]0X7V;TB(CTERA3B\0Q%5J:=&GM?K[FGFF9>"$LYW&DI3M^'4#+L70."PD2
M20L5+V<KS1F-KW8)@BO&I#]3-;D#9 N(J8Z1 Z)P_B>"L>":A4Y10"8(;.&,
M+J'$A6T2H!8*?M:%%!T./*BH88$W<>?*H68:Q$QT9K@L5R (>Y]EXB@; ^MN
M!X9MXU9F]0W<!J9@'&6?BN6BFJS(@BOSV24LZ K;D.3%>91)D)8<>FRI&A7!
M++HJ9=^@FSR!_9%B+:>\45"@M"]-'2C&5/=6;EBU$8DSCQIDGJG:IYPBXZZ
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M+G*7U(J:F3<P\AO2)HQ,V@K7*KGR"?RY"BS?F@O["@<)!T1*:[N:;$OM[#O
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M?2K&#<[U8]V],*G(H'BL8>[HT*V$>76!X*N$PIH,CY<H%K)JUR1+,]L:!DX
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M)T>'_XLQFR[+!PY%V570[/.=%4POL]J?I=DG) EWWY%QS+W<[1;22CR)K4&
MKH:W]?Q=*?K<)94] YI#"$W:HNX6B_2H47=81YG[;O,'>\JTF"=1)I67=#,W
M.<\D,O(.'A[</SH^VIN.P 8<R:J8X*S]B^HD\QFWO9<_9M)MB,-S;$A,F*=1
M?B%P/_X!3G!]3H>#CN&>XL3"T(Y"UZ5]+TELD_:GJ_T_)-C.TR18PY65"O+%
M^C7:G?\O/?_W#U24UZ;4)<Y[6@,_6,NS)N1A57 7MV!04/ZW>:K/\F56)C-?
MO*,C@<62</=6)C=S48NUBX\71]Z>W_>K$IM@,G(5X0YT1!F7Z3K!2H"8QRZ
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M4QFO93JI6+J *V"D-$(CV=#87H=V=3,T3ZG(+G",I?H>IDF'0\^^CXIQ!";
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M@@"Q8(^0^=MM?B:LL6T(7ZE+Y]"=B0O>4$M@%U+7VI&\?\&6J R8Y"(V;L/
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MM<]H%[S*,V9T>VNV ]40J%O\LX1[/ [D!I%<_?9B56(U1 :FU8IMRO?+K+P
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M.;1-?H:K.K&<TQ\BUW&_-L2A;?9_E,B%6,[.8L]-C)K;-&1PV@&%N?'27DO
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M3,.42XNN5:',C-[2W!+;487K^XTKMQ,I8%(=NX!QH!-73S/ILJ[KC'LZF:=
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M=U!9F0RIO#!)JXF,S71HH?S]AI#\):XQ'N:WA/$O1Y,] ^D@YUM0\2F0A[>
M?-L6*ZKI]D0+#UZ%E7K\&?-QOH7GBB)7+_;X14ISG8$7F*?($/:2&"%*O('_
M,2WE]!-?B52D\.KI9>2R.=!M=-J$!$T6+'!.I[5I#J/20P<-M*<_?H4U[H/)
M_9Y%#G]\[AIW%)N_R&0\*7:([S[(&D]0QZT:-T[9T( (&L%0JB9^C,/RYWG)
MF09Z7IBYIW%[(:_LYH;?ITXQ%#4VJL;I#<'H/GZW.WRI%_M-XA(?*;.\O1#-
MMFI&P]N+4MUC\R/8ZF-6J#$86O8W;,F0+TJD&^FUXRN+$P@T&H?V>U$,>$[\
MEV^-94+ :^O]P5=N/%]7;G0J-YZO*S?6QVN><VPS;DIL'+PP8RQ+Z(\C--+1
M8-O2!G2_R,X)%U>UX SSU K>)]/VHJKS_TD$I%=5M5["Y%)*H(S8O^Z6H_:8
M3MTD^S)W(KUC_@UHXI9=@T;L6EB.T*3=0)I3=*T>99/11@X7+=Y8@YGZ(/U;
M!Y9ZNG@H3-]KBLSKHPCSV7=K1)PF)A=UO%/VK6*4,VG0TD.6)A-\7L;)0_@4
M-=I/D)N;^C[H1;*.Z[OVGI2!87YY(X23%&/VJ'<?<%;C$:1=GNE"KH]LRTHX
MR<UPNO7X/2=U7O>3:?$P;63XD2Z=LC3=&N6;"6%@ Y8SMH:IMB^,;"/.U3ZU
M?+$3L!:&[Q2&?4L8_*#S]38>?S:\?*::@'[W!Y<R-+$*= =BVJH"R<[>76<0
M5@.HO,",Z&=36*2&M!:E[Q0EU5N-60XT*:2_>83AY:TCOY5!CGKV;9(K7A[^
MS4?8U"<(BT3ML+)+UY("-)8</31CN'Y;'X6,%)&(M1EP3V: H1O[[%9#L?7[
MARZ',K7&JY5MF6X\B=;UUT9U^8CQS]0'/K\B=G%5@C" #1$TFSN17VIEZ7:1
MVV-7)<LJ=[RY0<#1$@%S>M/-V7!Y=QS'8.[45YZBK[N[<UR?JGLZ58:IRJ"0
MP78I?^I[:VSF>7L=W%?MXE%@G N@7<].XTJP!"F?C@*S&EI>0P"/V+'#4<T;
M!TB_HF6P4"P"<!)D&-MUOAGB(JCB6QO?W6++]G5055LJ*%;)CM&T&.6%CDZ;
MKYO"R%BI):VG7AJ_WTDD4G[/0W[O8?O6.2%-<M@/'=?8 ] ! DE]#KH-P($>
MX9Z&XCF[<^/V%_\O'IIE3M>3WN-U-\;8;8UVE0CVBW4$NQ/!?O&#1+ ?C$#>
M\/%9L.L!0E)_0$<[SI"6^ 82 ,&\QZ6&[@P%IAZ5?? #$#0=6>09WO80"Z9U
M2?8U*>;R-:SDS499R36RQ MXD=1CXIKS;06F<@)KO,@3!=BE@EFYZ:;(:ZL!
M2K$05C4:!F+)Q]$X&P_H'WCG5K,,E]*V*B[E\40<9;V)XV7&%KNZJ.CJKJNB
MRS)L >F/LX0A^V&H"L]@[ZBG9 #L%_69_5WU&8=Z<VM8%05/L.#E7I%[RO'=
M]1:"Z?$IJ<G?6W@R8T&2M!K42F\4]EKX[Y@M#U4)%AG7ZI$-!R8Q[-6P2/(Q
M%H&/.=?S#8&>R54"V1CD!==%)6U3(5DR\8"12R?51$Y+DUM4:#,(2]GT-@%=
M"&<BI2_FSDS<+RJF$X:EN+]JS:W(A&E6HX1 J.E%\V8+MK.>;+S4U)(:7@+F
M\I0L8JHNBP9)HQ"YMHZW>XH[:C2(LW.JONL4?L#^>&4=QNL79WD>8<GU.G3Y
M,R)O5*15.SA 2CJ9#()Z= +4N;:W+LP.!UOI=L^YM&MVZ/5+<X3$4J+J5-N$
M^SBI3%@<M#G81+KL9>LU5W!5"D?:;!8,1/U2U^#<Y89$W?W8W+B'#0FT0BJW
M\Q8V9*4FZ95JG+Q")1S8U@D?6;2!35;GFC$ZQ1"G.]6LSH>E(EQ86YSD!4J.
M]P[, '/'83]9FLTO1$VOI.ZQEE94M_W\E@K#=5.=4D\]GUKHN,<LD9+4%\%@
M3AP<2AQ,U 5K/%NKK89S+P(A:G4H)HUF*J+7.DTG?9?<YH;2^]$UU#[)B];[
MEM)7%0W#BK<7E@JL.KBWX.U(.067 F,NP6]!U^"_26CQQY-M"Q-293,MQ*8C
M 8W<4G"77HM3EV)ZD-'D"M/ND!C:*QZJ-5),I/$;K?'*H%QX485#F6.L%AXR
MUK<35<,7AL48"S,65@G3X\P%O;FQC#W"#9.(4:68L*GA0D-^!F67#0<./TE!
M9:MUB1.5<DRZ]J*NIN<7=-C.0>TU"*<,9TYAWR'!_&A:H#;!:-ATB.RHIOX5
MM,!X0&S6ODW;M79@;\<3G V)$_P5'S/B<PD6"I7-C#(;P%56I[$K1[!EJ];4
M\["Z\U\:"+U9)P!/'AT!Q'IEIJQ*W(R8VW!&TA,BEF4LS-%9PMUPH#)1F.N4
MSBE1#)?"?JUL0R2SM&TW,X.0=E&;# LRSZ);\63'VDZD!6:>6EE;[NCC(;WT
M?,X>'R'@?*N#BT=JH5,!YT ]^_=7%]45FM[+?7$UO:!/#"F'[D''$.YLL?WL
MGLX%MC&UZ7BF+][V?";9R-+'V;*NJ,1N*?-J:=M%W7FL-!:A@JB#N* 67*6V
M-$6;S%J),U[=>2MDVPJ!V<;=[  .J4T<4"X8 7\SV,Z1[F5UVH09OV](O0ZH
M.Z:-95')!6J]C%(2[*E*>0IC(>"FX<JWP2RUCH-;3'G$/TYW,ZD8% 0;/A5E
M+_L&UW9#K5O$CL=)/)1#R>Y$RE8QAU<7FAO26:Y-U^J"<C1&X\*+T)W#>GG\
M=(V?;M@Z&,-9SU0_!/J6YB'8B7H)]P6=C$ S'"54DD4.ZY+,S^N(VFU&U/87
M1M2L/311M6ZS_;*1-=W?9_V@3X@5-'-3X!CPDA;]_J+<%>)EZGAT8V71@E 9
M]^_<0:Q,#?%:83+M]YHPF8(&E6'T/7Z%"%FT;(",+/?;C9#QM=0[*2LXAK&T
M6XR.K6A+(9[0_.A8WA<=Z[8^+1T ZXFKN%;#,H&56PMTL3&U:O']]T3 Z*.:
MXEU95V3#+Q7#NJE857!)*2M_B[&J599TA2#6BF$I![MO4>>= 7*^B?8[1! B
MH"Q2ENS^E\4LY,_CS_YI9(@#99%?)7=HV08*'4'%W9ME&W+GW:;@P(6F''=I
M=UG:96>HECZ=W_6(468L=]WQUB/MK =]]8ZKWN.H^_&!H$^(6.A\;=R.Y[V#
MM)/X>LT$0QN,7G5CFN%S,&:<L-D^A]PHY"N @KR3'+U4KDK7,-0WJ1^(XU)^
MA'(0RZVMP" &.Z\A=@8I1QQK9:O1F@+O"-8]P0M5V//A^!.FDN.^')HEBH$.
M=M?%0'XQT,'N#U(,]$,XS0]O]$<6]Q#UL*9@*PF_W"<5D%9(IJ#))AS8+[5W
MC)<37QD]&I/T)6AGL$[R869*1Y%Z>F@,?\MEHMI/\_C-#7X^*6[V@/G2"?A/
M!"9'=AA9*\:=,]X\WAT+!TS&%'R8KR;[NVHTB(,K]G#/E,BTXCF]C!Y@K-C8
M?E:F1*9M;X&U8B:.3 1DEQFF@E2TUJJB,&Q_Z*52A&Z>="@6$I_(#C$ &24O
MA-4$=LX_IBG(%-VM;$/P1#A*8,CA8C0]44+FSCDL)'.G',V;,?HXP8-BPH[4
M;31G97:B=Q:5G0.9!"(^H-14&Y)R_;*8>S]RBV=^SO[**8KG[S_RB(ZE_1*-
M2DXLVD,D4R9$B1@B5.PNT!8OYM"IQ8>1:P@M72*NW PPHQI][ */C'&]#!,P
MF^_="6[O1,>DZT19:2"WT%KUC5X5T>$J3>PVL?!B43Y: 8-I.D/EV"P\B":A
MTSL@%K#.J?,]% 7\I.UO@R?<R2N&7M-3Q=\C(A:=J 61/:R:EE$Z'9_!Z,]5
MM6/T/<J10S;=F5K-(50E0NXZ9@BH!C)JT/\2C"Q%P>@?8B$;(P]UF$\D&M._
M7IL;Z,V3XNKX2>J3ZG5;<]8V\I=VV\;B%/T[<0;0F?_FQK2DZ/>6A)9XWB9,
M M_4JMOQVQ6D!<?SU/W9+2IQ"A;DLA]1C,:+Z'=%6RHE),CC>5M+/C=P8I0G
M2>$T?UD<"\5J&H*[*F_XR*!&T/I'[J!:-9A%54E)5*+3XN,H4M!8:2FL:FDM
M-*\T'U'-E%Q'>( 3W2;%V@ [C9P'A-6)"A3*=@;T#6XGWI@<-%EX 4B4GH]#
M]QX(\NIVCYFD,A);B"=@!U2$U$L\C8FMK0-VF$Z2*JU3]\TPK3+.4J8YE7>@
MSI/@B?5]?E^O:J=(@UQ>2<.M9ERMT)T=W<08*>H9D'5 5-%-5BB@DCY-TSW"
M_M-%5I>X6;KZ+;SO6TB4V#E<EGT57%&- +EP25O.=.7E-#,1K6WW,K%#AV&E
MI?M4NW.VB( 94+G)4=10,?1%[WJOQIZ7+W<WJC6YI^NN3U9L ZPG'H@*S-F0
MVL@F7ES292=XC$T^!I54ZU)!KC?,A2F<HN,)R)E=*<99):OX3G\*)(N0*:ER
MT?0Q.F'SV#*35">FI52"5ZKA-J3)R6RP[K8>DXBWH+W*;-80USB69C)Q3J\,
M;(4J':HAH<?2Z=U6<6QZA45.C7GBI'4NS5 R&[7-/ LP['PA'WNYH$JLJCN7
M],AS-Y2L+'I5?W1[!U$U_Z&9:_W ZP%?P*2,QQ1JG20SVKY!QW=S!],9A\KO
M4Q4IYTFT*:TR W#5?]NVA<0JP/-%Q3@6?;$+!>KIJ1%"W>RMMEL0OU^]U@YO
MPU6+[8(Q_-C.8N-AX\PQ(:'.MIE2A?8(ZW-S>GB3M6UA=3J8+F*,,)Y7&.Z.
M/E2]5U),8ZK$"&8ZE26]/^IEYO<SFL882RUSR>*K+ZOH0]DR28(N9/5)E7'H
M/5#86OE1U3>9EZ8T(':K'G7.RC-I>4AMG0^(LP"%JT@IL\C>_KP#!HYS1A)6
MD5'4MQID/L)@IWRW::A<_7=)=F['VM0GG6;V,+96,;(6$3T".5<-E_KI'G&"
M6BLR,1 H*1F\)P.=V?,B"#W*EB,T((=N8:)U@7C7%>\6$R' )+0YJ/FYK$(%
M9%GA?H:D)%1R:1@9@=4S+7!QIL5$O18_Y=<B!Q*>04_34XG=A!?>1U515%=$
M,([I!%BOF#&?>TP[]R9TCN6U15N\9:1))T1E@4G E4;'QS^G.K[#/SK!C&EI
M^0GXD(NL$/U7)+,LW9:\]DB&+H ,UFLV-^3!9'ZSX\4OTD[IHI=0C<5(?#2B
M/-;:0 ,YP!+ H1F-'.^>*^MCWIG %E *NN$&!?ECH*HL''60H&/:*5)RZV\'
M"DC06)7V)M=Z*CMP!6N#A./JCB$S/_ A"(64!$WZ(NQ.^7O("<+5G'>EQMT
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MQ61ZS05L0J1@'0DE(,T&]" "L)[9X_3P\5]&@19:6D,$211F!A]B^+F#%XW
MYID Z#@M0B-IX'9L<H<A(D>8VV1FE3\3)T&("ABO)YX!_/4RKPH3;5JX'\1K
MIK=C'6VZ)V5N.O*.%4:]CF<Z-BV)!+*N('/-F/" &&K&8/0W;3VESVKD+OB
M A)I.VC_ZSV_ISU_:E ERC9'=D2]S4$XMZVV.F?_4KLA["9:?9:$9E -I_P3
MTP*:I@(;X:'J@1[/&VL<VU9VEEO],QJJ>658IL(D.W)/L%>KD&3$=\)_2Z!]
MBMT668J86P2?0%!BWAP=)ZKQ!H%H,@A(@QW7?"KBY0>T$*+[P4K48S\/SPR
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MW^T\^-X%?NSVKG_8+6-UOK1-_/O/>V]^G\G^&3##Y17YZ?6)T@T3U<-!%PS
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M<XHNL@P(0#3/(NM!0B"31!<5HM\*237'W1EV#1<H2G#8&NSB *L&NM>9M'=
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M4<^:U33O]=F.+\M0^$QB5>0J.&%$?"#4\[)\7[?1KA1CQV@&U[>B<4@S#@6
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M2VHW,%V!?6&#I1S/[Z ..1>2QA!&EJI<M$^JQ@U@RA"Y;(.VCKUC4YR?+4P
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M6@[>=0\ B-_#V^&7R9R2A:H8KE)T#K>!@1D$WLM):3Q+5"6BR5D,0GU:1!?
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M=MU97\'Z/[?ZF4?N5/VJ^<SFQB-:.YP"E[1J>6*+G@C^7G^@E?UYH:5G[$
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MDV%YV-%NI2BIB6@&T##3*0QNJ>\/,XY9+U0%!8YL+-#J-/'PQ$C;97^WOE%
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MFW1;_\+CFSY("58XVH8RM5Y+UM@F<P25OX<+M^D#J_#%%7V8]1]02P,$%
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M+X6T6D$1-C8Z7])6E2&+X.O8#<_G!8X_RCRDR8 7\X 7(WR'P@D.I&6PR_J
M S>M<(M\  B(1D1;A8-N5A:Z*OC<)^AXWN8WA&G-O$2F44$F8!6_3P'G-+(^
M%<[I;F<,!J$B$1PJA"+YS$R;>]J3\$(Z9"!:GPAX%/Z=5!Y(N0;_LF0[J9*L
M3-LG///(8"6"]X5XW5U;>XB]MF<DF2875#XKQ;I$N[A TL. I)'#ROASR)3>
M%!9:MV,>B@HE>-P$Y@!\B9S7IE:A"KPD'=I%-@-P3HR,"1?'"%PV0_ZN 1C<
M_4GC02Y'P,)517(!G2K(;*<B&]?HW8B)M*Y*EM;!94-*4.Q"FYS=]G;8YH5$
M8'W0?;:SL]/;?G.P,]QYC:@1#U*7%A$^QO>TU76T4C$%Q?DCRK::^#BL GH)
MPM^>GR[0NV+7*)_#O:JQHO.I2#+?NRPDJ:(<)^L3V]OA1+_;6=%?58YKC6D%
MCG$^%UQYB$O 4_OJ7**LCTBP3")SDH\MOL OBR(+RB&FZ/HEA-O:"@+<>6#A
M+9#6)JP!("I^;IM<7$>+1Z6Q0+_C];E 4) RY+&Q)*2SGJ?ZSCIN&K(!D\9B
M+=5SPBA&*Z"A1!=2-%Q]10D0)F*S*7CD#UQFE'&CE9/?8#) ]._1W!,I:B/&
MCOO. 09\D#;4C$J:&D0A0&)\$82S9K-9'Z[0G^@'RCHQ02'E B#H=OX3>(C8
MR#E$YOF74KHYNYTK"C!0/A,%-[YV1F@VT1I^T 9JO1"IS_[OY60ZXW,$?4E\
M[ X&$3O1"6>?N".J%YG&M4"X.[L[VRAT8$OD4"=Q;.M+?E$U=PM?[D-KE1PH
MK:*8^C[+L<TW!P>OV>[N0>]P'R'P4M*@)!Q"F!QN(0CXIQI$E79D1>QRI?-]
MG/<2'VQ6H+VK\!QPGDQ09^O*46_T(*7T"<2V$T4$RK[O PD/DCV4 6RP/*N1
MT](!5/3PW?F&SC!-Q[J=S_AN8<2 /]$*327Z:EOB?YZ!:(DU#]+]%3-=HI&.
MJ3/(^&Q<4A1);>I86,K46/Y20F,TM?$+'D4%N1L&NQW0"3F.V"0&&E[;3#Z?
MPSR[;[1&K#_U>NR"1@)'[(9/Q%OL_U(*],\@RWJ]:N1^?';YC_K.]M![N+UF
MZKU/:[$V4%VS=I+QY)X-^WNXGNR4@H45*> G.;6<WR',TT'K=\WB@]C'6Q!F
MC5RQ$?R^%X#T$9 O*:--='\-49*_+4E+RVVC+5W9TO@6J3QH^7_434[>C0A3
MKDX97LX\^KOFR]3NLKP>L*2 :(FHY\+5J'71!&6\5,FTZH,>7=6]U/GR&Y/F
M/ON[A]XT!RV04,($I_[L<VFK">MVK!#W_L8*5+C0?"&9I0(I$3G/S0CX$*.9
M>*1BZ_N],:6W9!Z%?$R@C=\'=%"$].?F3]F$QT]9:_#L1Y22"/L207-PU6>7
M8+T&H]+SABV&\#6P"=6<*NM.4<O1=U+B5"DWU'JR239'V^(QDP)ZRGP[6 A=
M4!(G?)5*#I%@<!?XE0XBSM&G-!"\1#])\_)ZBAZ@$3$@?8M8[6L()=1FUY,*
M0PR!#^#5ZOB+]' VXS0ZI<KF =\-1TD\DS?"*!XQ3F[%K28T6#D\J_P=:AP+
M;]JJ+8>ML)25T&V"GE2!$R%,GUZU0GWUMY#>GP39-;95=WI^/,35H=INPNV
M_O9>^_>%.]PD<FRN3$872_40@J/J L)["X6-.[*(A<9[Z4VEC]MA9:G&5%^:
MZ54-M GH39TK[-'65A[8[%6"$RY\(:AO1.B+\@(V(V<0QI;>QI0!"' 9434H
M-))Q<Z]Z+$A3SUBI/]0S9+)GG ?\J)=83Q>-]@R9I7>EM<\6MW47;I^Y>,5
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M+VLZD/_W*>+V6_;1OX3;(W;%T6*__*'B'S?AVZ*_=PY_ $U_)_UO4$L#!!0
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M;]6ZI:O#;ILIBS @DF!W #^5\H/Z@&0,NJ6A0#-]0U.G_J&9#H5F&C0TT_=
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M<BYH=&U02P$"% ,4    "  +B(M;2B--H77,  !)T00 '
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H9"TR,#(U,3(Q,%]P<F4N>&UL4$L%!@     *  H R0(  &ZX 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>ea0269264-8k_modular_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="modd-20251210.xsd" xlink:type="simple"/>
    <context id="AsOf2025-12-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2025-12-10</startDate>
            <endDate>2025-12-10</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-12-10" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-12-10" id="Fact000004">0001074871</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-12-10" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-12-10" id="Fact000010">2025-12-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-12-10" id="Fact000011">MODULAR MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityFileNumber contextRef="AsOf2025-12-10" id="Fact000012">001-41277</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-12-10" id="Fact000013">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-12-10" id="Fact000014">87-0620495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-12-10" id="Fact000015">10740 Thornmint Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-12-10" id="Fact000016">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-12-10" id="Fact000017">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-12-10" id="Fact000018">92127</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-12-10" id="Fact000019">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-12-10" id="Fact000020">800-3500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-12-10" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-12-10" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-12-10" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-12-10" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-12-10" id="Fact000025">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-12-10" id="Fact000026">MODD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-12-10" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-12-10" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
